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Abstract
Title: Crystallographic studies on host-interacting proteins of the phage K virion
Author: Antonio Pichel Beleiro
Phage K is a lytic bacteriophage that infects a broad range of staphylococci, including
some methicillin-resistant Staphylococcus aureus strains. Phage K attaches to its host via a
baseplate. The contracted conformation of the baseplate contains a fiber and two receptorbinding proteins responsible for the interaction with the host. The native conformation of the
baseplate also includes a tail central spike that shears off after contraction.
The aim of the thesis is the structural characterization of phage K receptor-binding
proteins and tail central spike. Experimentally, the thesis relies on crystallographic methods,
which encompass: production of suitable sample, crystallization, diffraction, and data
processing.
Phage K has two receptor-binding proteins: gp146 and gp144. Both receptor-binding
proteins are β-structure homotrimers organized in four trimeric modules. Trimeric modules I, II,
and III are mixed β-sheets that form the “shaft” of the structures. The tip (domain IV) is an antiparallel β-sandwich with topological differences between the apical regions of the gp146 and
gp144 domains. Gp146 has an additional peripheral domain with a galectin-like folding. The
crystal structure of gp144 can be fitted in the fiber of the contracted baseplate. The location of
gp146 in the baseplate is uncertain.
Functionally, gp146 and gp144 interact with wall teichoic acid. In the galectin-like
domain of gp146, a binding site was identified by co-crystallization with a synthetic analog of
the wall teichoic acid. Additionally, the co-crystallization with rac-glycerol 1-phosphate
suggests three possible binding sites in gp146 and one in gp144.
Phage K tail central spike is gp155. The carboxy-terminal domain of gp155 is a
glycerophosphodiester phosphodiesterase. Gp155 carboxy-terminal domain is very similar to
bacterial phosphodiester phosphodiesterases; it consists of a TIM-barrel and an insertion
domain. The active site of gp155 carboxy-terminal domain has two pH-dependent
conformations that resemble the conformations of bacterial phosphodiester phosphodiesterases.
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Preface
Life is not engineered, but constrained by evolutionary history. Species adapt to their
environment by natural selection. “Variations of individuals” have an effect on their “habits and
capacities”, and selection acts by the accumulation of some of those variations through
differential survival and propagation [Darwin & Wallace 1858]. Variations of individuals are
explained by genetic variation, and, when it comes to protein-coding sequences, the effect
(function) ultimately relies on protein structure. Thus, selection does not act on sequences, but
on protein structure, and it is restrained by the preexisting diversity of folding architectures.
Functional promiscuity of proteins allows the appearance of new proteins on a similar
structural scaffold [Arnold 2015], giving families and superfamilies of proteins. Evolutionary
divergence in function and neutral amino-acid substitutions may result in proteins that show
very low sequence identity or similarity but belong to the same superfamily; in these cases, their
evolutionary relationship may only be reflected in their structure similarity [Orengo & Thornton
2005]. Besides divergence of a common ancestor, the protein structure similarity may be the
consequence of the convergence of unrelated ancestors since the number of folds physically
possible is limited and the functional capabilities of some structural elements (secondary
structure, folding motifs) fosters their independent recurrence [Orengo & Thornton 2005,
Goldstein 2008]. Uncovering new structures may facilitate the comprehension of the
mechanisms underlying protein folding and protein evolution.
In order to find novel structures or to assign new sequences to an already described
protein superfamily, we should focus on organisms with a higher evolutionary rate. The
evolutionary rate is related to, among other factors, the generation time and the population size.
Species with shorter generation times accumulate more DNA replication errors, which generates
more variability [Weller & Wu 2015]. Variability is also facilitated in larger populations because
they produce more mutations and negative selection of deleterious mutations is less efficient
than in smaller populations [Lanfear et al. 2014]. Furthermore, positive selection is more
effective in larger populations [Lanfear et al. 2014]. Therefore, species with short generation
times and large populations evolve faster and show a higher capability of adaptation to
environmental changes. Considering these two demographic parameters, bacteria and viruses
reveal as evolutionary sprinters.
Besides their demographic features, the simplicity of bacteria and viruses enables lateral
gene exchange (viral recombination and bacterial horizontal gene transfer) as an additional
source of variation. A virus is a molecular parasite that enters into the host cell, uses the host
metabolic machinery to reproduce, and encapsidates its genome to exit; so it can incorporate
fragments from the host genome or a concurring viral genome to its own genome by
recombination. A bacterium is a unicellular organism, so any horizontal gene transfer (mediated
iii

by transformation, conjugation, transduction, gene transfer agents, nanotubes, or membrane
vesicles) to its genome will affect the whole organism and will be heritable and susceptible of
selection. Despite the neutral or deleterious consequences of most bacterial horizontal gene
transfer episodes, this mechanism is especially advantageous in stressful environments [Darmon
& Leach 2014].
A reciprocal evolutionary relationship (coevolution) is established between bacteria and
the viruses that infect bacteria (phages). Antagonistic host-parasite coevolution is the reciprocal
evolution of host defense (bacterial resistance) and parasite infectivity (phage infectivity)
[Buckling & Brockhurst 2012, Scanlan 2017]. Bacterial resistance may thwart the phage
adhesion mechanisms by losing or modifying phage receptors, or producing an extracellular
matrix; which phage evolution counteracts by recognizing new receptors, modifying their
receptor-binding proteins, and producing hydrolases and lyases to break the extracellular
polymers, respectively [Labrie et al. 2010, Buckling & Brockhurst 2012]. Antagonistic
coevolution also explain the appearance of post-entry resistance systems and phage mechanisms
to overcome those systems; the CRISPR-Cas system can be avoided by mutation of the phage
sequence matching the spacer and by anti-CRISPR proteins [Pawluk et al. 2018], the restrictionmodification system is counterbalanced by losing the restriction sites and by methylation and
modification of bases, and the abortive infection systems are circumvented by the expression of
specific proteins for each abortive infection mechanism [Labrie et al. 2010, Buckling &
Brockhurst 2012]. The course of antagonistic coevolution is also affected by genetic
mechanisms such as pleiotropy (deleterious side effect cost of a phage resistance/infectivity
gene), epistasis (effect of a resistance/infectivity gene on other genes) and second-order
selection (acquisition of mutator alleles) [Scanlan 2017]. Antagonistic coevolution may follow
an arms race dynamics (directional selection mediated by recurrent selective sweeps leading to
an increase in both host resistance and phage infectivity) or fluctuating selection dynamics
(continuous fluctuation of phage and bacterial genotypes with different infectivity and
resistance profiles that results from phage adaptation to common bacterial resistance genes
allowing the rise of rare resistance genes) [Buckling & Brockhurst 2012, Scanlan 2017]. The
balance between both dynamics depends on the ecological context that determines
environmental factors such as the dispersion (favors arms race dynamics by increasing the
encounter rate) or the resource supply (favors arms race dynamics by reducing the effect of
epistasis) [Koskella & Brockhurst 2014, Scanlan 2017].
In conclusion, bacteria and phages are two evolutionary fast runners pushing each other.
This competition results in the appearance of novel structural solutions to common
physiological problems that may provide new insights into protein structure architectures. Here,
I focus on proteins involved in phage adsorption to the staphylococcal receptors; these receptor-
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FIGURE 0.1. Diffraction pattern. X-ray diffraction image from a gp146 crystal.

binding proteins are one of the main targets of coevolution and, therefore, they are a promising
object of structural studies.
This thesis presents the results of a structural study on three proteins from phage K
baseplate: gp146, gp144, and gp155. Here I report structural models of crystals built from these
proteins. The main core of the work consisted of the cloning, expression, purification, and
crystallization of the proteins for structure solution. The crystals obtained were used to diffract a
high-quality X-ray beam at a synchrotron radiation facility. In an X-ray diffraction experiment,
a set of diffraction images is collected. These images contain spots (reflections) in a particular
pattern and with specific intensities [FIG 0.1]. In order to generate an atomic-resolution
structural model from this data set, it is required to know the diffraction pattern and the
amplitude (proportional to the square root of the intensity) and phase of the reflections. The
diffraction pattern at a given wavelength is determined by the crystal lattice dimensions and
crystal symmetry (space group), and the amplitude and phase of the reflections depend on the
content of the unit cell. The phase cannot be directly measured in the experiment; instead, it
must be derived either by the iterative comparison of the experimental Patterson map calculated
from the intensities and the theoretical Patterson maps calculated with a similar known protein
structure (molecular replacement), or by the inclusion of heavy atoms in the crystal to produce
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differences in the intensities (isomorphous replacement: SIR (single isomorphous replacement),
MIR (multiple isomorphous replacement); or anomalous scattering: SAD (single-wavelength
anomalous diffraction), MAD (multi-wavelength anomalous diffraction), MIRAS (multiple
isomorphous replacement with anomalous signal), SIRAS (single isomorphous replacement
with anomalous signal)) [Taylor 2010]. The high evolutionary rate of phages hinders the search
of homologous genes whose product-protein structure is solved and increases the requirement of
experimental phasing. In this work, both SAD and molecular replacement were used to solve
the crystal structure of the studied proteins. The structural models presented here contribute to
the elucidation of previous hypotheses on the function and organization of the respective
proteins, which could potentially be applied for bacterial detection and phage engineering.
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1. Introduction and literature review

1. Introduction and literature review

1.1. Staphylococcus aureus and methicillin-resistant Staphylococcus aureus
(MRSA)
Staphylococci are Gram-positive spherical (cocci) bacteria of 0.5 to 1.5 µm in diameter
[FIG 1.1 a] that usually appear as grape-like bunches. They are non-motile, non-spore-forming,
mesophile (they proliferate at temperatures between 291 K and 313 K), and halotolerant (they
can grow at 10% NaCl). Except for two strictly anaerobic species (Staphylococcus
saccharolyticus and Staphylococcus aureus anaerobious), staphylococci are facultative
anaerobes and their metabolism is respiratory and fermentative. Most staphylococci species are
catalase positive and cytochrome oxidase negative. For clinical identification purposes, they are
classified according to their coagulase activity in coagulase-positive (mainly Staphylococcus
aureus)

and

coagulase-negative.

(e.g.,

Staphylococcus

epidermidis,

Staphylococcus

haemolyticus, Staphylococcus saprophyticus). [Becker et al. 2015]
Staphylococci can be found as part of the resident microbiota of the skin and mucous
membranes. Despite being present in asymptomatic individuals, staphylococci may infect their
carriers and even become fatal. According to the WHO mortality database [WHO 2018],
confirmed1 staphylococcal infections accounted for 1467 deaths in the USA during 2015
(0.054% of the annual aggregate of deaths) 2. S. epidermidis is the most abundant species of
staphylococci found in the human body surface, but it is considered an opportunistic nosocomial
pathogen affecting immunocompromised patients and patients with indwelling devices.
However, the clinically most relevant pathogen of the Staphylococcus genera is S. aureus
[Becker et al. 2015].
S. aureus colonizes primarily the anterior nares (30% of humans are either permanent or
intermittent carriers of S. aureus) and can be transferred to other areas of the skin, especially the
perineum and axillae [Becker et al. 2015]. Its pathogenicity is enhanced by the formation of
biofilms and several virulence factors, such as adhesins, enzymes, and toxins. Diseases caused
by S. aureus include infections (superficial, deep and systemic) and toxin-mediated syndromes.
S. aureus is the main etiologic agent of bacteremia, infective endocarditis, osteomyelitis, septic
arthritis, prosthetic joint infections, skin and soft tissue infections (like impetigo, furuncles, and
1
2

In 2015, 38074 deaths (1.40% of the yearly total) were attributed to unspecified sepsis in the USA
[WHO 2018], some of these cases might have been caused by Staphylococcus spp and were not
included in the data.
In order to put this datum in perspective, here are the data of some other causes of death
corresponding to the same period and country (in brackets, number of deaths and percentage of the
annual aggregate): tuberculosis (470 – 0.017%), cystic fibrosis (489 – 0.018%), thyroid cancer (1894
– 0.07%), influenza virus (5251 – 0.19%), HIV (6465 – 0.24%), chronic viral hepatitis C (6744 –
0.25%), enterocolitis due to Clostridium difficile (7410 – 0.27%), motor neuron disease including
amyotrophic lateral sclerosis (8166 – 0.30%), breast cancer (41987 – 1.55%), bronchus and lung
cancer (153722 – 5.67%), atherosclerotic heart disease (163786 – 6.04%) [WHO 2018].
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FIGURE 1.1. Staphylococcus aureus. (a) S. aureus strain RN4220 ΔspAspA imaged by phase-contrast
microscopy. Scale bar 1 µm. (b) Diagram of the organization of the non-proteic components of the cell
envelope of S. aureus. WTA, wall teichoic acid; LTA, lipoteichoic acid.

cellulitis), pleuropulmonary infections, and device-related infections [Tong et al. 2015]. The
incidence and severity of the infections caused by S. aureus depends on the affected organs 3.
The main toxin-related diseases caused by S. aureus are acute food poisoning (due to
consumption of food contaminated with enterotoxins), toxic shock syndrome (caused by the
production of toxic shock syndrome toxin-1 or staphylococcal enterotoxin B or C), and scalded
skin syndrome (due to exfoliative toxins A and B) [Becker et al. 2015, Berkowitz & Jerris
2015].
3

S. aureus bacteremia has an incidence of 10 to 30 per 100,000 person-years, and 15 to 50% of those
cases are fatal. S. aureus vertebral osteomyelitis has an incidence of 2.5 per 100,000 person-years and
a mortality rate of 6 to 16%. Septic arthritis attributed to S. aureus has an incidence of 1.5 to 7.6 per
100,000 person-years. S. aureus infective endocarditis has an incidence of 0.24 to 2 per 100,000
person-years, and a mortality rate of 22 to 66%. S. aureus also accounts for 40% of health-careassociated pneumonia and 3% of community-acquired pneumonia. S. aureus is responsible for 4.9 to
6.4% of bacterial meningitis. S. aureus toxic shock syndrome has an incidence of 0.32 per 100,000
person-years. [Tong et al. 2015]
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Penicillin G was the initial treatment for S. aureus, but soon resistance appeared due to
the enzyme penicillinase/β-lactamase, encoded by blaZ gene. The blaZ gene is usually located
in a plasmid transposon, which favored the spread of the resistance. β-Lactamase-producing
strains were subsequently treated with β-lactamase-resistant penicillins: methicillin, cloxacillin,
and nafcillin. The use of these modified penicillins led to the emergence of resistant strains,
primarily in hospitals, although resistance has also reached community and livestock strains.
Methicillin-resistant Staphylococcus aureus (MRSA) refers to strains insensitive to all βlactams, whose resistance is mediated by the production of an additional penicillin-binding
protein: PBP2a (encoded by the mecA gene) [Peacock & Patterson 2015]. The mecA gene is
located in the staphylococcal chromosome cassette mec (SSCmec), in which the mecA gene
expression is controlled by mecI (encoding the repressor protein) and mecR1 (encoding the
signal transducer protein) [IWG-SSC 2009]. The SSCmec is a mobile element flanked by direct
repeat sequences that enable the specific integration into the bacterial genome by the cassette
chromosome recombinases (encoded in the SSCmec) [IWG-SSC 2009]. Vancomycin is the
preferred treatment to MRSA, though resistant strains have already been identified [Becker et
al. 2015].
Most of the antibiotics utilized to treat S. aureus infections target its cell envelope. S.
aureus is a Gram-positive bacterium; therefore, its cell envelope consists of a lipid membrane
and a thick cell wall of peptidoglycan with teichoic acids [FIG 1.1 b]. The peptidoglycan layer
is composed of chains of the disaccharide N-acetylglucosamine (β1→4) N-acetylmuramic acid.
The N-acetylmuramic acid is bound to a stem pentapeptide composed of L-Ala-γ-D-Glu-L-LysD-Ala-D-Ala which is cross-linked to another stem pentapeptide by a pentaglycine bridge
between 3 L-Lys and 4 D-Ala. The synthesis of the peptidoglycan layer begins in the
intracellular side of the membrane with the stepwise formation of the disaccharide-pentapeptide
units bound to an undecaprenyl phosphate, giving lipid II. Lipid II is translocated to the external
side of the membrane by the flippase MurJ [Taylor et al. 2017]. The addition of the
disaccharides to the nascent peptidoglycan chain (transglycosylation) and the cross-linking
(transpeptidation) are carried out by monofunctional transglycolases (SgtA and MGT) and
penicillin-binding proteins (PBPs) 1 to 4 4 [Rajagopal & Walker 2017]. Transpeptidation is the
target of vancomycin and β-lactam antibiotics. Vancomycin binds to and blocks the D-Ala-DAla end of the pentapeptide stem. β-Lactam antibiotics are analogs to the D-Ala-D-Ala and
covalently bind to and block the transpeptidase site of the PBPs; especially PBP2, although
some β-lactam antibiotics target specifically other PBPs 5 [Foster 2019]. MRSA strains express
4
5

PBP1 is a transpeptidase involved in the initiation of the peptidoglycan synthesis, PBP2 elongates the
peptidoglycan chain by a dual transglycosylase and transpeptidase activity, PBP3 (FtsI) is a
transpeptidase at the division septum, and PBP4 completes the cross-linking of the peptidoglycan.
Carbapenems target PBP1, cephalexin and piperacillin target PBP3, and cefotoxin targets PBP4.
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an additional PBP: PBP2a. PBP2a does not bind β-lactam antibiotics because the transpeptidase
site is hidden in a groove that opens after allosteric activation. PBP2a-mediated resistance can
be overcome by the fifth-generation cephalosporin ceftaroline fosamil, which activates the
allosteric binding site. In addition, the adequate disposition of PBP2a depends on functional
membrane microdomains, the divisome and wall teichoic acid, so inhibitors of these elements
act synergistically with β-lactams [Foster 2019].
Combinations of β-lactam antibiotics with other available drugs have been proven
effective against MRSA [Foster 2019] if the clinical management of the infection is appropriate.
Furthermore, the implementation of improved health-care hygiene protocols has led to a
decrease in the proportion of hospital-associated MRSA infections [Hassoun et al. 2017].
Despite the apparent epidemiological control of MRSA, research on alternative treatments
against S. aureus infections has been developed in prevision of a resistance wave. Among the
research efforts to find new agents against MRSA, phage therapy has drawn attention due to its
potential efficacy. This work is set within the research efforts to use phages against MRSA.
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1.2. Antibiotic resistance and phage therapy
The emergence of antibiotic resistance in S. aureus is not an exceptional event but a
generalized trend in clinical microbiology. The acquired resistance mechanisms arise from
adaptation by natural selection [Holmes et al. 2016]. Alteration of the “physical conditions in
the district” (environmental conditions) of a population would favor the survival and
propagation of the most fit individuals, resulting in a more adapted population [Darwin &
Wallace 1858], or the extinction of the population. Thus, the presence of an antibiotic in an
infecting population of bacteria would lead to the appearance of resistance or the disappearance
of the pathogenic population (i.e., healing). The generalized use and abuse of antibiotics in
human and veterinary medicine and food production have favored the emergence of antibioticresistant strains [Holmes et al. 2016] that challenge public health.
Bacteria may acquire antibiotic resistance by horizontal gene transfer of resistance
genes and by mutations on genes encoding the antibiotic target, transporters of the antibiotic,
regulators of modifying enzymes, and efflux pumps [Martinez 2014]. Resistance mechanisms
include the decrease of the concentration of antibiotic (by reduced permeability or increased
efflux), the inactivation of the antibiotic (by hydrolysis or chemical modification) and the
modification or protection of the target [Blair et al. 2015]. Additionally, transient changes in
bacterial physiology may also confer phenotypic resistance to antibiotics [Martinez 2014]; this
is the case of biofilms, in which the extracellular matrix hinders the diffusion of the antibiotics
and the low metabolic activity of the embedded bacteria limits their action.
The emergence of antibiotic resistance must be addressed by optimization of the clinical
management of the bacterial diseases (improving the diagnosis and reducing the prescription of
antibiotics) and by the development of new antimicrobials [Holmes et al. 2016]. Several
alternative treatments have been proposed to fight antibiotic resistance. In the short term, the
most realistic alternative treatments are antibodies, probiotics, and vaccines; whilst the
feasibility remains unclear for other therapeutic approaches such as immune stimulation,
antimicrobial peptides, lysins, and phage therapy [Czaplewski et al. 2016].
Bacteriophages (phages) are viruses that infect bacteria. Phages specifically recognize
their host, they attach to the bacterial surface, and those of the Caudovirales order inject their
genome into the host cell. After entry, phages can either replicate using the host’s molecular
machinery and release the progeny by lysis (lytic cycle) [FIG 1.2] or remain dormant (lysogenic
cycle) as prophages (integrated into the host genome or as a plasmid) [Guttman et al. 2005].
Phages can be strictly lytic (virulent) or lysogenic (temperate). The capability of virulent phages
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FIGURE 1.2. Life cycle of phage K. Phage K attaches to the staphylococcal cell envelope by its
baseplate and injects its genome inside the host after tail contraction. Using the host's molecular
machinery, the phage genome is replicated and transcribed, and the coding transcriptome is translated.
Copies of the genome are packaged into capsids and the tails are assembled. Mature virions are released
from the host by lysis mediated by holins and lysins. Review of phage life cycle in [Guttman et al. 2005].

to destroy their host points to their usability in treating bacterial pathogens. In fact, soon after
their discovery [Twort 1915], the therapeutic application of phages was suggested [d’Herelle
1917] and implemented to treat bacterial diseases such as dysentery [d’Herelle 1931]. However,
the development of antibiotic-based treatments in the 1940s [Mohr 2016] rendered phage
therapy obsolete in western countries and the practice of phage therapy was only continued in
the Soviet Union. Currently, most of the phage therapy practice is circumscribed to the Eliava
Institute of Bacteriophages, Microbiology and Virology (Tbilisi, Georgia) and, to a lesser extent,
the Hirszfeld Institute of Immunology and Experimental Therapy (Wrocław, Poland) [Kutter et
al. 2010].
Two main methods have been applied in phage therapy: the administration of phage
cocktails and the phage bank strategy [Kutter et al. 2010]. The phage cocktails, used in the
Eliava Institute, consist of a mix of phages that targets a cohort of pathogenic bacteria. In the
phage bank approach, applied in the Hirszfeld Institute, one or more lytic phages from a phage
collection are selected for their activity against a bacterial isolate from an individual patient.
Published data showed both methodologies to be effective, though the use of phage cocktails is
more extended because of the higher activity of the Eliava Institute in phage therapy.
7
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Most of the advantages of phage therapy are intrinsic to the functional properties of
phages [Kutter et al. 2010, Kakasis & Panitsa 2019]:
•

Phage infection of bacteria is independent of the mechanisms of action of antibiotics.
Therefore, phage therapy can act synergistically with antibiotics and antibiotic
resistance does not affect their effectiveness.

•

The self-replicating nature of phages favors the maintenance of the optimal
concentration on the bacterial infection focus, avoiding the local exhaustion of the
antibacterial agent by consumption.

•

Host specificity allows the elimination of the target pathogen minimizing the impact on
the healthy microbiota.

•

Phages typically show low toxicity against the patient, which is explained by their
specificity and the clearance by the reticuloendothelial system.

•

Phages usually contain enzymes that degrade extracellular components of the bacteria
[Labrie et al. 2010] and make them relatively effective against biofilms.

•

As biological entities, phages are subject to evolution, so bacterial resistance to phage
infection may be overcome in natura (by obtaining a new isolate) or in laboratory (by
multiple passages on the resistant bacterial strain).
Molecular biology techniques allow the engineering of phages to enhance their

performance as therapeutics and avoid some inconveniences. Thus, synthetic biology has
enabled the amelioration of the synergy with antibiotics, the use of phages for the delivery of
antibiotic-sensitizing genes, the improvement of the activity against biofilms, host range
modification, immunogenicity reduction, and the increase of resistance to clearance [Pires et al.
2016]. In addition, phage engineering broadens the availability of phages suitable for therapy by
converting temperate phages into virulent [Monteiro et al. 2019].
Nevertheless, there are still some concerns around phage therapy [Kutter et al. 2010,
Kakasis & Panitsa 2019]:
•

Phages generate an immune response and can be neutralized by antibodies and removed
by the reticuloendothelial system, limiting their effectiveness in systemic applications.

•

Phage therapy acts by the lytic activity of phages on the bacteria, which may release
toxins from the bacteria and cause septic shock.

•

The risk of a septic shock may also derive from traces of toxins from the production
host if the purification of phages is deficient.

•

Bacteria develop resistance to phage infection and the complexity of the phage infection
cycle offers the bacteria more chances of resistance by targeting phage adsorption
(modification of the receptors, production of an extracellular matrix), phage DNA entry
8
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(superinfection exclusion), the phage genome (restriction-modification and CRISPRCas systems) or the infected-host integrity (abortive infection systems) [Labrie et al.
2010].
•

Phages mediate transduction (a bacterial horizontal gene transfer mechanism), which
may mobilize virulence or resistance genes. This mechanism is usually very infrequent;
except for S. aureus because of the presence of a specific kind of phage-induced mobile
genetic elements known as SaPIs (S. aureus pathogenicity islands) [Torres-Barceló
2018].

•

Coevolution of phage and bacteria might increase diversity in the bacterial population
[Koskella & Brockhurst 2014], making the management of the infection more complex.

•

Approval and licensing requirements for every single phage therapy treatment raise
concerns on their profitability for the traditional pharmaceutical industry, especially
considering that the specificity and the emergence of resistance would limit the
applicability and commercial lifespan of the product. This might be overcome by the
production of the phage treatment at the point of care, but the aforementioned risk of
containing toxins would impose very stringent quality controls and regulations.
Despite all the limitations and disadvantages of phage therapy compared to

chemotherapy, phage therapy is still very convenient as last resource treatment for infections
resistant to conventional antimicrobials, although the practicality of its generalized usage is yet
doubtful.
The structural study of the receptor-binding proteins facilitates the engineering of
phages that would improve the collections of phages available for therapies based on phage
banks.
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1.3. Phage adsorption to Gram-positive hosts
Phage adsorption initiates the infection of the host cell. Since it is the first contact with
the bacteria, adsorption is the earliest mechanism of specificity. Adsorption usually entails two
steps: reversible recognition of the host and irreversible attachment to the bacterial surface
[Dunne et al. 2018]. These two steps may involve distinct receptors and receptor-binding
proteins, or different interactions between the same receptor and receptor-binding protein.
Most known phages belong to the Caudovirales order. Caudoviruses possess a tail that
can be either long and contractile (Myoviridae), long and non-contractile (Siphoviridae), or
short and non-contractile (Podoviridae) [Veesler & Cambillau 2011]. The adsorption machinery
is usually located at the distal end of the tail and it may be organized in specialized frameworks
(tail fibers or a baseplate) that orchestrate the proper disposition of the receptor-binding
proteins. The receptor-binding proteins are modular homotrimeric proteins attached to the phage
particle by the amino-terminal domain, whereas the carboxy-terminal domain binds to the hostcell surface [Nobrega et al. 2018]. The modular organization allowed the productive
evolutionary exchange of modules, resulting in functional receptor-binding proteins with
different binding properties [Dunne et al. 2018]. According to their shape, the receptor-binding
proteins are classified as spikes (short proteins that often carry enzymatic activity) or fibers
(long proteins without enzymatic activity) [Nobrega et al. 2018].
Due to their industrial impact, most of the described receptor-binding proteins of Grampositive phages are those of lactococcal siphoviruses. The adsorption apparatus of lactococcal
siphoviruses consists of a baseplate that usually harbors lysin proteins and receptor-binding
proteins arranged around a central hexamer of the Dit protein [Dowah & Clokie 2018]. Some
baseplates are assembled in the active conformation (e.g. lactococcal phage TP901-1 baseplate),
whilst other baseplates must undergo a conformational change to achieve the active position of
their receptor-binding proteins. The conformational change may be Ca 2+-dependent (e.g.
lactococcal phage P2) or Ca2+-independent (e.g. lactococcal phage 1358) [Dunne et al. 2018].
The receptor-binding proteins of lactococcal siphoviruses are organized in a carboxy-terminal
head domain (host-binding), a neck domain (linker), and an amino-terminal stem and
(optionally) shoulder domains (particle-binding) [Legrand et al. 2016] [FIG 1.3]. However, this
arrangement is not common to the receptor-binding proteins of siphoviruses that infect other
Gram-positive bacteria, such as S. aureus phage ϕ11 [Koç et al. 2016] [FIG 1.3].
The host receptors of Gram-positive phages can be proteins, peptidoglycan, and teichoic
acids. Receptor-binding proteins that interact with protein receptors are usually sharp-shaped
and interact with high affinity, so a single receptor-binding trimer per phage suffices for binding
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FIGURE 1.3. Receptor-binding proteins of Gram-positive phages. Structure of the receptor binding
proteins from lactococcal phage TP901-1 (PDB:id 3U6X [Veesler et al. 2012]), lactococcal phage P2
(PDB:id 4V5I [Sciara et al. 2010]), and staphylococcal phage φ11 (PDB:id 5EFV [Koç et al. 2016]).

(e.g., Bacillus subtilis phage SPP1), whilst the lower affinity to saccharide receptors is typically
compensated by the synergistic binding of multiple receptor-binding complexes [Dowah &
Clokie 2018]. A special type of protein-mediated adsorption is that to the flagellum (e.g., B.
subtilis phage PBS1), which increases the chances of encountering the host and takes advantage
of the flagellar rotation to transport the phage particle to the cell surface [Dunne et al. 2018].
Gram-positive bacteria possess a thick layer of peptidoglycan, whose components may
also act as receptors for phages (e.g. Clostridium phage α2 interacts with N-acetylglucosamine
and N-acetylmuramic acid, Bacillus thuringiensis phage Bam35 binds to N-acetylmuramic
acid). Additionally, some phages use peptidoglycan as co-receptor (e.g., Listeria phage A511, S.
aureus phage ϕ11) [Dunne et al. 2018].
Possibly, the most frequent receptors of phages infecting Gram-positive bacteria are
teichoic acids. Besides the peptidoglycan, teichoic acids are the other major component of the
cell wall, representing up to 60% of the cell wall mass [Brown et al. 2013, Caveney et al. 2018].
Teichoic acids are covalently attached to the cell envelope; either to the peptidoglycan (wall
teichoic acids) or to membrane lipids (lipoteichoic acids) [FIG 1.1 b]. S. aureus wall teichoic
acid consists of a poly(ribitol 5-phosphate) chain bound to a N-acetylmuramic acid of the
peptidoglycan by a linker of two glycerol 3-phosphate molecules and the disaccharide Nacetylmannosamine (β1→4) N-acetylglucosamine 1-phosphate [Brown et al. 2013] [FIG 1.4 a],
whilst the lipoteichoic acid is a poly(glycerol 3-phosphate) chain linked to a membrane
diacylglycerol by a gentiobiose disaccharide [Reichmann & Gründling 2011] [FIG 1.4 b]. Both
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FIGURE 1.4. Structure of teichoic acids. (a) Chemical structure of the wall teichoic acid. ManNAc, Nacetylmannosamine; GlcNAc, N-acetyl-glucosamine; PG, pepdtidoglycan. Y = D-alanine; X = α- or β-Nacetylglucosamine. (b) Chemical structure of the lipoteichoic acid. DAG, diacylglycerol. Z = D-alanine
or N-acetylglucosamine.
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acetylglucosamine. Functionally, teichoic acids are essential for S. aureus viability, though wall
teichoic acids are dispensable in vitro. Teichoic acids are involved in cell division, cation
homeostasis, phage binding, protein scaffolding and location (including PBPs and lysins),
resistance to β-lactams, host immune evasion, and adhesion [Brown et al. 2013, Rajagopal &
Walker 2017].
Due to their more exposed location [Reichman 2011, Brown et al. 2013], wall teichoic
acids are the predominant receptors for phages infecting Gram-positive bacteria, although the
lipoteichoic acids have also been identified as receptors for some phages, such as Lactobacillus
phage LL-H [Räisänen et al. 2004].
Whereas lipoteichoic acids are polymerized on the external surface of the membrane by
a single enzyme (LtaS) that adds glycerol 3-phosphate units from phosphatidylglycerol
[Reichmann 2011], wall teichoic acids are fully synthesized inside the cell by a multi-step
pathway. The synthesis of wall teichoic acids is initiated by TarO, which transfers an Nacetylglucosamine-1-phosphate to an undecaprenyl phosphate carrier. In S. aureus, TarA, TarB,
and TarF sequentially incorporate an N-acetylmannosamine and two glycerol 3-phosphate,
respectively, to complete the linker and, subsequently, TarL polymerizes the ribitol 5-phosphate
backbone [Brown et al. 2013]. There are other accessory enzymes that provide the active units
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1. Introduction and literature review

of the molecule: MnaA produces UDP-N-acetylmannosamine for TarA, TarD synthesizes CDPglycerol used by TarB and TarF, and TarI and TarJ generate CDP-ribitol for TarL [Brown et al.
2013]. The glycosylation of the poly(ribitol 5-phosphate) chain is catalyzed by TarM or TarS,
which add α-O-N-acetylglucosamine or β-O-N-acetylglucosamine, respectively, to the position
C4 [Caveney et al. 2018]. The TarS β-glycosylation is required for MRSA [Brown et al. 2012],
but it can be substituted by an alternative glycosyltransferase (TarP) that incorporates a β-Nacetylglucosamine in position C3 [Gerlach et al. 2018]. After glycosylation, the wall teichoic
acid is translocated to the surface by ABC transporter formed by TarG and TarH [Taylor et al.
2017]. On the cell surface, wall teichoic acids are D-alanylated (which requires the DltABCD
proteins and a previous D-alanylation of the lipoteichoic acid [Reichmann et al. 2013]) and they
are attached to the peptidoglycan by the LytR-CpsA-PsR (LCP) family of enzymes [Caveney et
al. 2018].
Wall teichoic acids are the receptors for most Gram-positive phages including
podoviruses (e.g., phage 44AHJD) [Li et al. 2015], siphoviruses (e.g., phage ϕ11) and
myoviruses (phage K and its related phages) [Xia et al. 2011]. Alterations on the anabolic
enzymes of wall teichoic acids affect their composition and determine phage adsorption and
infectivity. Bacteria lacking wall teichoic acid by deletion of tarO or tarA, are resistant to the
infection of all phages that use wall teichoic acids as receptors [Xia et al. 2011, Li et al. 2015].
Deregulation of the glycosyltransferases resulting in lack of α-O-N-acetylglucosamine or β-ON-acetylglucosamine decorations prevents the infection by staphylococcal siphoviruses [Xia et
al. 2011] or podoviruses [Li et al. 2015] respectively; whilst the infectivity of staphylococcal
myoviruses (phage K) was not affected by these modifications.
This study focuses proteins involved in the recognition and attachment of phage K to
staphylococci, which might clarify the adsorption mechanisms.
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1.4. Phage K
Phage K (species Staphylococcus virus K, genus Kayvirus, subfamily Spounavirinae,
family Myoviridae, order Caudovirales; NCBI:txid 221915) is a virulent bacteriophage that
infects a broad range of staphylococci, including some strains of MRSA [O’Flaherty et al.
2004]. These features have encouraged the research on this phage due to its therapeutic potential
against antibiotic-resistant strains of S. aureus.

1.4.1. Biology and applications of phage K
Phage K is the “polyvirulent highly active antistaphylococcus phage” used by Krueger
and Northrop in their experiments on bacterial lysis kinetics [Krueger & Northrop 1930]. It is a
stable phage with a strictly lytic cycle (isolated from non-lysogenic staphylococci) and it was
ascribed to the serological group D [Rountree 1949, Rippon 1956]. Early studies on the phagehost DNA dynamics showed the typical behavior of a virulent virus: host DNA-synthesis
inhibition, degradation, and reincorporation to the newly-synthesized phage DNA [Rees & Fry
1981].
The phage K genome consists of a single linear double-stranded DNA of 148,317 bp
(NCBI:RefSeq NC_005880.2 [Gill 2014]). According to the current RefSeq database [O’Leary
et al. 2016] annotation, phage K genome contains 233 open reading frames. Like other phages,
the phage K genome is arranged in functional modules, encoding cell lysis proteins (endolysin,
holin), structural proteins [FIG 1.5], and DNA replication and transcription components
[O’Flaherty et al. 2004]. In addition, phage K DNA includes four tRNA genes: Met-tRNA, TrptRNA, Phe-tRNA, and Asp-tRNA [O’Flaherty et al. 2004, Gill 2014]. As result of antagonistic
coevolution with its host, phage K genome is relatively resistant to S. aureus restrictionmodification systems by lacking the restriction target-sequences: its genome does not include
any GATC sites (recognized by Sau3A1), and it only contains one GGNCC site (recognized by
Sau96I) [O’Flaherty et al. 2004].
Several lytic staphylococcal myoviruses have been isolated and their genomic sequence
evidenced that most of them are related to phage K. A BLASTN (BLASTN 2.8.0+ [Zhang et al.
2000]) of phage K genome on the RefSeq Representative Genomes database identified 12
annotations of phage genomes with an identity > 95% and a coverage > 82% [TABLE 1.1]; nine
of these annotations are currently recognized as Kayvirus species by the International
Committee on Taxonomy of Viruses [Lefkowitz et al. 2018]. However, a BLASTN (BLASTN
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FIGURE 1.5. Phage K structural genes. Representation and assignment of the genome module
encoding the structural proteins of phage K. The genes labeled are those encoding proteins identified as
structural by a mass-spectrometry analysis on the virion (Supplementary material of [Novacek 2016]).
The genes encoding the proteins studied in this thesis are in bold. The position in the genome is according
to the annotation NC_005880.2.

2.8.0+ [Zhang et al. 2000]) including non-curated databases (Nucleotide collection nr/nt
database) detected 40 “different” phages related 6 to phage K.
Wall teichoic acid is the primary receptor of phage K since S. aureus ΔtarO strains are
resistant to phage K infections [Xia et al. 2011]. In contrast to other staphylococcal phages, S.
6

Excluding variants or partial sequences of the same phage, the BLASTN on a non-curated database
identified 40 annotations with an identity > 91% and a coverage > 57%; 37 of those annotations have
an identity > 95% and a coverage > 82%. The “different” staphylococcus phages detected were: 812,
676Z, Staph1N, A5W, Fi200W, P4W, B1, MSA6, vB_SauM-fRuSau02, JA1, A3R, HYZ21,
vB_SauM_0414_108, G1, ISP, IME-SA119, Team1, IME-SA2, pSa-3, SA5, IME-SA1, IME-SA118,
JD007, Sb-1, phiSA012, phiSA039, vB_Sau_CG, vB_SauM_LM12, S25-3, phiIPLA-RODI,
qdsa002, GH15, MCE-2014, S25-4, P108, HSA30, VB_SavM_JYL01, vB_Sau_Clo6, vB_Sau_S24,
and pSco-10.
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TABLE 1.1. Phages similar to phage K. Highest score results of a BLASTN of phage K genome on the
RefSeq Representative Genomes database. (*)Phages recognized as a different species by the
International Committee on Taxonomy of Viruses [Lefkowitz et al. 2018].

aureus ΔtarM and/or ΔtarS strains are susceptible to phage K infection and, therefore,
glycosylations of wall teichoic acid do not affect the binding of phage K [Xia et al. 2011, Li et
al. 2015]. Nevertheless, three point mutations on a receptor-binding protein of a phage closelyrelated to phage K can hamper its binding to S. aureus strains with wall teichoic acid decorated
with α-N-acetylglucosamine [Takeuchi et al. 2016]. Phage K does not adsorb to lipoteichoic
acids since depletion of lipoteichoic acids does not affect its infectivity [Xia et al. 2011].
Altogether, these experiments have shown that the binding of phage K to S. aureus is more
resistant to wall teichoic acid modifications than the binding of staphylococcal siphoviruses and
podoviruses, which explains the wider host-range of phage K and makes it the preferential
choice in S. aureus phage therapy studies.
Phage K has a wide host spectrum of both coagulase-positive and coagulase-negative
staphylococci [Rountree 1949], including several MRSA strains [O’Flaherty et al. 2005c]. Tests
for sensitivity to phage K on S. aureus strains (both clinical and veterinary isolates) result
positive for over 80% of the strains [Kelly et al. 2011, Freyberger et al. 2018]. Resistance to
phage K infection can be easily overcome by multiple passages on the phage-resistant strains,
which circumvents both restriction-modification mechanisms [Kelly et al. 2011] and adsorption
inhibition [Takeuchi et al. 2016]. The translation of these results to the therapeutic practice may
16
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depend on the environment of application; phage K is active in hand-wash solutions and
bismuth-based creams [O’Flaherty et al. 2005c], but its activity is inhibited by raw milk
[O’Flaherty et al. 2005a]. Other promising features of phage K as therapeutic are its limited
effect on the induction of inflammatory responses [Freyberger et al. 2018], and its potential
against biofilm-embedded bacteria. Phage K and cocktails based on phage K have been
consistently demonstrated effective in removing biofilms of laboratory [Kelly et al. 2012] and
clinical [Alves et al. 2014] strains of S. aureus, including MRSA, and biofilms of clinical strains
of S. epidermidis [Cerca et al 2007]. An additional study has shown its efficacy in reducing
biofilm formation on central venous catheter material [Lungren et al. 2013]. Collectively, these
data support the suitability of phage K as central species for staphylococcal phage therapy. A
commercial preparation of phage K and closely related phages, Stafal® (Bohemia
Pharmaceuticals s.r.o., Prague, Czech Republic), is already available to treat and prevent
staphylococcal infections and it has also been reported effective in eliminating staphylococcal
biofilms [Dvořáčková et al. 2019].
Besides the therapeutic use of phage K, the endolysin encoded in phage K genome
might also be utilized as a treatment against staphylococcal infections; since, when expressed
heterologously, it can inhibit pathogenic strains of S. aureus (including MRSA) [O’Flaherty et
al. 2005b]. In addition, a stable amino-terminal catalytic domain of the endolysin [Horgan et al.
2009] can lyse staphylococci and other Gram-positive bacteria [Fenton et al. 2011] and it has
been proven effective in eliminating S. aureus from mice nares [Fenton et al. 2010].

1.4.2. Structure of the phage K virion
Phage K is a myovirus; hence, the phage K virion is composed of an icosahedral head
and a long contractile double-layered tail. At the end of the tail, a baseplate is responsible for the
attachment to the host cell wall [FIG 1.6 a].
The morphology of the phage K virion was initially studied by metal shadowing
electron microscopy. According to the first description, the particle consisted of a “round head”
of 50-60 mµ (nm) in diameter and a “long slender tail” of 200-250 mµ (nm) in length [Smiles et
al. 1948]. Further electron microscopy analysis on the virion evidenced the double-layered
nature of the tail and the presence of a tail terminal “bob” [Hotchin 1954]. Improved electron
microscopy studies and the use of negative staining led to the identification of an icosahedral
head and a long contractile tail ending in a baseplate; this structural organization resembled that
of the T-even phages of Escherichia coli [Rees & Fry 1981] which allowed the allocation of
phage K to the Myoviridae family. Analyses performed on micrographs of other spounaviruses
described the baseplates of this subfamily of myoviruses as “double-layered baseplates that
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resemble a Victorian side table thick legs” and this morphology has been associated with the
presence of a VrlC-like protein [Habann et al. 2014].
In 2016, Nováček et al. published a detailed cryo-electron microscopy (cryo-EM) study
on phi812 (Staphylococcus phage 812, NCBI:txid 307898; unclassified kayvirus). Phi812 is
closely related to phage K (arguably the same species); they share 99% of genomic sequence
identity on a 99% cover (BLASTN 2.8.0+ [Zhang et al. 2000]) and 99% to 100% of sequence
similarity of proteins identified as virion proteins by a mass spectrometry analysis
(Supplementary material of [Nováček et al. 2016]). Therefore, it is adequate to assume that the
structure described for phi812 virion is identical to that of the phage K virion.
The phi812 head consists of an isometric T=16 icosahedral capsid of 90 nm in diameter
that encloses the packaged genome. The asymmetrical unit of the capsid 7 includes 16 copies of
the major capsid protein (phage K gp173) and five and one-third copies of the cement protein
(phage K gp110). The 5.1-Å resolution cryo-EM density map of the capsid allowed the
construction of atomic-resolution models for both proteins [Nováček et al. 2016]. The major
capsid protein [FIG 1.6 b] comprises the HK97 capsid fold [Wikoff et al. 2000] (typical of tailed
bacteriophages) and an additional insertion domain that protrudes on the external surface of the
capsid. The cement protein [FIG 1.6 b] stabilizes the capsid by interacting with the insertion
domain of the major capsid protein. This arrangement diverges from other caudoviruses; the
HK97 capsid is stabilized by covalent isopeptide bonds between major capsid proteins [Wikoff
et al. 2000] and the T4 insertion domain interacts directly with other major capsid proteins and
vertex proteins [Chen et al. 2017].
The vertex of the capsid linked to the tail displays a connector complex instead of the
regular pentamer of major capsid proteins. According to the low-resolution cryo-EM maps
obtained for this area [FIG 1.6 c], the connector complex is composed of a portal complex, a
gateway complex, whisker proteins and neck proteins [Nováček et al. 2016]. The portal
complex is located in place of the major capsid proteins of the vertex, expanding to the interior
of the capsid, and resembles the portal structure from other myoviruses [Sun et al. 2015]. The
gateway complex is assembled between the portal complex and the neck proteins, which, in
turn, join the connector complex to the tail tube and the domain IV of the tail sheath. An
additional electron density, assigned as whisker proteins, is surrounding the neck proteins in the
native conformation, but it disappears after tail contraction. In the contracted conformation, the
portal complex shows twelve-fold symmetry and the rest of the connector six-fold symmetry;
this contrasts with the five-fold symmetry of the icosahedral vertex. In the native conformation,
both the portal and the gateway complex adapt to the pentagonal shape of the vertex, so the
7

The icosahedral capsid consists of 60 asymmetrical units. All asymmetrical units are equal except for
those contacting the vertex linked to the tail.
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FIGURE 1.6. Phage K virion structure. (a) Diagram of phage K virion organization. (b) Capsid. On the
left, cryoEM map of the phi812 capsid (EMDB:id 8304 [Nováček et al. 2016] with the contouring
threshold level recommended by authors: 4.00). On the right, structure of phi812 major capsid protein
(PDB:id 5LII [Nováček et al. 2016]), consisting of the HK97 fold (green) and an insertion domain (red),
and phi812 cement protein (blue) (PDB:id 5LIJ [Nováček et al. 2016]). The major capsid protein gp23
from T4 (PDB:id 5VF3 [Chen et al. 2017]) is aligned (grey ribbon) on the HK97 fold. ( c) Cross-sections
of the connector. From left to right: native connector (EMDB:id 8201, contour level: 1.60 [Nováček et al.
2016]), contracted connector with full capsid (EMDB:id 8204, contour level: 1.60 [Nováček et al. 2016]),
and contracted connector with empty capsid (EMDB:id 8207, contour level: 1.80 [Nováček et al. 2016]).
(d) Tail. On the left, representation of a disk of the native tail tube (blue) and sheath (green) (PDB:id 5LI2
[Nováček et al. 2016]) and a disk of the contracted tail sheath (red) (PDB:id 5LI4 [Nováček et al. 2016]).
On the right, representation of a monomer of the native tail tube (blue) and tail sheath (domains I-yellow,
II-cyan, III-green, IV-orange). The structure of the tail sheath gp18 from T4 (PDB:id 3FOA [Aksyuk et al.
2009]) is displayed (grey ribbon) fitted on domain III.

symmetry mismatch is resolved by an asymmetry in the gateway-neck junction, which appears
to be related to the asymmetric binding of the phage DNA to one of the gateway subunits
[Nováček et al. 2016].
Tail contraction triggers the ejection of the genome through the connector complex
[Nováček et al. 2016]. The conformational change of the tail sheath propagates through the neck
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proteins and cause the DNA to detach from the gateway subunit. Then, the alteration of the tail
tube disrupts the neck-tube constriction and allows the genome ejection.
The phi812 tail is made up of an internal tube and an external sheath. Atomic-resolution
structural models of both elements have been modeled to low-resolution from the cryo-EM
maps of the native and contracted tail [Nováček et al. 2016]. The tail tube is built of piled disks
of six tail tube proteins (phage K gp165) organized into a six-entry helix. Alike T4 phage tailtube protein, phage K tail-tube protein is a six-stranded β-barrel topped by two α-helices from
the cap loop [FIG 1.6 d], which interacts with other tail tube proteins from the same and
consecutive disks. In native conformation, the axes of the β-barrels from the same disk lie on an
orthogonal plane to the sixfold axis of the tail, but they are rotated 50º after genome ejection
[Nováček et al. 2016].
The 202-nm-long native tail sheath of phi812 is formed by hexameric disks of the tail
sheath protein (phage K gp166) with the same helical arrangement as the tail tube. The tail
sheath protein consists of four domains similar to those of phages T4 [Aksyuk et al. 2009] and
phiKZ [Aksyuk et al. 2011] but with a different organization [FIG 1.6 d]. Domains I and II are
packed together on the sheath surface, domain III establishes inter-monomer interactions with
an adjacent domain II and with an underlying domain IV, and the internal domain IV contacts
the tail tube [FIG 1.6 d]. Contraction of the phi812 tail sheath involves the displacement of the
sheath proteins and changes in their inter-domain configuration, resulting in the reduction of the
sheath length to 80.8 nm and its separation from the tail tube. After contraction, domain II
interacts with an underlying domain III and domain IV disrupts the contact to the tail tube to
associate with other domains IV [Nováček et al. 2016].
The attachment of phage K to the host-cell wall is accomplished by a distal baseplate.
Cryo-EM maps of phi812 baseplate have been obtained with three conformations: native (13.4Å resolution), intermediate (18.6-Å resolution) and contracted (10.8-Å resolution) [Nováček et
al. 2016].
The phi812 contracted baseplate is organized in six radial branches; each branch
accommodates three presumed binding components [FIG 1.7 b, c]. A boom complex affixes the
binding components to the branch. The boom complex is attached to the tail via a gooseneck
protein which forms a ring around the tail tube and interacts with the spacer proteins that join
the baseplate to the sheath proteins. The outer binding component was described as a tail fiber
and consists of a base linked to the boom complex and a long shaft whose tip might interact
with the host. The only virion protein predicted as tail fiber protein is phage K gp150. The other
two binding components of the baseplate branch are compact conical blocks with three-fold
symmetry: the receptor-tripod complexes. Each receptor-tripod complex is composed of an
upper trimer of tripod proteins and a bottom trimer of receptor-binding proteins. The tripod
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trimer includes a trimeric apex and three peripheral protrusions. The apex of the tripod welds
the receptor-tripod complex to the branch (the outer complex to the bloom and the inner
complex to the bloom and the gooseneck). The peripheral protrusions dimerize with their
counterparts from adjacent receptor-tripod complexes or interact with the tail fiber protein. The
protein predicted to constitute the tripod in phage K is gp148, which has been assigned as
possible VlrC-like protein [Habann et al. 2014]. The alleged receptor-binding cryo-EM density
was described as a protein complex consisting of a central domain fo rming a bowl-like
structure, three peripheral domains protruding from the central domain, and a flexible receptor
binding domain. The authors of the cryo-EM study stated that the receptor-binding protein
structure resembles the structure of the receptor-binding protein of lactococcal phage P2
[Nováček et al. 2016], despite it has no significant similarity to any protein from phage K
(BLASTP 2.8.0+ [Altschul et al. 1997]). The receptor-binding regions of both the fiber and the
receptor-binding proteins lie on the same plane; suggesting a concurring binding to the cell wall
[Nováček et al. 2016].
Phage K possesses two receptor-binding proteins: gp146 and gp144. Their location in
the baseplate and their involvement in the phage adsorption to Staphylococcus aureus has been
proven on orthologous-gene products from the kayviruses phiSA012 (species Staphylococcus
virus SA12, NCBI:txid 1924730) [Takeuchi et al. 2016] and phage ISP (Staphylococcus phage
ISP, NCBI:txid 1028375; species Staphylococcus virus G1) [Habann et al. 2014]; both phages
are very similar to phage K8.
The cryo-EM reconstruction of the phi812 native baseplate showed a compact spheroid
shape with a drastic rearrangement of its components [FIG 1.7 a]. In addition, there are two
components of the native baseplate that are shed during contraction: a terminal spike (assigned
to phage K gp155) and a tubular peptidase (predicted as phage K gp157) [Nováček et al. 2016].
According to the cryo-EM map of the native baseplate, both receptor-tripod complexes
are rotated compared to its position in the contracted baseplate: the inner complex turns 20º and
the outer complex turns 210º. The protrusions of the tripod from the outer complex interact with
tail sheath proteins, stabilizing the native conformation of the sheath. The tail fibers lie between
outer receptor-tripod complexes; though they are loose in a presumed intermediate
configuration of the baseplate. The gooseneck proteins appear as a ring around the tube and
contact with the tip of the tail tube and the inner receptor-tripod complex. The spacer proteins
contact both tail-tube and tail-sheath proteins. [Nováček et al. 2016]

8

Compared to phage K, phiSA012 presents a 97% of genomic sequence identity on a 91% cover and
phage ISP has a 99% of genomic sequence identity on a 96% cover (BLASTN 2.8.0+ [Zhang et al.
2000]).
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FIGURE 1.7. Phage K baseplate. Side-view (left) and bottom-view (right) of phi812 baseplate in two
conformations: (a) native (EMDB:id 8210 [Nováček et al. 2016] with the contouring threshold level
recommended by authors: 2.00) and (b) contracted (EMDB:id 8212 [Nováček et al. 2016] with the
contouring threshold level recomended by authors: 1.10). (c) Side-view segmentation of a branch of the
contracted phi812 baseplate according to the authors.
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The baseplate structure of phi812 differs substantially from the structures of other
phages described in detail, particularly T4 [Taylor et al. 2016], even though functional
parallelisms may be established [Nováček et al. 2016].
In conclusion, according to the available structural data, phage K is a myovirus with the
structural features of the typical myovirus capsid and contractile tail but it presents a novel
baseplate whose detailed structure, especially the structure of their receptor-binding proteins,
remains unknown.
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1.5. Host-interacting proteins considered in this study
The thesis project was focused on phage K proteins involved in recognition and
attachment to the host cell: the receptor binding proteins gp146 and gp144, and the tail terminal
spike gp155.

1.5.1. gp146
Gene product 146 (gp146) (NCBI:RefSeq YP_009041342.1) is a 640-amino-acid
protein encoded by CPT_phageK_gp146 (formerly orf66). The full-length protein has a
predicted molecular weight of 72533.01 Da and a theoretical pI 6.53 (calculated with ExPASy
ProtParam [Gasteiger et al. 2005]).
At the beginning of the project 9, no significantly similar proteins were found in the
Protein Data Bank (PDB) [Berman et al. 2000]. According to the Conserved Domain Database
(NCBI: CDSEARCH/cdd) [Marchler-Bauer et al. 2017], there is a predicted carbohydrate
binding module of the CBM_4_9 superfamily (cl19911) [Johnson et al. 1996] between positions
213-336 and a PHA01818 (superfamily cl10348) domain between residues 448-592 10.
The gp146 orthologous protein on the related kayvirus phiSA012 has been positively
characterized as receptor-binding protein [Takeuchi et al. 2016]. The functional features of the
gp146 ortholog on phiSA012 can be unequivocally attributed to phage K gp146, since the
orthologs have a 99% of sequence identity (631/640) and similarity (635/640) (BLASTP 2.8.1+
[Altschul et al. 1997]) and the effect of wall teichoic acid alterations on the infectivity of
phiSA012 [Azam et al. 2018] is the same as that of phage K [Xia et al. 2011, Li et al. 2015], i.e.
the ΔtarO strains are resistant and the ΔtarM and/or ΔtarS strains are susceptible. Gp146
ortholog has been located in the baseplate by immunogold labeling electron-microscopy
[Takeuchi et al. 2016]. Three point mutations in gp146 ortholog (Asn248Asp11, Gly583Asp, and
Thr615Arg) are enough to redirect the tropism of phiSA012; whereas the wild-type phage can
bind and infect S. aureus SA003 and RN4220, the mutant can adsorb to S. aureus SA003 and
SA003R1112 but it does not bind to RN4220 because, unlike SA003, RN4220 expresses tarM,
which adds α-N-acetylglucosamine to the wall teichoic acid [Takeuchi et al. 2016]. These
9

The crystal structure of a carboxy-terminal fragment of gp144 was solved and uploaded to the PDB
(PDB:id 5M9F) shortly after the beginning of my lab work. The description of that structure is
included within the description of the full length gp144 in the Results chapter.
10 The identification of this domain was subsequent to the upload to the PDB of the carboxy-terminal
domain of gp144.
11 Asn248Asp is one of the nine differences between phage K gp146 (Asp248) and phiSA012 ortholog
(Asn248). However, it has been shown that phage K can be propagated in RN4220 strain [Alves et al.
2014], so probably the Asn248Asp mutation is not responsible for the altered binding.
12 SA003R11 is a S. aureus strain resistant to wild type phiSA012 adsorption with point mutations in
genes involved in peptidoglycan and wall teichoic acid synthesis [Takeuchi et al. 2016].
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results have also been confirmed by antibody blocking experiments [Takeuchi et al. 2016].
Accordingly, gp146 is a receptor-binding protein that binds to α-N-acetylglucosamine on wall
teichoic acid.
This thesis reports the crystal structure of phage K gp146.

1.5.2. gp144
Gene product 144 (gp144) (NCBI:RefSeq YP_009041344.1) is a 458-amino-acid
protein encoded by CPT_phageK_gp144 (formerly orf68). The predicted molecular weight of
gp144 is 50424.35 Da and has a theoretical pI 6.02 (calculated with ExPASy ProtParam
[Gasteiger et al. 2005]).
Gp144 was described as receptor-binding protein in phage ISP [Habann et al. 2014],
whose ortholog is identical to gp144 (BLASTP 2.8.1+ [Altschul et al. 1997]). GFP-tagged
gp144 was able to bind S. aureus cells, anti-gp144 antibodies were able to cross-link phage ISP
tails laterally (suggesting a peripheral location in the native baseplate), and immunogold
labeling electron-microscopy revealed its location at the bottom of the baseplate [Habann et al.
2014]. Furthermore, infection inhibition studies in phiSA012 using antibodies blocking gp144
ortholog13 showed an inhibitory effect irrespective of the presence of α-N-acetylglucosamine in
the wall teichoic acids [Takeuchi et al. 2016].
The crystal structure of a carboxy-terminal fragment of gp144 was solved 9 (PDB:id
5M9F) and thereafter its sequence was assigned as a member of the PHA01818 domain
superfamily

(superfamily

cl10348)

in

the

Conserved

Domain

Database

(NCBI:

CDSEARCH/cdd) [Marchler-Bauer et al. 2017]. Here I report the structure of the full-length
protein.

1.5.3. gp155
Gene product 155 (gp155) (NCBI:RefSeq YP_009041333.1) is a 848-amino-acid
protein encoded by CPT_phageK_gp155 (formerly orf58). Full-length gp155 has a theoretical
molecular weight of 96095.88 Da and a pI 4.86 (calculated with ExPASy ProtParam [Gasteiger
et al. 2005]).
The prediction of conserved domains [Marchler-Bauer et al. 2017] in gp155 sequence
resulted in a glycerophosphodiester phosphodiesterase domain (cl26103) at the carboxyterminal region (residues 609-848) and coiled-coil domain of the Spc7 superfamily (cl25508)
[Kerres et al. 2004] at residues 313-440. A search for similar proteins in the PDB [Berman et al.
2000] resulted in the glycerophosphoryl diester phosphodiesterase from Gram-positive bacteria
13 The orthologs have a 91% of sequence identity (419/458) and a 97% of sequence similarity (447/458)
(BLASTP 2.8.1+ [Altschul et al. 1997]).
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(top hits: Bacillus subtilis PDB:id 5T91, S. aureus PDB:id 2OOG). The B. subtilis GlpQ
(PDB:id 5T91) is a secreted exo-phosphodiesterase with a TIM barrel domain involved in
degradation of the wall teichoic acid during phosphate starvation [Myers et al. 2016].
Functionally, gp155 is predicted as a tail central spike (Supplementary material of
[Nováček et al. 2016]). Location of the ortholog on Listeria phage A511 baseplate was assessed
by immunogold labeling electron-microscopy and by frontal antibody-mediated cross-linking of
native baseplates of phage A511 [Habann et al 2014]. However, phage K gp155 and the
ortholog on phage A511 only have 31% of sequence identity and 50% of similarity on a 56%
cover (BLASTP 2.8.1+ [Altschul et al. 1997]) and phage A511 ortholog lacks the carboxyterminal glycerophosphodiester phosphodiesterase domain. Remarkably, the central tail spikes
of Gram-negative phages, like T4 [Taylor et al. 2016], possess a β-helical domain instead of the
coiled-coil domain of phage A511 and phage K.
This thesis shows the attempts to structurally characterize gp155.

26

1. Introduction and literature review

1.6. Overview of the methodology: protein crystallography
The technical approach applied in this thesis is macromolecular crystallography. The
workflow [FIG 1.8] of a classical crystallography study comprises: sample production (cloning,
expression, purification), crystallization, diffraction, data processing, and analysis.
Sample production. Protein crystallography requires the production of large amounts (mg) of
homogeneous and pure (> 97% of purity) sample. The lack of a suitable sample often causes
failure of crystallization or crystallization of a contaminant (e.g., Appendix B).
In this thesis, the samples are recombinant proteins heterologously-expressed and
purified. This type of samples are produced by cloning, expression, and purification
procedures14.
The DNA-sequence encoding the protein of interest is cloned into an expression vector.
The expression vector may harbor a number of features to favor the expression and purification
of the insert. The expression vector used in this thesis (pET28a+) expresses insert fused to a
histidine-tag that facilitates the purification. The expression of the recombinant protein in this
vector is controlled by a T7-RNA-polymerase promoter with a lac operator, so the induction of
the expression is double since the expression of the T7-RNA-polymerase is also controlled by a
lac operator.
The expression of the constructs may become a limiting step if the protein does not fold
properly in the expression system. Escherichia coli is the most common protein expression
system; it allows a rapid, cheap, and simple production of recombinant proteins. However,
proteins from other organisms (like eukaryotes) may not fold appropriately in E. coli due to the
absence of specific chaperones or post-translational modification enzymes. The phage proteins
of this thesis are naturally expressed in bacteria (Staphylococcus aureus), which reduces (to
some extent) the possibility of misfolding. However, the lack of other phage proteins and the
cellular stress associated to the overexpression may hinder the production of soluble protein
(e.g., Appendix B).
Preparative purification of proteins usually involves several steps of chromatography.
Chromatography is a technique based on the differential partitioning of a compound between a
mobile phase and a stationary phase. Chromatographic methods allow the purification of
proteins according to a particular attribute: specific binding (affinity chromatography), charge
(ion-exchange chromatography), size (size exclusion chromatography), or hydrophobicity
(reverse-phase chromatography).
14 Description of these basic molecular biology techniques can be found in [Sambrook et al. 1989].
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FIGURE 1.8. Experimental workflow. Overview of the experimental workflow applied in the project. A
classical crystallographic study starts with a cloning to obtain a construct that enables an efficient
expression of the protein. After expression, the protein must be purified to reach the quality standards for
crystallization (>97% purity). Crystals can diffract an X-ray beam and processing of the diffraction data
allows the construction of an atomic-resolution model of the protein.

Crystallization. Crystallization is the formation of a crystal (a highly ordered solid) 15.
Crystallization can be regarded as a special type of precipitation that involves a solubility
equilibrium between two phases: solid (crystal) and liquid (protein solution). Crystallization
encompasses two steps: nucleation (formation of small nuclei) and growth. Both steps require a
shift in the solubility of the protein until it reaches a critical level (supersaturation); this can be
achieved by several methods like addition of a precipitant, changes in pH or ionic strength, and
concentration of the protein. There are several crystallization techniques such as batch, vapordiffusion, diffusion, or dialysis. In this thesis, the applied procedure is sitting-drop vapordiffusion, in which a drop with equal volumes of sample and reservoir solution is set on an
elevated platform in a sealed chamber with reservoir solution, so the concentration of protein
and precipitant in the drop increases due to solvent equilibration through the vapor phase.
From a practical perspective, crystallization is a trial-and-error procedure that can be
accomplished by an initial high-throughput screening of crystallization conditions followed by
optimization of the initial conditions (pH, precipitant concentration, protein concentration,
additives, temperature). If the screening fails, tests on the stability of the protein (such as
thermofluor) or partial proteolytic digestion of the protein may facilitate the crystallization.

15 Basics of crystallization are reviewed in [McPherson & Gavira 2014].
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Diffraction. A crystal can diffract16 a beam of X-rays (in crystallography, λ = 0.5-1.6 Å) into
specific directions determined by the nature of crystalline matter (commented in Appendix A). A
crystal is formed by the translational repetition of a unit cell, which may consist of more than
one asymmetric unit related by rotational and/or roto-translational symmetry operators that
define the space group of the crystal. The application of the Fourier transform to a crystal (real
space) results in the reciprocal space. The diffraction images are records of the reciprocal space,
which must be processed with a reverse operation (Fourier series) to generate an electrondensity map of the unit cell of the crystal.
Protein crystals are imperfect and fragile. The X-ray diffraction of a protein crystal is
usually weak and limited by crystal damaging; because of this, protein crystallography relies on
high-quality X-ray beams at synchrotron radiation facilities. A synchrotron offers high-flux
beamlines with low beam divergence at adjustable wavelengths (energies). These features
improve the quality of the collected images and allow the performance of anomalous scattering
experiments at wavelengths specific to the absorption spectrum of heavy atoms included in the
crystal.
Data processing. The outcome of a diffraction experiment is a set of diffraction images
containing spots (reflections) with specific intensities and arranged in a determined pattern. The
first step in the processing of these data is the location of the reflections and the calculation of
the space group and cell dimensions; this is known as indexing. Then, the intensity of each
reflection is measured and quantified (integration). The subsequent scaling step combines the
integrated values and normalizes them according to the symmetry restraints. The estimation of
the phases (phasing) (reviewed in [Taylor 2010]) is required for the application of the Fourier
series in order to obtain an electron-density map from the diffracted data. The initial electrondensity map is usually improved by a density modification step. A structural model is build
(automatically and/or manually) on the electron-density map and it is optimized by several
cycles of refinement (reviewed in [Steiner & Tucker (2017)]).
Interpretation and analysis. The result of the experimental procedure is an atomic-resolution
model of the asymmetric unit of the crystal. The interpretation of this model must take into
account the enormous distance between the model and the physiological conditions of the
protein represented in the model. The models are static theoretical constructs based on
experimental data: the diffraction of an X-ray beam with a crystal. A crystal is not a naturally
occurring object but an artifact built out of purified protein. The purified protein was obtained
by overexpression of a construct in a heterologous system (E. coli). Per contra, in physiological
16 An introduction to basics of X-ray diffraction can be found in [Blow 2002].
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conditions, the protein is expressed and folded in the proper expression organism (S. aureus),
under specific circumstances (phage K infection), and with the availability to be stabilized by
binding to other phage components (baseplate proteins).
Despite the aforementioned limitations of crystallography, crystallographic models are
usually a good representation of the real (although static) structure of proteins. Protein crystals
are hydrated (average solvent content ~50%), so part of the surface of the crystallized proteins
may have the same conformation as in solution. Crystal models enable the formulation of
hypotheses about the function of specific amino-acids; these hypotheses must be confirmed by
additional functional analysis with techniques that reproduce better the physiological
environment of the protein.
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1.7. Objectives
•

Determination of the crystal structures of:
(a) gp146 (full-length and/or fragments);
(b) gp144 (full-length);
(c) gp155 (full-length and/or fragments).

•

Characterization of the binding of gp146, gp144, and gp155 to wall teichoic acid.
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2. Materials and methods

2.1 Materials
2.1.1. Primers
TABLE 2.1. Primers used in this study. Sequence 5’→3’ of the primers used for the cloning of gp146
and gp155 inserts. The restriction-enzyme target-sequence is underlined. The last column indicates the
constructs whose insert cloning required the respective primer.
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2.2. Methods applied to gp146
2.2.1. Construction of expression vectors of gp146
The complete CPT_phageK_gp146 gene (gp146(1-640)) and the fragments encoding
gp146(375-640), gp146(402-640), and gp146(517-640) were amplified by polymerase chain
reaction (PCR) using Taq DNA Polymerase (Roche Diagnostics GmbH, Mannheim, Germany),
a phage K genomic DNA template, and primers (Sigma-Aldrich, Hamburg, Germany) (TABLE
2.1) that incorporated BamHI and XhoI restriction sites to the 5' and 3' ends of the cloned
fragments respectively. The PCR products were checked by 1%-agarose-gel eletrophoreses, the
amplicon bands were cut, and their DNA extracted with the GeneJET Gel Extraction Kit
(Thermo Fisher Scientific Baltics UAB, Vilnius, Lithuania). The amplicons of the full-length
construct and the fragment gp146(375-640) were subcloned into the pCR TMII-TOPO using the
TOPO®TA Cloning Kit Dual Promoter (Life Technologies Europe BV, Bleiswijk, Netherlands).
The pCRTMII-TOPO constructs, the amplicons, and the expression vector pET28a(+) (Novagen/
Merck, Nottingham, England) were digested with FastDigest® BamHI and FastDigest® XhoI
(Thermo Fisher Scientific Baltics UAB, Vilnius, Lithuania). Restriction fragments were
separated by 1%-agarose-gel electrophoreses, the proper size bands were cut, and their DNA
extracted with the GeneJET Gel Extraction Kit (Thermo Fisher Scientific Baltics UAB, Vilnius,
Lithuania). The restricted vectors and inserts were ligated with the T4 DNA Ligase (Thermo
Fisher Scientific Baltics UAB, Vilnius, Lithuania) and subsequently transformed into freshlyprepared chemically competent Escherichia coli DH5α cells [Sambrook et al. 1989]. The
resultant

constructs

(pET28a+gp146K,

pET28a+gp146K375,

pET28a+gp146K402 and

pET28a+gp146K517) encode the proteins fused to an amino-terminal tag containing six
histidines, a thrombin cleavage site, and a T7 tag. The sequence of the inserts was confirmed by
DNA-sequence analyses (Secugen S.L., Madrid, Spain).

2.2.2. Expression and purification of gp146
Chemically competent Escherichia coli BL21(DE3) cells were transformed with
pET28a+gp146K or pET28a+gp146K402. Four 0.9 L cultures of gp146(1-640) or two 0.9 L
cultures of gp146(402-640) were grown in lysogeny broth (LB) (10 g/L tryptone, 5 g/L yeast
extract, 10 g/L NaCl) supplemented with 50 µg/mL kanamycin at 310 K to an optical density at
600 nm of 0.6-0.8. Cultures were cooled in ice and protein expression was induced with 1 mM
isopropyl-β-D-1-thiogalactopyranoside (IPTG). Expression was allowed for 16 h at 291 K. The
cultures were centrifuged (10 min at 4000 x g, 283 K). Harvested cells were resuspended in 40
mL of 50 mM Tris-HCl pH 8.5, 1 M NaCl [Guardado-Calvo et al. 2009] and frozen at 253 K.
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Bacteria were lysed with a French press (Thermo, Needham Heights, Massachusetts, USA) or
with a Q500 sonicator (QSONICA, Newtown, Connecticut, USA). Insoluble material was
removed by centrifugation (45 min at 14000 x g, 280 K). The supernatant was incubated with 2
mL of Nickel-Nitrilotriacetic (Ni-NTA) Agarose resin (Jena Bioscience GmbH, Jena, Germany)
for 1 h at room temperature and poured into an empty Econo-Pac® Chromatography Column
(Bio-Rad, Hercules, California, USA). The resin was washed with 20 mL of 50 mM Tris-HCl
pH 8.5, 1 M NaCl, 10 mM imidazole and protein was eluted with a step gradient of 50, 100,
200, 500, 1000 mM imidazole pH 8.0 (8 mL each).
Fractions with gp146(1-640) from the immobilized metal affinity chromatography
(IMAC) were dialysed against 10 mM Tris-HCl pH 8.5, 1 mM EDTA and loaded onto a
RESOURCETM Q 6 mL anion-exchange chromatography column (GE Healthcare Life Sciences,
Little Chalfont, Buckinghamshire, England) set on a ÄKTApurifier 10 (GE Healthcare Life
Sciences, Little Chalfont, Buckinghamshire, England). Elution was performed with a
continuous gradient of NaCl up to 1 M in 10 mM Tris-HCl pH 8.5 buffer (gradient volume: 15
column-volume; fractions: 3 mL, with new fraction when an 280-nm-absorbance peak is
detected). Fractions with eluted gp146(1-640) were pooled and concentrated with an Amicon
Ultra 15 Ultracel 10K concentrator (Millipore, Cork, Ireland), loaded onto a Superdex TM 200
Increase 10/300 GL size exclusion chromatography column (GE Healthcare Life Sciences,
Little Chalfont, Buckinghamshire, England) set on a ÄKTApurifier 10 (GE Healthcare Life
Sciences, Little Chalfont, Buckinghamshire, England), and eluted with 10 mM Tris-HCl pH 8.5,
150 mM NaCl (elution volume: 1.5 column-volume; fractions: 1 mL). Purified protein was
pooled and concentrated to 0.2 mM with an Amicon Ultra 15 Ultracel 10K concentrator
(Millipore, Cork, Ireland), performing two washes with 10 mM Tris-HCl pH 8.5 to eliminate
salt and small impurities. Protein absorbance at 280 nm was determined (NanoDrop ND-1000,
Wilmington, Delaware, USA) and Beer-Lambert law (A=ε c l) was applied using ε (Cys reduced)=
137060 M-1 cm-1, MW= 76076.91 Da (ExPASy ProtParam [Gasteiger et al. 2005]).
Fractions of gp146(402-640) from the IMAC were dialysed against 10 mM MES pH
6.0, 1 mM EDTA. Dialysed sample was loaded onto a RESOURCE TM S 6 mL cation-exchange
column (GE Healthcare Life Sciences, Little Chalfont, Buckinghamshire, England) and eluted
with a continuous NaCl gradient up to 1 M in 10 mM MES pH 6.0 (gradient volume: 15
column-volume; fractions: 3 mL, with new fraction when an 280-nm-absorbance peak is
detected). Fractions with protein were pooled and concentrated, loaded onto a Superdex TM 200
Increase 10/300 GL size exclusion chromatography column (GE Healthcare Life Sciences,
Little Chalfont, Buckinghamshire, England), and eluted with 10 mM MES pH 6.0, 150 mM
NaCl (elution volume: 1.5 column-volume; fractions: 1 mL). Purified gp146(402-640) was
pooled and concentrated to 0.8 mM, performing two washes with 10 mM MES pH 6.0. Protein
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absorbance at 280 nm was measured (NanoDrop ND-1000, Wilmington, Delaware, USA) and
Beer-Lambert law (A=ε c l) was applied using ε (Cys reduced)= 56840 M-1 cm-1, MW= 30795.33 Da
(ExPASy ProtParam [Gasteiger et al. 2005]).
In order to obtain selenomethionine-labeled gp146(1-640), methionine-auxotroph E.
coli B834(DE3) cells were transformed with pET28a+gp146K and two 1 L cultures were grown
in SelenoMetTM medium (Molecular Dimensions, Newmarket, Suffolk, England) supplemented
with 50 µg/mL kanamycin. Expression and purification procedures were the same as for the
native protein except for the size exclusion chromatography step which was skipped in order to
avoid protein loss.
Every purification step was assessed by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) (12% acrilamide [Sambrook et al. 1989]) using MiniPROTEAN® Tetra Cell electrophoresis system (Bio-Rad, Hercules, California, USA).

2.2.3. Crystallization of gp146
Sitting-drop MRS crystallization plates (Swissci AG, Neuheim, Zug, Switzerland) were
used for vapor-diffusion crystallization, which took place in an isothermal room at 294 K.
Commercial screen formulation kits (JBScreen Classic 1 to 10, JBScreen PEG/Salt 1 and 2, and
Pi-minimal Screen (Jena Biosciences, Jena, Germany) 1) were used for initial condition
screenings on 96-well plates with 50 µL reservoir and drops of 1 µL (equal volumes of reservoir
and protein solution; 0.5 µL each). The productive screening conditions were optimized on 48well plates with 150 µL reservoir and 2 µL drops. Co-crystallization was achieved with a
previous 16-h incubation at 277 K of the protein sample with 100 molar equivalents of racglycerol 1-phosphate sodium sal hydrate (Sigma-Aldrich, Hamburg, Germany) or 12 molar
equivalents of [4-(α-O-GlcNAc)-RboP-(RboP)2]2-(CH2)6NH2

2

(provided by J. Codée (Leiden

Institute of Chemistry, Leiden, Nethelands), hereinafter referred to as “SA-378”, see Appendix
C). Crystals were cryo-protected by transferring them to reservoir solution containing 20% v/v
glycerol. Cryo-protected crystals were set on Litholoops (Molecular Dimensions, Newmarket,
Suffolk, England) and frozen for transportation to the synchrotron radiation facilities.

2.2.4. Crystallographic data collection and processing
Cryoprotected crystals were used for remotely controlled X-ray diffraction at the
beamline BL13-XALOC of the ALBA synchrotron light source (ALBA, Cerdanyola del Vallès,
1

2

JBScreen Classic kits 1 to 10 and JBScreen PEG/salt kits 1 and 2 contain 24 crystallization
conditions each. Pi-minimal Screen kit includes 96-crystallization conditions. The crystallization of
some constructs/co-crystals was not tested with all the kits because of shortage of ligand sample
(especially synthetic analogs) or success with the first kits attempted.
RboP, ribitol 5-phosphate. GlcNAc, N-acetylglucosamine.
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Barcelona, Catalonia). Crystals of the selenomethionine derivative protein were diffracted with
an X-ray wavelength of 0.979260 Å, close to the absorption edge of selenium to allow
anomalous scattering. The crystallographic data from the crystal of gp146(402-640) incubated
with rac-glycerol 1-phosphate and from the co-crystal of gp146(1-640) and SA-378 were
integrated with iMOSFLM [Battye et al. 2011], indexed with POINTLESS [Evans 2006], and
scaled with AIMLESS [Evans & Murshudov 2013]. The rest of the crystallographic data were
automatically processed using autoPROC [Vonrhein et al. 2011]; which included XDS [Kabsch
2010] for indexing and integration, POINTLESS [Evans 2006] for reindexing, and AIMLESS
[Evans & Murshudov 2013] for data scaling. Structure factor amplitudes were obtained using
CTRUNCATE of the CCP4 suite [Winn 2011].
Experimental SAD phasing was performed on the derivative data with the pipeline
SHELX [Sheldrick 2010], which includes SHELXC [Sheldrick 2008] for preparation of the data
files, SHELXD [Schneider & Sheldrick 2002] for heavy atom location, SHELXE [Sheldrick
2010] for phasing and density modification, REFMAC5 [Murshudov et al. 2011] for refinement,
and BUCANEER [Cowtan 2006] for automated building. Density modification was performed
with PARROT [Cowtan 2010] and an initial model was built with CBUCCANEER [Cowtan
2006]. The model was manually completed with COOT [Emsley et al. 2010] using the gp146(1640) and gp146(402-640) models.
Native structures were solved by molecular replacement using MOLREP [Vagin &
Teplyakov 2010] for the co-crystal of gp146(1-640) and rac-glycerol 1-phosphate and PHASER
[McCoy et al. 2007] for the rest of the crystal structures. A preliminary selenomethionine model
was used as template for the molecular-replacement processing of ligand-free models and their
building was completed with ARP/wARP [Perrakis et al. 2001]. In turn, the ligand-free models
were used as templates for the molecular-replacement processing of ligand-added models. The
SA-378 ligand was manually built with UCSF Chimera [Pettersen et al. 2004] and its
stereochemical information was derived with AceDRG [Long et al. 2017].
The models were refined with REFMAC5 [Murshudov et al. 2011] and manual
corrections were made with COOT [Emsley et al. 2010]. The low-resolution selenomethionine
derivative model and the model of the co-crystal of gp146(1-640) and SA-378 were also refined
with the LORESTR pipeline [Kovalevskiy et al. 2016].
The models were validated with MOLPROBITY [Chen et al. 2010]. Secondary
structure was assigned with DSSP [Kabsch & Sander 1983]. Quaternary structure interfaces
were analyzed with QtPISA [Krissinel 2015]. ProSMART [Nicholls et al. 2014] was used for
structure alignment. PyMOL (The PyMOL Molecular Graphics System, Version 1.8
Schrödinger, LLC) and UCSF Chimera [Pettersen et al. 2004] were used for visualization of the
models.
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2.2.5. Indirect immunofluorescence assay
Staphylococcus aureus RN4220 ΔspA cells were grown overnight in TSB (tryptic soy
broth). When the culture reached an optical density at 600 nm of 3.0 (~ 2.5 x 109 cells/mL), 2
mL of culture were washed with phosphate-buffered saline (PBS) and resuspended in 1 mL of
PBS. A combination of 50 µL of resuspended cells and 40 µL of purified gp146(1-640) (1.4
mM) was incubated for 1 h at room temperature. After a PBS wash, the cells were fixed with
4% paraformaldehyde for 7 min. Fixed cells were washed twice with PBS, applied on coverslips
pre-treated with 0.1% of poly-L-lysine, and allowed to sediment for 40 min. The coverslips
were washed with PBS and blocked with 2% bovine serum albumin (BSA) for 30 min. A 1:500dilution in 0.5% BSA of the polyclonal anti-(6x His) tag antibody (Rockland Inc., Limerick,
Pennsylvania, USA) was added to the sample and incubated for 2 h at room temperature. After
five PBS washes, the coverslips were incubated with a 1:500-dilution of anti-Rabbit Alexa
Fluor® 546 (ThermoFisher Scientific, Life Technologies Europe BV, Bleiswijk, Netherlands)
for 2 h at room temperature. The coverslips were washed five times with PBS and mounted on
slides with ProLong™ Gold Antifade Mountant (ThermoFisher Scientific, Life Technologies
Limited, Paisley, Scotland) and dried for 48 h. The sample was visualized with a Leica SP8 TCS
STED 3X system (Leica Microsystems CMS GmbH, Mannheim, Germany) at the Advanced
Light Microscopy Service of the National Center for Biotechnology (CNB-CSIC, Madrid,
Spain).
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2.3. Methods applied to gp144
2.3.1. Expression and purification of gp144
Chemically competent Escherichia coli BL21(DE3) cells were transformed with the
expression vector pET28a-gp144(2-458) 3, which encodes the gp144(2-458) fused to an aminoterminal tag of six histidines, a thrombin cleavage site, and T7 tag. Four 0.9 L cultures were
grown in LB supplemented with 50 µg/mL kanamycin at 310 K to an optical density at 600 nm
of 0.6-0.8. Cultures were cooled in ice and protein expression was induced with 1 mM IPTG.
Expression was allowed for 16 h at 291 K. The cultures were centrifuged (10 min at 4000 x g,
283 K). Harvested cells were resuspended in 40 mL of 50 mM Tris-HCl pH 8.5, 1 M NaCl
[Guardado-Calvo et al. 2009] and frozen at 253 K. Bacteria were lysed with a Q500 sonicator
(QSONICA, Newtown, Connecticut, USA). Insoluble material was removed by centrifugation
(45 min at 14000 x g, 280 K). The supernatant was incubated with 2 mL of Ni-NTA Agarose
resin (Jena Bioscience GmbH, Jena, Germany) for 1 h at room temperature and poured into an
empty Econo-Pac® Chromatography Column (Bio-Rad, Hercules, California, USA). The resin
was washed with 20 mL of 50 mM Tris-HCl pH 8.5, 1 M NaCl, 10 mM imidazole and protein
was eluted with a step gradient of 50, 100, 200, 500, 1000 mM imidazole pH 8.0 (8 mL each).
Fractions containing the eluted protein were dialysed against 10 mM Tris-HCl pH 8.5, 1 mM
EDTA and loaded onto a RESOURCETM Q 6 mL anion-exchange chromatography column (GE
Healthcare Life Sciences, Little Chalfont, Buckinghamshire, England) set on a ÄKTApurifier 10
(GE Healthcare Life Sciences, Little Chalfont, Buckinghamshire, England). Elution was
performed with a continuous gradient of NaCl up to 1 M in 10 mM Tris-HCl pH 8.5 (gradient
volume: 15 column-volume; fractions: 3 mL, with new fraction when an 280-nm-absorbance
peak is detected). Fractions with eluted gp144(2-458) were pooled and concentrated with an
Amicon Ultra 15 Ultracel 10K concentrator (Millipore, Cork, Ireland), loaded onto a
SuperdexTM 200 Increase 10/300 GL size exclusion chromatography column (GE Healthcare
Life Sciences, Little Chalfont, Buckinghamshire, England) set on a ÄKTApurifier 10 (GE
Healthcare Life Sciences, Little Chalfont, Buckinghamshire, England), and eluted with 10 mM
Tris-HCl pH 8.5, 150 mM NaCl (elution volume: 1.5 column-volume; fractions: 1 mL). Purified
protein was pooled and concentrated to 0.3 mM with an Amicon Ultra 15 Ultracel 10K
concentrator (Millipore, Cork, Ireland), performing two washes with 10 mM Tris-HCl pH 8.5 to
remove the elution buffer. Protein absorbance at 280 nm was determined (NanoDrop ND-1000,
Wilmington, Delaware, USA) and Beer-Lambert law (A=ε c l) was applied using ε (Cys reduced)=
58790 M-1 cm-1, MW= 53837.05 Da (ExPASy ProtParam [Gasteiger et al. 2005]).
3

I did not produce the expression vector.
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SDS-PAGE (12% acrilamide [Sambrook et al. 1989]) in the Mini-PROTEAN® Tetra
Cell electrophoresis system (Bio-Rad, Hercules, California, USA) was utilized to check the
progress of the purification.

2.3.2. Crystallization of gp144
Crystallization by vapor-diffusion on sitting-drop MRS crystallization plates (Swissci
AG, Neuheim, Zug, Switzerland) was performed at 294 K in an isothermal room.
Crystallization was tested with commercial screen formulation kits JBScreen Classic 1 to 8
(Jena Biosciences, Jena, Germany)4 on 96-well plates with 50 µL reservoir and drops of 1 µL
(0.5 µL of protein sample and 0.5 µL of reservoir solution). For co-crystallization, the protein
sample was firstly incubated with 100 molar equivalents of rac-glycerol 1-phosphate sodium
salt hydrate (Sigma-Aldrich, Hamburg, Germany) for 16 h at 277 K. Co-crystallization
conditions were optimized on 48-well plates (100 µL reservoir and 2 µL drops). Co-crystals
were cryo-protected by soaking into the crystallization solution supplemented with 20% v/v
glycerol. Crystals were fished with Litholoops (Molecular Dimensions, Newmarket, Suffolk,
England) and frozen in liquid nitrogen for transportation to the ALBA synchrotron light source
facilities.

2.3.3. Crystallographic data collection and processing
Crystals were diffracted in remote at the X-ray beamline BL13-XALOC of the ALBA
synchrotron (ALBA, Cerdanyola del Vallès, Barcelona, Catalonia). Crystallographic data were
automatically processed with autoPROC [Vonrhein et al. 2011]; which employs XDS [Kabsch
2010] for indexing and integration, POINTLESS [Evans 2006] for re-indexing, and AIMLESS
[Evans & Murshudov 2013] for data scaling. The subsequent processing was performed with
programs from the CCP4 suite [Winn et al. 2011].
The intensities of the ligand-free data set were converted to structure factor amplitudes
with CTRUNCATE. Phases were estimated by molecular replacement with PHASER [McCoy
et al. 2007], defining a search for three units of chain A from the carboxy-terminal model of
gp144 (PDB:id 5M9F) and six units of the fragment 39-114 from the gp146 model modified
with CHAINSAW [Stein 2008]. Density modification was performed with PARROT [Cowtan
2010] and an initial model was built with CBUCCANEER [Cowtan 2006].
The co-crystallization model was solved by molecular replacement with PHASER
[McCoy et al. 2007], inputting the individualized domains of the ligand-free gp144(2-458)

4

JBScreen Classic kits 1 to 8 contain 24 crystallization conditions each.
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model as templates and defining a search for three units of each template. The positioned
domains were manually linked with COOT [Emsley et al. 2010].
The models were manually completed and refined with COOT [Emsley et al. 2010] and
automatically refined with REFMAC5 [Murshudov et al. 2011]. The statistics of the models
were obtained with MOLPROBITY [Chen et al. 2010]. Secondary structure was assigned with
DSSP [Kabsch & Sander 1983]. Quaternary structure interfaces were analyzed with QtPISA
[Krissinel 2015]. The models were visualized with PyMOL (The PyMOL Molecular Graphics
System, Version 1.8 Schrödinger, LLC) and UCSF Chimera [Pettersen et al. 2004].
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2.4. Methods applied to gp155
2.4.1. Construction of expression vectors of gp155
The complete CPT_phageK_gp155 gene (gp155(1-848)) and the fragments encoding
gp155(1-248), gp155(1-444), gp155(315-848), gp155(597-848), and gp155(614-848) were
amplified by PCR using Taq DNA Polymerase (Roche Diagnostics GmbH, Mannheim,
Germany), a phage K genomic DNA template, and primers (Sigma-Aldrich, Hamburg,
Germany) (TABLE 2.1) that added BamHI and XhoI restriction sites to the 5' and 3' ends of the
amplicons respectively. The PCR products were purified with GeneJET PCR Purification Kit
(Thermo Fisher Scientific Baltics UAB, Vilnius, Lithuania). The amplicons encoding the
fragments gp155(1-248) and gp155(1-444) were subcloned into the pCR TMII-TOPO using the
TOPO®TA Cloning Kit Dual Promoter (Life Technologies Europe BV, Bleiswijk, Netherlands).
The pCRTMII-TOPO constructs, the amplicons, and the expression vector pET28a(+) (Novagen/
Merck, Nottingham, England) were digested with FastDigest® BamHI and FastDigest® XhoI
(Thermo Fisher Scientific Baltics UAB, Vilnius, Lithuania). Restriction fragments were
separated by a 1%-agarose-gel electrophoresis, the proper size bands were cut and their DNA
extracted with GeneJET Gel Extraction Kit (Thermo Fisher Scientific Baltics UAB, Vilnius,
Lithuania). The digested vectors and inserts were ligated with the T4 DNA Ligase (Thermo
Fisher Scientific Baltics UAB, Vilnius, Lithuania) and transformed into freshly-prepared
chemically competent Escherichia coli DH5α cells [Sambrook et al. 1989]. The resultant
expression

constructs

(pET28a+gp155K,

pET28a+gp155K248,

pET28a+gp155K444,

pET28a+gp155K315, pET28a+gp155K597 and pET28a+gp155K614) harbor the proteins fused
to an amino-terminal tag containing the T7 tag, a thrombin cleavage site, and a six-histidine tail.
The sequence of the inserts was confirmed by DNA-sequence analyses (Secugen S.L., Madrid,
Spain).

2.4.2. Expression and purification of gp155
Chemically competent Escherichia coli BL21(DE3) cells were transformed with
pET28a+gp155K or pET28a+gp155K614. Four 0.9 L cultures of each construct were grown in
LB supplemented with 50 µg/mL kanamycin at 310 K to an optical density at 600 nm of 0.60.8. Cultures were cooled in ice and protein expression was induced with 1 mM IPTG.
Expression was allowed for 16 h at 291 K. The cultures were centrifuged (10 min at 4000 x g,
283 K). Harvested cells were resuspended in 40 mL of 50 mM Tris-HCl pH 8.5, 1 M NaCl
[Guardado-Calvo et al. 2009] and frozen at 253 K. Bacteria were lysed with a Q500 sonicator
(QSONICA, Newtown, Connecticut, USA). Insoluble material was removed by centrifugation
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(45 min at 14000 x g, 280 K). The supernatant was incubated with 2 mL of Ni-NTA Agarose
resin (Jena Bioscience GmbH, Jena, Germany) for 1 h at room temperature and poured into an
empty Econo-Pac® Chromatography Column (Bio-Rad, Hercules, California, USA). The resin
was washed with 20 mL of 50 mM Tris-HCl pH 8.5, 1 M NaCl, 10 mM imidazole and protein
was eluted with a step gradient of 20, 50, 100, 200, 500, 1000 mM imidazole pH 8.0 (8 mL
each).
Fractions with gp155(1-848) from the IMAC were concentrated with an Amicon Ultra
15 Ultracel 10K concentrator (Millipore, Cork, Ireland), loaded onto a Superdex TM 200 Increase
10/300 GL size exclusion chromatography column (GE Healthcare Life Sciences, Little
Chalfont, Buckinghamshire, England) set on a ÄKTApurifier 10 (GE Healthcare Life Sciences,
Little Chalfont, Buckinghamshire, England), and eluted with 10 mM Tris-HCl pH 8.5, 150 mM
NaCl (elution volume: 1.5 column-volume; fractions: 1 mL). Purified protein was pooled and
concentrated to 7.57 µM with an Amicon Ultra 15 Ultracel 10K concentrator (Millipore, Cork,
Ireland), performing two washes with 10 mM Tris-HCl pH 8.5. Protein absorbance at 280 nm
was determined (NanoDrop ND-1000, Wilmington, Delaware, USA) and Beer-Lambert law
(A=ε c l) was applied using ε (Cys reduced)= 91110 M-1 cm-1, MW= 99639.77 Da (ExPASy ProtParam
[Gasteiger et al. 2005]).
Fractions with gp155(614-848) from the IMAC were dialysed against 10 mM Tris-HCl
pH 8.5, 1 mM EDTA. Desalted sample was loaded onto a RESOURCE TM Q 6 mL anionexchange column (GE Healthcare Life Sciences, Little Chalfont, Buckinghamshire, England)
and eluted with a continuous NaCl gradient up to 1 M in 10 mM Tris-HCl pH 8.5 (gradient
volume: 15 column-volume; fractions: 3 mL, with new fraction when an 280-nm-absorbance
peak is detected). Fractions with protein were pooled, concentrated, and loaded onto a
SuperdexTM 200 Increase 10/300 GL size exclusion chromatography column (GE Healthcare
Life Sciences, Little Chalfont, Buckinghamshire, England) and eluted with 10 mM Tris-HCl pH
8.5, 150 mM NaCl (elution volume: 1.5 column-volume; fractions: 1 mL). Purified protein was
pooled and concentrated to 0.3 mM, performing two washes with 10 mM Tris-HCl pH 8.5.
Protein absorbance at 280 nm was measured (NanoDrop ND-1000, Wilmington, Delaware,
USA) and Beer-Lambert law (A=ε c l) was applied using ε (Cys reduced)= 23380 M-1 cm-1, MW=
30157.16 Da (ExPASy ProtParam [Gasteiger et al. 2005]).
In order to obtain selenomethionine-labeled gp155(614-848), methionine-auxotroph E.
coli B834(DE3) cells were transformed with pET28a+gp155K614 and two 1 L cultures were
grown in SelenoMetTM medium (Molecular Dimensions, Newmarket, Suffolk, England)
supplemented with 50 µg/mL kanamycin. Expression and purification procedures were the same
as for the native protein.
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The purifications were tracked with SDS-PAGE (12% acrilamide [Sambrook et al.
1989]) using Mini-PROTEAN® Tetra Cell electrophoresis system (Bio-Rad, Hercules,
California, USA).

2.4.3. Crystallization of gp155(614-848)
Crystallization was performed by vapor-diffusion on sitting-drop MRS crystallization
plates (Swissci AG, Neuheim, Zug, Switzerland) in an isothermal room at 294 K. Commercial
screen formulation kits JBScreen Classic 1 to 8 and 1 to 4 (Jena Biosciences, Jena, Germany) 5
were used for the crystallization attempts of the native and the derivative protein, respectively,
on 96-well plates with 50 µL reservoir and drops of 1 µL (0.5 µL of protein sample and 0.5 µL
of reservoir solution). The crystallization conditions of the native protein were optimized on 48well plates with 100 µL reservoir and 2 µL drops. In order to attempt co-crystallization, 100
molar equivalents of rac-glycerol 1-phosphate sodium salt hydrate (Sigma-Aldrich, Hamburg,
Germany) were added to the purified protein sample and incubated for 16 h at 277 K before
setting the crystallization plate. Crystals were cryoprotected by adding a solution of the same
composition as the crystallization condition supplemented with 20% v/v glycerol, and they were
subsequently fished with Litholoops (Molecular Dimensions, Newmarket, Suffolk, England)
and frozen in liquid nitrogen for transportation to the synchrotron radiation facilities.

2.4.4. Crystallographic data collection and processing
Cryo-protected crystals were diffracted remotely at the X-ray beamlines ID23-1 of the
European Synchrotron Radiation Facilities (ESRF, Grenoble, France) and BL13-XALOC of the
ALBA synchrotron light source (ALBA, Cerdanyola del Vallès, Barcelona, Catalonia), using an
X-ray wavelength of 0.978720 Å to allow anomalous scattering. Crystallographic data were
automatically processed with autoPROC [Vonrhein et al. 2011]; which encompasses XDS
[Kabsch 2010] for indexing and integration, POINTLESS [Evans 2006] for re-indexing, and
AIMLESS [Evans & Murshudov 2013] for data scaling. The remaining processing-steps were
performed with the CCP4 suite [Winn et al. 2011].
Data from the selenomethionine derivative co-crystallized with rac-glycerol 1phosphate were processed with experimental phasing pipeline SHELX [Sheldrick 2010], which
includes SHELXC [Sheldrick 2008], SHELXD [Schneider & Sheldrick 2002], SHELXE
[Sheldrick 2010], REFMAC5 [Murshudov et al. 2011], and BUCANEER [Cowtan 2006]. The
model was manually and automatically refined with COOT [Emsley et al. 2010] and
REFMAC5 [Murshudov et al. 2011], respectively.
5

JBScreen Classic kits 1 to 8 contain 24 crystallization conditions each.
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Data from the native crystals were inputted in MOLREP [Vagin & Teplyakov 2010] to
automatically solve the structure by molecular replacement using the selenomethioninederivative model as template. Refinement was performed manually with COOT [Emsley et al.
2010] and automatically with REFMAC5 [Murshudov et al. 2011].
The models were validated with MOLPROBITY [Chen et al. 2010]. Secondary
structure was assigned with DSSP [Kabsch & Sander 1983]. Models were compared by
superposition with ProSMART [Nicholls et al. 2014]. PyMOL (The PyMOL Molecular
Graphics System, Version 1.8 Schrödinger, LLC) and UCSF Chimera [Pettersen et al. 2004]
were used for visualization of the models.

2.4.4. Negative staining electron microscopy of gp155
Samples of purified gp155(1-848) were adjusted to 0.1 g/L and 0.05 g/L. Carbon-coated
copper grids were glow-discharged, incubated on 10-µL drops of sample for 5 minutes, and side
blotted to remove excess of sample. The grids were stained and blotted three times on 5-µL
drops of uranyl acetate 2% w/v.
The samples were visualized with a JEOL JEM 1011 transmission electron microscope
(JEOL, Inc., Peabody, Massachusetts, USA) with a Gatan ES1000Ww camera at the Electron
Microscopy Service of the National Center for Biotechnology (CNB-CSIC, Madrid, Spain).
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3.1. Phage K receptor-binding protein: gp146
3.1.1. Expression and purification of gp146
The construct pET28a+gp146K expressed enough soluble tagged protein to be
effectively purified. Full-length gp146 eluted from the IMAC at 50, 100, 200 mM of imidazole.
Considering the theoretical isoelectric point of the recombinant protein (pI 7.60), the subsequent
purification steps were performed at pH 8.5. Anion-exchange chromatography rendered the
protein between 0.23-0.30 M of NaCl and the size exclusion chromatography showed a single
population of molecules in size. SDS-PAGE analyses [FIG 3.2] confirmed that the purified
protein reached the purity requirements for crystallography (> 97% purity). No oligomers were
identified in non-boiled samples loaded in the SDS-PAGE. The efficiency of the expression and
purification was up to ~1 mg of purified protein per liter of culture.
Initially, expression of a shorter carboxy-terminal fraction including residues 375-640
[FIG 3.1] was also attempted with the same purification protocol as for the gp146(1-640).
Despite the efficient expression and purification, purified protein aggregated during
concentration and crystals did not form. The structural model of gp146 showed that the
gp146(375-640) fragment did not match the domain organization, which explains its instability.
The structural model resultant from gp146(1-640) crystals turned out incomplete (see
Section 3.1.2). In order to complement the model, two additional constructs encoding for
carboxy-terminal portions gp146(402-640) and gp146(517-640) were designed [FIG 3.1] in
conformity with the domain arrangement of the structure. Expression tests showed that both
fragments expressed protein, but only gp146(402-640) was soluble. After big-volume
expression, gp146(402-640) was recovered from the IMAC in fractions 50, 100 and 200 mM of
imidazole. The basic theoretical isoelectric point of gp146(402-640) (pI 8.33) prompted a
cationic purification strategy maintained with buffers at pH 6.0. Protein eluted from the cation-

FIGURE 3.1. Fragments of gp146. Top diagram, linear representation of the full-length gp146 protein;
the box indicates the position of the predicted carbohydrate-binding module [Marchler-Bauer et al. 2017].
Bottom bars, representation of fragments cloned to attempt the expression of gp146 for crystallographic
purposes.
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FIGURE 3.2. Expression and purification of gp146(1-640). Features of the expressed recombinantprotein (table top-left), calculated with ExPASy ProtParam [Gasteiger et al. 2005]. Purification outcome:
IMAC (top-right) (FT: flow-through; W: wash), anion-exchange chromatography (bottom-left), size
exclusion chromatography (bottom-right). The chromatograms plot absorbance (280 nm) vs elution
volume; dotted line in the anion-exchange chromatogram represents conductivity (proportional to the
concentration of NaCl). (*) Loaded sample.

exchange chromatography between 0.46-0.55 M of NaCl in two overlapping populations, which
were not separable by size exclusion chromatography [FIG 3.3]. The production of gp146(402640) delivered up to 2 mg of purified protein (> 97% purity) per liter of culture.
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FIGURE 3.3. Expression and purification of gp146(402-640). Features of the expressed recombinantprotein (table top-left), calculated with ExPASy ProtParam [Gasteiger et al. 2005]. Purification outcome:
IMAC (top-right) (FT: flow-through; W: wash), cation-exchange chromatography (bottom-left), size
exclusion chromatography (bottom-right). The chromatograms plot absorbance (280 nm) vs elution
volume; dotted line in the cation-exchange chromatogram indicates conductivity (proportional to the
concentration of NaCl). (*) Loaded sample.

3.1.2. Crystallization and structure determination of gp146
The early crystallization screening tests of the full-length gp146 produced orthorhombic
crystals of the P 212121 space group (crystallization condition: 10 % w/v polyethylene glycol
8000, 100 mM HEPES pH 7.5, 200 mM magnesium acetate) and trigonal crystals of the H 3
space group (crystallization condition: 8 % w/v polyethylene glycol 8000, 200 mM lithium
chloride, 50 mM magnesium sulfate) 1. Since there was no significantly similar proteins in the
PDB, experimental phasing was required to solve the structure. In order to include anomalous
scatterers into the crystals, methyl-mercury and tetrachloroaurate soaking was initially
1

An additional batch of trigonal crystals of the H 3 space group was obtained but the unit cell
dimensions were incompatible with a full-length gp146 (see Appendix A).
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attempted. Only the methyl-mercury-soaked orthorhombic crystals showed significant
anomalous signal, although at very low resolution (anomalous correlation coefficient 0.15 at
7.47 Å), which did not suffice for phasing. Selenomethionine labeled protein was produced and
crystals of the orthorhombic family [FIG 3.4 a, b] appeared with the same range of optimization
conditions as those of the native protein: 10 % w/v polyethylene glycol 8000, 100 mM HEPES
pH 7.5, 200 mM magnesium acetate. These crystals diffracted to 3.37 Å resolution [TABLE 3.1]
(anomalous correlation coefficient 0.15 at 3.85 Å) at the selenium absorption peak wavelength,
so phases could be obtained by single-wavelength anomalous scattering (SAD). The asymmetric
unit of the orthorhombic crystals contains two trimers of gp146 and forty-two selenium atoms
were located, corresponding to the seven methionine residues present in the ordered part of each
monomer (residues 33 to 639). The model also includes six acetate molecules, two phosphate
oxoanions, six sodium cations, two magnesium cations, and 34 water molecules.
The structure of an H 3 native crystal [FIG 3.4 c, d] (grown in 8 % w/v polyethylene
glycol 8000, 200 mM lithium chloride, 50 mM magnesium acetate) was solved by molecular
replacement using the derivative model as template. The asymmetric unit of the crystal included
a whole monomer whose model was refined to 2.11 Å resolution [TABLE 3.1]. However, only
the intervals 24-524, 532-547, 556-572, 590-605, and 632-640 were built, whilst the distal part
of the carboxy-terminal domain was disordered and could not be modeled. The model also
contains a glycerol molecule, six acetate molecules, a phosphate oxoanion, a carbonate
oxoanion, two chloride anions, a magnesium cation, and 430 water molecules.
The result from the full length gp146 crystals were a 2.11-Å resolution partial model
and a 3.37-Å resolution complete model. The resolution of the complete model was insufficient
to reliably fit the side chains of the carboxy-terminal domain into the electron density map. The
structure of gp146 carboxy-terminal domain was eventually determined by the crystallization of
the fragment gp146(402-640). Orthorhombic crystals of the P 212121 space group crystallized in
3 M sodium formate [FIG 3.4 e, f]. The structure of gp146(402-640) was determined by
molecular replacement and refined to 2.70 Å resolution [TABLE 3.1]. A trimer of gp146(402640) (residues 418 to 640) was modeled in the asymmetric unit together with a magnesium
cation, three sodium cations, and 73 waters.
The partial structural models of the native gp146 fit well into the 3.37-Å resolution
derivative model (superposition on the 2.11-Å resolution gp146 and on the 2.70-Å resolution
gp146(402-640) resulted in root-mean-square deviations (rmsd) of 1.09 Å and 1.88 Å,
respectively). The similarity legitimized the assembly of a merged structural model of gp146
that encompasses amino-acids 24 to 640.
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FIGURE 3.4. Crystals of gp146. (a) Crystals of selenomethionine-labeled gp146(1-640) in the condition
10 % w/v polyethylene glycol 8000, 100 mM HEPES pH 7.5, 200 mM magnesium acetate. (b) Fished
crystal from (a). Scale bar: 100 µm. (c) Crystal of gp146(1-640) in the condition 8 % w/v polyethylene
glycol 8000, 200 mM lithium chloride, 50 mM magnesium acetate. (d) Fished crystal from (c). (e)
Crystals of gp146(402-640) in the condition 3 M sodium formate. Scale bar: 100 µm. ( f) Fished crystals
from (e). Scale bar: 50 µm.

In order to characterize the binding of gp146 to its possible ligands, soaking and cocrystallization assays were attempted. Some gp146(1-640) crystals were soaked in
crystallization condition supplemented with Fondaparinux and the poly(ribitol 5-phosphate)
compound SA-325. Co-crystallization was tested with N-acetylglucosamine, ribitol, racglycerol 1-phosphate, sn-glycerol 3-phosphate, Fondaparinux, and the poly(ribitol 5-phosphate)
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compounds SA-325, SA-385, SA-378, and SA-463 (see Appendix C) 2. No ligands were
identified in the ligand-soaked crystals. Co-crystallization with N-acetylglucosamine and with
Fondaparinux resulted in crystals diffracting to low resolution in which the identification of
possible ligands was not conclusive (the electron-density map was not clear enough to recognize
the ligand) nor consistent (the inconclusive electron density of the putative ligand was not in all
monomers of the asymmetric unit). Only the co-crystals of gp146 with rac-glycerol 1-phosphate
(hereinafter referred to as “gp146:G1P”) and with SA-378 (hereinafter referred to as
“gp146:SA378”) led to the successful detection of a ligand.
The gp146:G1P co-crystal whose diffracting data were processed was a trigonal crystal
of the H 3 space group (produced in 9.96% w/v polyethylene glycol 4000, 41.5 mM lithium
sulfate, 83 mM MES pH 4.75) very similar to the native crystal [TABLE 3.2]. The structure was
solved by molecular replacement using the merged model of gp146 as template. The gp146:G1P
model was refined to 1.7 Å resolution and its asymmetric unit consisted of a monomer of gp146
(residues 24 to 640), three glycerol-phosphate molecules (two assigned as glycerol 3-phosphate
and one assigned as glycerol 1-phosphate), ten glycerol molecules, four phosphate oxoanions,
two carbonate oxoanions, a sodium cation, and 687 water molecules.
The co-crystallization of gp146 and SA-378 was achieved in 10% w/v polyethylene
glycol 4000, 200 mM magnesium chloride, 50 mM TRIS pH 7.5, producing monoclinic crystals
of the P 21 space group [TABLE 3.2]. The structure was solved by molecular replacement using
as search models six copies of the gp146:G1P model lacking domain I and six independent
copies of domain I, to compensate the flexibility of this domain. The asymmetric unit of the
3.12-Å resolution model includes two gp146 trimers (residues 26 to 640), six fragments of SA378, two glycerol molecules, four phosphate oxoanions, two carbonate oxoanions, six chloride
anions, six sodium cations, four magnesium cations, and 20 water molecules.
In an attempt to clarify the possible location of the glycerol-phosphate ligand in the
carboxy-terminal domain, co-crystallization of gp146(402-640) and rac-glycerol 1-phosphate
was tried. Monoclinic crystals of the I 2 space group grew in the condition 466.9 mM tri-sodium
citrate, 66.7 mM TRIS pH 8.75. The crystal structure was solved by molecular replacement. The
resulting electron-density map did not evidence the presence of any molecules of glycerolphosphate but the resolution of these data improved that from the ligand-free crystal, so the
model was refined to 1.99 Å resolution [TABLE 3.2]. The asymmetric unit of this model
included a trimer of gp146(402-640) (residues 417 to 640), two glycerol molecules, three
sodium cations, three magnesium cations, and 214 water molecules.

2

Forty-six samples with presumed crystals with ligand were sent to the synchrotron radiation facilities;
twenty-two of those samples resulted in diffracting crystals (see Appendix D).
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TABLE 3.1. Crystallographic statistics of gp146. Crystallographic data collection parameters and
structure solution and refinement statistics. (Ramachandran plots in Appendix E).
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TABLE 3.2. Crystallographic statistics of gp146 co-crystalized with ligands. Crystallographic data
collection parameters and structure solution and refinement statistics. (Ramachandran plots in Appendix
E).
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3.1.3. Crystal structure of gp146
The crystallographic model of gp146 represents a 17.5-nm-long homotrimer that can be
divided into five domains [FIG 3.5]: four trimeric domains and one insertion domain. Trimeric
domains I (37-116), II (122-184 and 395-401), III (411-513), and IV (514-640) form a central
axis, whilst the insertion domains (185-394) protrude from the axial trimer adopting a peripheral
position. Within the central axis, the oblong domain IV (“tip”) can be differentiated from the
rounded domains I, II, and III (“shaft”). Domain I and insertion domain from chain A are
aligned with domain III from chain B and domain IV from chain C; this is consequence of interdomain rotations: ~60º between domains I and II and between domains II and III, and ~120º
between domains III and IV.
All five gp146 domains are formed by β-sheets with small helices in some loops [FIG
3.6]. Along the central axis, there are two additional α-helices: before domain I (26-31) and
between domains II and III (404-410). Like the axial domains, these helices interact with their
counterparts from the other monomers.
The gp146 trimer has a surface area of 70 x 103 Å2 and each monomer (residues 24-640)
of the trimer has a surface area of 33 x 103 Å2. Therefore, 29 % (9.7 x 103 Å2) of the surface of
each monomer is buried in the quaternary interface, forming 124 inter-chain hydrogen bonds
and 44 inter-chain salt bridges. The gp146 trimer is thermodynamically stable (estimated
dissociation energy: ΔG0diss = +173 kcal/mol).
Shaft domains. Domains I, II and III of gp146 form the central trimeric shaft. The shaft
domains have the same topology [FIG 3.6]: a mixed six-stranded β-sheet whose first two
strands (AB) are parallel strands connected by a loop with a short helix and the last five strands
(BCDEF) form an anti-parallel up-and-down sheet. The differences between the shaft domains
arise in the loops. Loop E-F from domain II is disrupted by the insertion domain. Domain III
(the biggest of the shaft domains) contains longer loops A-B and C-D and an additional short βhairpin at the amino-terminus.
The outer side of the shaft domains β-sheet is covered by loops A-B and B-C, forming a
hydrophobic core in each monomer. The inner side of the β-sheet is involved in the
trimerization, interacting with the other monomers at both ends of the β-strands and molding a
hydrated cavity in the middle.
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FIGURE 3.5. Crystal structure of gp146. Ribbon diagram of the gp146 crystal-structure model.
Domain color-code: I-green, II-cyan, III-blue, IV-red, insertion domain-orange.
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FIGURE 3.6. Topology of gp146. Topological diagram of the gp146 model. Arrows represent β-strands,
rectangles represent α-helices and 3.10-helices, and lines represent non-assigned secondary structure.
Domain color-code: I-green, II-cyan, III-blue, IV-red, insertion domain-orange.
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Along the central axis of the shaft, some bulky electron densities were modeled as ions
involved in inter-chain interactions. In domain I of the gp146:G1P model, a trigonal planar
electron density was assigned as a carbonate interacting with Asn57 from the three monomers.
In domain II, up to three ions were detected in a central position: a phosphate oxoanion
(interacting with Lys159 and Asn157), a Mg 2+ cation (stabilized by Glu170; a water was
modeled instead in the gp146:G1P model), and a carbonate oxoanion (interacting with the
amide carbonyl of Ile402; absent in the selenomethionine derivative model). A peripheral Cl anion was modeled in domain II of the ligand-free gp146 model and the gp146:SA378 model 3,
interacting with the amide amine of Val130 and Asn145 (a cation (Cu 2+) could have been
modeled based on the resemblance to the Biuret reaction, but it would require alkaline
conditions).
Tip domain. Domain IV (tip) of gp146 is also part of the central trimeric axis of the complex. It
does not have the topology of the shaft domains, but it is a β-sandwich formed by two fourstranded anti-parallel β-sheets [FIG 3.6]. This β-sandwich is twisted and glided, so an apical and
basal β-sheets can be differentiated. The apical β-sheet (VWXY/S) is an up-and-down sheet
except for the short strand S, which forms antiparallel secondary structure interactions with the
amino-terminal part of strand X. The basal β-sheet (RZTU) contains the amino- and carboxyterminal ends of the domain (strands R and Z) and a hairpin (TU). Both sheets form a
hydrophobic core in between. The monomers are interlocked laterally, with the U/V edge buried
in the center of the trimeric tip.
The trimeric tip is held together by hydrophobic interactions at the apex of the domain
and by ionic interactions at the base. In the gp146:G1P model, the inter-chain ionic interactions
also involve a phosphate oxoanion modeled at the central axis of the tip surrounded by Lys559
from the three chains; however, this phosphate was not visible in the gp146(402-640) models.
At the surface of the tip of the gp146(402-640) models, two cations were identified interacting
with two monomers each: Na+ (interacting with Asn576, amide carbonyl Ile577, and Asn579
from a monomer and Glu590 from the adjacent monomer) and Mg 2+ (coordinated with Gly613,
Asn616, and Ser584 from a monomer and Thr618 from the flanking monomer).

3

The domain II chloride anion was modeled only in two monomers of the asymmetric unit of
gp146:SA378.
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FIGURE 3.7. Local B-factors of gp146 models. Representation of the local B-factors relative to each
model: gp146:SeMet (res.: 3.37 Å; mean B: 94.4), gp146 (res.: 2.11 Å; mean B: 50.3), gp146(402-640)
(res.: 2.70 Å; mean B: 57.3), gp146:SA378 (res.: 3.12 Å; mean B: 69.0), gp146:G1P (res.: 1.70 Å; mean
B: 36.4), gp146(402-640):G1P(added) (res.: 1.99 Å; mean B: 21.0). The highest values of each model are
represented as a thick red string and the lowest values of each model are depicted as a thin blue string.

Despite the apparent compactness of gp146 tip, the disorder found in the
crystallographic results points to a flexible nature of the apical part of the domain. The gp146
model lacks the apex of the tip because it was not visible in the electron-density map; this may
be attributed to disorder in that area since visible portion of the model is restrained by the
tertiary structure (a proteolytic cleavage would be expected to impose constraints derived from
the primary structure disruption). The disorder in the distal portion of domain IV is also
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reflected in the higher local B-factors of this area in the gp146:G1P model and, to a less extent,
in the selenomethionine-derivative model and the gp146:SA378 model [FIG 3.7]; although the
chain was traceable in the electron-density maps and it was included in the models. The
conformation of the side chains of gp146 domain IV could only be determined in the
gp146(402-640) models, whose domain IV was more ordered probably due to a tighter crystal
packing.
Insertion domain. The insertion domain is the only domain of gp146 that does not establish
trimeric interactions but protrudes laterally from the shaft. It was predicted to belong to the
carbohydrate binding domain superfamily CBM_4_9 (pfam02018) [Marchler-Bauer et al.
2017]. Indeed, the structural model represents a 10-stranded β-sandwich with a galectin-like
jelly roll topology [FIG 3.6] consisting of two five-stranded β-sheets stacked together with a
hydrophobic core. The inner β-sheet of gp146 insertion domain (HIPKN) is packed against the
long linkers that connect the insertion domain to the shaft domain II. These linkers appear
ordered in the crystals, although without any conventional secondary structure arrangements.
The outer β-sheet (GJOLM) forms a cleft resemblant to the binding site of other domains from
the same family. The cleft has positive charge due to the guanidinium groups of Arg311 and
Arg352 that arise at the bottom of the cleft, whilst the sides of the cleft constitute a more apolar
environment because of the presence of four tyrosines (Tyr208, Tyr250, Tyr290, and Tyr307).

3.1.4. Structure of gp146 bound to rac-glycerol 1-phosphate
The co-crystallization of gp146 with rac-glycerol 1-phosphate resulted in the
identification of glycerol-phosphate ligands in three positions: domain III, domain II, and
insertion domain [FIG 3.8].
In domain III binding site, two different ligands were modeled with 0.5 occupancy each:
a glycerol 3-phosphate and a combination of glycerol and phosphate 4 [FIG 3.9 a, b]. The
glycerol 3-phosphate is attached to the binding site by interactions of the phosphate group (with
Tyr450, Ser463, Arg465, and three waters), the 2-hydroxyl group (with Asp473 and the amide
amine from Lys474), and the 1-hydroxyl group (with Tyr420 and Asp471). The interaction of
the glycerol 3-phosphate ligand involves to monomers (Tyr420, Tyr450, Ser463, and Arg465
belong to a monomer; whilst Asp471, Asp473, and Lys474 belong to an adjacent monomer).
Alternatively, a glycerol is in place of the glycerol 3-phosphate and a phosphate is interacting
with Tyr450, Gln452, Ser463, and four waters. In the ligand-free gp146 model and in two
4

A tetragonal electron-density was modeled as a phosphate oxoanion. The crystallization condition did
not contain any phosphate, so the assignment of the phosphate was on the basis of a plausible
contamination or degradation of the rac-glycerol 1-phosphate. A sulfate from the crystallization
condition could have been modeled instead.
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FIGURE 3.8. Modelling of gp146:G1P. Location of the three possible binding sites of rac-glycerol 1phosphate in the surface representation of the gp146:G1P model (left) and fitting of the modeled ligands
in the electron-density map of each binding site (top-right: domain II; middle-right: insertion domain;
bottom-right: domain III).

monomers from the gp146:SA378 model, a chloride anion is interacting with Arg465 instead of
the glycerol 3-phosphate.
A glycerol 1-phosphate was modeled in the interface between domain II and the
insertion domain, although the electron-density map is not clear enough to positively assign its
stereospecificity. The phosphate group interacts with Arg236 (from the insertion domain) and
four water molecules, the 2-hydroxyl group forms a hydrogen bond with Asn150, and the 3hydroxyl group interacts with the amide carbonyl from Asn175 [FIG 3.9 c].
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FIGURE 3.9. Binding sites of glycerol 1-phosphate on gp146. (a) Representation of the binding site of
gp146 domain III. A glycerol 3-phosphate is interacting with Tyr450, Ser463, Arg465, and Tyr420 from a
gp146 monomer and with Asp471, Asp473, and Lys474 from an adjacent monomer. (b) Representation of
the alternative occupation of the binding site of gp146 domain III. A glycerol occupies the position of the
glycerol 3-phosphate in (a) and a phosphate is interacting with Tyr450, Gln452, and Ser463. (c)
Representation of the binding site at the interface between domain II and the insertion domain. A glycerol
1-phosphate is interacting with Asn150 and Asn175 from domain II of a gp146 monomer and with
Arg236 from the insertion domain of other monomer. (d) Representation of the binding site of gp146
insertion domain. A glycerol 3-phosphate (occupancy: 0.5) is interacting with Lys304, Tyr307, and
Ser340. (Interaction distances in Appendix F).

The electron-density map of the glycerol-phosphate ligand found in the insertion
domain does not support a glycerol-phosphate molecule and it is insufficient to determine its
stereospecificity; a glycerol 3-phosphate was modeled with an occupancy of 0.5. The glycerol
3-phosphate is fixed to the insertion domain by interactions of the phosphate group (with
Lys3045, Ser340, and a water molecule) and the 2-hydroxyl group (with amide amine from
Tyr307 and a water molecule) [FIG 3.6 d]. In addition, the insertion-domain crevice is also
5

The salt bridge between the phosphate and Lys304 is not supported geometrically in the model, but it
might be possible considering the partial occupancy of the ligand.
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occupied by a phosphate4 (interacting with Asn305, Arg352, and three water molecules) and a
glycerol molecule (interacting with Asp248, amide carbonyl from Tyr250, Arg352, and two
water molecules). In the ligand-free gp146 model, the phosphate and the glycerol are replaced
by two acetates from the buffer interacting with Arg352.
The binding of the glycerol-phosphate ligands did not drastically alter the conformation
of the structure (the comparison of gp146 and gp146:G1P models resulted in a rmsd of 0.514
Å). Locally, the binding of the glycerol-phosphate to the insertion domain modified the
arrangement of loop N-O [FIG 3.9 d], which adopts a configuration closer to the ligand
allowing the interaction between Ser340 and the phosphate group. The displacement of the N-O
loop explains its relatively higher local B-factor [FIG 3.7].

3.1.5. Structure of gp146 bound to SA-378
The insertion-domain cleft was identified as a binding site in the co-crystallization assay
of gp146 with SA-378. The location of the α-glycosylated-poly(ribitol 5-phosphate) SA-378 in
the insertion-domain cleft is incontestable, but the precise binding of the ligand cannot be
determined in the gp146:SA378 model. The resolution of the model is below the resolution
recommended for a reliable identification of a ligand (1.5-2.5 Å) [Deller & Rupp 2015].
Furthermore, the SA-378 is a long and repetitive molecule and only a fragment can be fitted in
the insertion-domain cleft; the multiple binding possibilities of the repetitive unit could have
caused heterogeneity that might also be affecting the sharpness of the electron-density map of
the ligands. The modeling of the whole SA-378 molecule resulted in the assignment of high Bfactors to the unbound portions [FIG 3.10 a]; so the SA-378 ligands were trimmed to fit the
visible electron-density map [FIG 3.10 b], assuming that the non-modeled part of the molecule
is disordered.
Although the modeling is not precise and the specific interactions represented in the
model are arbitrary, some features of the binding can be inferred from the location of the SA378 in the area. In the six binding sites represented in the asymmetric unit, the binding is
primarily mediated by the ionic interaction and hydrogen bonding of the pairs Arg352/Asn305
and Arg311/Asn354 with two continuous phosphate groups from the SA-378 molecule. Tyr250
and Tyr290 also appear recurrently involved in the binding of SA-378 [FIG 3.11]. Molecules of
α-N-acetylglucosamine were modeled in five binding sites of the asymmetric unit, although the
definition of the electron-density map was not as clear as for the ribitol 5-phosphate backbone
[FIG 3.10 b].
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FIGURE 3.10. Modelling of gp146:SA378. (a) Representation of the relative B-factors of a complete
SA-378 ligand in a surface representation of an insertion domain gp146:SA378 model. Color code: black
- lowest B-factor, white - highest B-factor. The portions with the highest B-factors were trimmed from the
model. (b) Fitting of the trimmed SA-378 ligands in the electron density maps of the six binding sites of
the asymmetric unit of the P 21 crystal.
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FIGURE 3.11. Binding of SA-378 to gp146 insertion domain. Representation of the binding of the
trimmed SA-378 ligands to the six insertion domains of the asymmetric unit of the P 21 crystal. The
binding of the SA-378 ligand involves Asn305, Arg311, Arg352, and Asn354. (Interaction distances in
Appendix F).
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Although the electron-density map does not unravel the direction of the SA-378
molecule in the binding site, all ligands were arranged keeping Arg352 close to 5-hydroxylphosphate end and Arg311 close to 1-hydroxyl group and the phosphate group from the next
(ribitol 5-phosphate)-unit. This orientation of SA-378 is purely hypothetical; it was based on the
preservation of the consistency with wall teichoic acid structure 6, so the wall-teichoic-acid
linker would remain in the distal part of the protein (tip domain). Notwithstanding, considering
the flexibility of the wall teichoic acid, the opposite orientation of the SA-378 molecule would
also be plausible.
The gp146:SA378 model is very similar to the ligand-free gp146 model (rmsd 1.32 Å).
The only significant difference between these models is the relative disposition of domain I
(which explains the use of an independent template for domain I during the molecularreplacement phasing; see Section 3.1.2). This difference does not seem related to the binding of
SA-378 but it is probably derived from the flexibility of domain I and the crystal packing
interactions.

3.1.6. Binding of gp146 to Staphylococcus aureus
In order to analyze the functionality preservation of the heterologously expressed
gp146, the binding of purified gp146 to S. aureus was tested by an immunofluorescence assay.
The experiment was performed with the S. aureus strain RN4220; this strain is susceptible to
phage K infection [Alves et al. 2014] and the infection of S. aureus strain RN4220 by the
kayviruses phiSA012 requires a functional gp146-ortholog [Takeuchi et al. 2016]. The result of
the binding assay was positive [FIG 3.12], confirming that the purified gp146 remains
functional.

6

For comparison of the chemical structures of wall teichoic acid and SA-378 see [FIG 4.8].
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FIGURE 3.12. Binding of gp146 to S. aureus. Immunofluorescence assay for the detection of Histagged gp146 on S. aureus RN4220 ΔspAspA cells. (a) Negative control (no gp146 added). (b) Test of gp146
binding (gp146 added); the signal from the Alexa Fluor® 546 in the periphery of the cells indicates that
gp146 in bound to the cell envelope of S. aureus. Scale bars: 1 µm.
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3.2. Phage K receptor-binding protein: gp144
3.2.1. Expression and purification of gp144
Expression and purification of the recombinant gp144(2-458) 7 were adequate for
crystallography studies [FIG 3.13]. The protein was released from the IMAC with 50, 100, 200
mM of imidazole. In accordance with gp144(2-458) acidic isoelectric point (pI 6.71), the
desalted purification steps were carried out at pH 8.5. The protein was cold-sensitive at low
ionic strength conditions; i.e., protein aggregated and precipitated if kept in ice, but resolubilized after warming up. The recombinant protein eluted from the anion-exchange

FIGURE 3.13. Expression and purification of gp144(2-458). Features of the expressed recombinantprotein (table top-left), calculated with ExPASy ProtParam [Gasteiger et al. 2005]. Purification outcome:
IMAC (top-right) (FT: flow-through; W: wash), anion-exchange chromatography (bottom-left), size
exclusion chromatography (bottom-right). The chromatograms plot absorbance (280 nm) vs elution
volume; dotted line in the anion-exchange chromatogram represents conductivity (proportional to the
concentration of NaCl). (*) Loaded sample.
7

I did not produce the expression vector.
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FIGURE 3.14. Crystals of gp144(2-458). (a) Crystals of gp144(2-458) in the condition 8 % w/v
polyethylene glycol 8000, 200 mM lithium chloride, 50 mM magnesium sulfate. (b) Fished crystal from
(a). Scale bar: 50 µm. (c) Fished crystal of gp144(2-458):G1P. Scale bar: 50 µm.

chromatography in two distinct populations: 0.12-0.20 M of NaCl and 0.21-0.32 M of NaCl.
The population bound with lower affinity showed fewer impurities in the SDS-PAGE and it was
subjected to size exclusion chromatography to obtain the sample suited for crystallization.

3.2.2. Crystallization and structure determination of gp144
Monoclinic crystals of the P 21 space group were obtained by sitting-drop crystallization
of gp144(2-458) with 8 % w/v polyethylene glycol 8000, 200 mM lithium chloride, 50 mM
magnesium sulfate [FIG 3.14 a, b]. The structure was solved by molecular replacement using
the carboxy-terminal model of gp144 (PDB:id 5M9F) and domain I from the gp146 structure
model. The asymmetric unit of the 2.45-Å-resolution crystal structure of gp144(2-458) consists
of a trimer for which residues 62 to 458 were modeled. An extra density parallel to β-strand B
(residues 76 to 80) allowed the tracing of the backbone of a loose chain at the amino-terminal
end of chains B and C, but the side chains were not evident and the amino-acids could not be
identified. The model includes three sulfate oxoanions, one ferric cation, one magnesium cation,
and six water molecules.
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TABLE 3.3. Crystallographic statistics of gp144(2-458). Crystallographic data collection parameters of
gp144(2-458) crystals and refinement statistics of the structure models. (Ramachandran plots in Appendix
E).
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Co-crystallization of gp144(2-458) with rac-glycerol 1-phosphate and SA-325 was
attempted. The sample incubated with rac-glycerol 1-phosphate (hereinafter referred to as
“gp144:G1P”) crystallized in 4.15 % w/v polyethylene glycol 8000, producing monoclinic
crystals of the C 2 space group [FIG 3.14 c]. The structure of gp144:G1P was solved to 2.88 Å
resolution [TABLE 3.3] by molecular replacement, using the domains from the ligand-free
structure. The model of the asymmetric unit of the crystal encompasses a trimer of gp144
(residues 33 to 458), two glycerol-phosphate molecules (assigned as glycerol 3-phosphate), and
one calcium cation.

3.2.3. Crystal structure of gp144
The crystallographic models of gp144 represent an ~18-nm-long homotrimer organized
in four β-structure trimeric domains [FIG 3.15]: I (60-149), II (152-226), III (237-336) and IV
(337-458). There are ~30º rotations between domains I and II and between domains II and III,
and a ~120º rotation between domains III and IV. Aside from the domains, there are two helices:
an amino-terminal α-helix (33-47) and a 3.10 helix (229-235) between domains II and III. The
10-residue-long gap between domains II and III enables a ~10º tilt between domains I-II and
domains III-IV; this is probably a crystallographic artifact but may reflect the flexibility of this
area. The flexibility of the II-III-linker is also supported by the comparison between the two
full-length models (gp144 and gp144:G1P); the models primarily differ in the configuration of
the II-III-linker, since the difference found in the superposition of full-length chains (rmsd 1.79
Å) is reduced when comparing the carboxy-terminal moieties (domains III-IV) (rmsd 0.732 Å)
and the carboxy-terminal moieties (domains I-II) (rmsd 0.916 Å).
The surface area of a gp144 monomer (residues 33 to 458) is 25 x 103 Å2 and the surface
area of the gp144 trimer is 49 x 103 Å2. Therefore, 35 % (8.7 x 103 Å2) of the surface of each
monomer is buried in the trimer, forming 80 inter-chain hydrogen bonds and 18 inter-chain salt
bridges. The gp144 trimer has an estimated dissociation energy (ΔG0diss) of +138 kcal/mol,
which indicates that the complex is thermodynamically stable.
Shaft domains. Topologically, the shaft domains (domains I, II and III) of gp144 are sixstranded mixed β-sheets; strands BCDEH are anti-parallel and strands AB are parallel with a
helix in the connecting loop [FIG 3.15]. Domain I does not have a proper β-strand A, but the
loop connecting β-strand B and the amino-terminal α-helix runs close to β-strand B and Lys61
forms a β-bridge with it. Domain III possesses an additional β-hairpin at its amino-terminus.
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FIGURE 3.15. Crystal structure of gp144. Ribbon diagram of the gp144 crystal-structure model (left)
and topological diagram of the model (right). Domain color-code: I-green, II-cyan, III-blue, IV-red. In the
topological diagram, arrows represent β-strands, rectangles represent α-helices and 3.10-helices, and lines
represent non assigned secondary structure.

Loops AB and BC are folded against the external side of the β-sheet, forming a
hydrophobic core in each shaft domain monomer. The inner side of the β-sheet of the shaft
domains is involved in the trimerization, interacting with the other monomers by hydrophobic
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interactions (domains I and III) or by ionic interactions (domain II). Centrally located cations
are involved in the inter-chain ionic interactions of domain II. In the ligand-free gp144 model a
Mg2+ and Fe3+ were included interacting with Asp188 and Glu209, respectively, from the three
monomers. The electron-density map also supported a Ca 2+ or a K+ instead of the Mg2+ and a
Cu2+ instead of the Fe3+, but the chosen ions have more favorable B-factors. In the gp144:G1P
model, the Fe3+ is absent and a Ca 2+ (not Mg2+) is interacting with Asp188. Neither iron nor
calcium were included in the crystallization conditions, so these ions should be kept along the
purification. Apparently, the binding of the glycerol-phosphate ligand does not affect the domain
II, so the disparity of the central cations of domain II between the models should be explained
by differences in the crystallization condition or the ligand solution.
Tip domain. The tip domain (domain IV) is distinct from the shaft domains; it is a twisted βsandwich of eight antiparallel β-strands (named VWXS/RZTU to keep the nomenclature applied
to gp146 tip domain). The β-sandwiches are packed together laterally, with the S/R edge facing
the exterior of the trimer and the V/U edge packed in the interior. Each β-sandwich has a
hydrophobic core, but the inter-chain interactions are mostly hydrogen bonds and ionic
interactions (amino-carboxyl and cation-π). In the apex of the tip domain, the protruding V-W). In the apex of the tip domain, the protruding V-W
loops surround a flat platform formed by Thr419, Phe422, and Gln 442.

3.2.4. Structure of gp144 bound to rac-glycerol 1-phosphate
The glycerol-phosphate ligand is bound to domain III of gp144. The phosphate group
interacts with Arg294 and Tyr279 [FIG 3.16 b]; the location of the phosphate group is
unequivocal in the electron-density map [FIG 3.16 a] and it is backed by the presence of an
equivalent sulfate in the ligand-free model. Notwithstanding, the electron density of the glycerol
moiety is not clear enough to determine the stereospecificity [FIG 3.16 a], which suggests a
weak binding. The resolution of the model does not reach the recommended resolution values
(1.5-2.5 Å) for a reliable identification of the ligand [Deller & Rupp 2015] but, considering the
discernibility of the phosphate group, the stereospecificity of the glycerol moiety should be
evident if the binding was avid. Additionally, only two binding sites of the trimer kept the
glycerol-phosphate in the crystal, the other binding site is occupied by an amino-terminal helix
from an adjacent asymmetric unit, which also indicates that the affinity is low (otherwise the
ligand should remain bound during the crystallization since, in a co-crystallization assay, the
interactions with the ligand (if any) precede any crystal interactions).
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FIGURE 3.16. Binding of glycerol 3-phosphate to gp144. (a) Location of the binding site of glycerol
3-phosphate in domain III of the gp144 (left, represented as surface) and fitting of the ligand in the
electron-density map of the binding site (right). (b) Representation of glycerol 3-phosphate bound to
domain III of gp144. The phosphate group of a glycerol 3-phosphate molecule interacts to Tyr279 and
Arg294. (Interaction distances in Appendix F).
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3.3. Phage K tail terminal spike: gp155
3.3.1. Expression and purification of gp155
Six constructs were designed to attempt the structural characterization of gp155 [FIG
3.17]. The isoelectric point of the constructs ranged from pI 4.96 to pI 6.26; therefore, a
common anionic purification strategy was used for all of them, keeping the buffer at pH 8.5.
The expression of the full-length construct was very poor and expression tests did not
show any improvement with different bacterial strains, induction time or induction temperature.
A small amount of gp155(1-848) eluted from the IMAC at 50, 100, 200 mM of imidazole. An
over-expressed band of apparent molecular weight ~25 kDa was evidenced in the SDS-PAGE
[FIG 3.18]; most of this unknown protein did not bind the resin, although a small band of the
same size co-eluted with gp155(1-848). This additional protein could be either a bacterial
protein induced by over-expression of the heterologous protein or a carboxy-terminal
proteolytic fragment of gp155(1-848) probably produced inside the cell since it also appeared
when protease inhibitors were added to the lysis buffer. Ion-exchange chromatography failed in
recovering any protein, so the fractions from the IMAC were directly loaded onto the size
exclusion chromatography column. The purity of the sample was very low and it could not be
enhanced by ammonium sulfate precipitation or by increasing the stringency of the IMAC
washes. Neither the quality nor the quantity of the sample was appropriate for crystallography,
but, considering the protein size and the detection of oligomers in the SDS-PAGE [FIG 3.18], it
was analyzed by electron microscopy.
The amino-terminal constructs did not properly express soluble protein. Some
expression of gp155(1-444) was detected, but most of it was insoluble. Soluble gp155(1-444)
was insufficient and oligomers did not appear in the SDS-PAGE analyses. Tests on induction
temperature and induction time did not improve the expression.

FIGURE 3.17. Fragments of gp155. Top diagram, linear representation of the full-length gp155 protein;
the boxes show the locations of the predicted coiled-coil domain and glycerophosphodiester
phosphodiesterase domain [Marchler-Bauer et al. 2017]. Bottom bars, representation of fragments cloned
to try the expression of gp155 for crystallographic studies.
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FIGURE 3.18. Expression and purification of gp155(1-848). Features of the expressed recombinantprotein (table top-left), calculated with ExPASy ProtParam [Gasteiger et al. 2005]. Purification outcome:
IMAC (top-right) (FT: flow-through; W: wash) and size exclusion chromatography (bottom) (the
chromatogram plots absorbance (280 nm) vs elution volume). (*) Loaded sample.

Regarding the carboxy-terminal constructs, gp155(315-848) and gp155(597-848)
expression quantity was enough for crystallization, but it failed for both proteins despite
microseed matrix screening attempts [Ireton & Stoddard 2004]. Like the full-length construct,
gp155(315-848) formed oligomers evidenced by SDS-PAGE, but the purity of the sample did
not reach crystallographic standards after IMAC, anion-exchange chromatography, and size
exclusion chromatography; neither ammonium sulfate precipitation nor modification of the
IMAC washes remove the impurities from the sample. The fragment gp155(597-848) was
expressed as apparent monomers that proteolysed in absence of EDTA [FIG 3.19 a], probably
due to some metalloprotease activity. The proteolytic profile of gp155(597-848) could be due to
an improper design of the construct; i.e., the amino-terminus might not correspond with the
amino-terminal end of the carboxy-terminal domain and that part may be partially proteolysed
and it may avoid crystallization. Accordingly, a construct encoding a shorter carboxy-terminal
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FIGURE 3.19. Expresion and purification of gp155 carboxy-terminal domain. (a) Samples of
purified gp155(597-848) after IMAC, anion-exchange chromatography, and size exclusion
chromatography. EDTA was either added only to the post-IMAC dialysis (left) or kept through the
purification (right). (b) Purification of gp155(614-848). Features of the expressed recombinant-protein
(table top-left), calculated with ExPASy ProtParam [Gasteiger et al. 2005]. Purification outcome: IMAC
(top-right) (FT: flow-through; W: wash), anion-exchange chromatography (bottom-left), size exclusion
chromatography (bottom-right). The chromatograms plot absorbance (280 nm) vs elution volume; dotted
line in the anion-exchange chromatogram indicates conductivity (proportional to the concentration of
NaCl). (*) Loaded sample.

fragment (gp155(614-848)) was designed. Expression of this construct was efficient and IMAC
delivered gp155(614-848) in fractions 50 and 100 mM of imidazole. The protein eluted from the
anion-exchange chromatography between 0.37-0.63 M of NaCl and was loaded onto the size
exclusion chromatography column to reach crystallography quality [FIG 3.19 b].
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FIGURE 3.20. Crystals of gp155(614-848). (a) Crystals of gp155(614-848) in the screening condition
20% w/v polyethylene glycol 8000, 100 mM HEPES pH 8.5. (b) Crystals of selenomethionine-labeled
gp155(614-848) with rac-glycerol 1-phosphate in the screening condition 20% PEG 1500, 100 mM
HEPES pH 7.5. (c) Fished crystal of gp155(614-848) grown in 5% w/v polyethylene glycol 8000, 83 mM
MES pH 3.0. Scale bar: 100 µm. (d) Fished crystal from (b). Scale bar: 100 µm.

3.3.2. Crystallization and structure determination of gp155(614-848)
The crystallization screening on the native ligand-free gp155(614-848) resulted
productive in several conditions. A first data set was collected from triclinic crystals of the P 1
space group (hereinafter referred to as “ligand-free-pH7.5”) crystallized in the screening
condition 18% w/v polyethylene glycol 8000, 2 % w/v 2-propanol, 100 mM HEPES pH 7.5,
100 mM sodium acetate. Both the precipitant concentration and the pH were further optimized
for the positive screening conditions. The optimization of the screening condition 20% w/v
polyethylene glycol 8000, 100 mM HEPES pH 8.5 [FIG 3.20 a] resulted in diffracting
monoclinic crystals of the P 21 space group (hereinafter referred to as “ligand-free-pH3.0”)
grown in 15% w/v polyethylene glycol 8000, 83 mM MES pH 3.0 [FIG 3.20 c].
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TABLE 3.4. Crystallographic statistics of gp155(614-848). Crystallographic data collection parameters
of gp155(614-848) crystals and refinement statistics of the resultant structure models. (Ramachandran
plots in Appendix E).
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Molecular replacement attempts did not work for the diffraction data initially obtained
from native crystals, so experimental phasing was used. Selenomethionine-labeled protein
incubated with rac-glycerol 1-phosphate8 was crystallized in 20% w/v polyethylene glycol 1500,
100 mM HEPES pH 7.5, delivering orthorhombic crystals [FIG 3.20 b, d] of the P 212121 space
group (hereinafter referred to as “ligand-bound”). Crystals diffracted to 1.62-Å resolution
[TABLE 3.4], with an anomalous correlation coefficient of 0.15 at 1.67 Å. The ligand-bound
selenomethionine derivative was solved by single-wavelength anomalous dispersion (SAD) 9.
The asymmetric unit of the selenomethionine derivative contains a single monomer of
gp155(614-848), for which residues 614-848 were modeled. The model includes three ligands
of glycerol-phosphate, a calcium ion and 119 waters. The derivative model was used as template
for molecular replacement of the native protein crystallized without ligand. The ligand-freepH3.0 model was refined to 1.52-Å resolution [TABLE 3.4] and it includes two monomers of
gp155(614-848) (residues 614-848) with the same conformation (rmsd 0.328 Å), two molecules
of MES, two molecules of glycerol, and 252 waters. The ligand-free-pH7.5 model (whose
diffraction data set had failed in the initial molecular replacement processing) was refined to
1.16-Å resolution [TABLE 3.4] and it consists of two monomers of gp155(614-848) (residues
614-848) with the same conformation (rmsd 0.396 Å), two molecules of HEPES, four sodium
ions and 399 waters.

3.3.3. Crystal structure of gp155 carboxy-terminal domain
As predicted, the model of the crystal structure of the carboxy-terminal domain of
gp155 represents a classical α/β barrel [FIG 3.21 a] like that of the triose phosphate isomerase
(TIM-barrel). The TIM-barrel consists of a twisted eight-stranded parallel β-sheet barrel
surrounded by eight α-helices that connect consecutive β-strands. The α-helices are packed
against the β-barrel by hydrophobic residues, whilst the external residues of the helices are
polar. The interior of the β-barrel is also hydrophobic except for the active site located at the
carboxy-terminal end of the parallel β-barrel. Besides the TIM-barrel, gp155 carboxy-terminal
domain also includes an insertion domain [FIG 3.21 a] that has already been described for
related glycerophosphodiester phosphodiesterases [Santelli et al. 2004]. The insertion domain
protrudes from the elongated β-strand β2 and includes a short β-strand antiparallel to the
carboxy-terminal fragment of β2, a 15-residue-long loop, a 3.10-helix, an α-helix and an 11residue-long loop that connects to α2 [FIG 3.21 b]. The loops from the insertion domain are
packed with the 12-residue-long loop β1α1.
8
9

Crystallization of the selenomethionine derivative was also attempted without the glycerol-phosphate
ligand, obtaining a crystal with very poor diffraction whose processing failed and with no apparent
anomalous signal.
Molecular replacement also worked for the derivative data set.

80

3. Results

FIGURE 3.21. Crystal structure of gp155(614-848). (a) Ribbon diagram of the gp155(614-848)
crystal-structure model. Color code: TIM barrel-green, insertion domain-orange. (b) Topological diagram
of the crystallographic model of gp155 (614-848). Arrows represent β-strands, rectangles represent αhelices and 3.10-helices, and lines represent non assigned secondary structure.

The ligand-bound structural model is more similar to the ligand-free-pH7.5 model
(rmsd 0.289 Å and 0.380 Å, when compared to the ligand-free-pH7.5 chain A and B,
respectively) than to the ligand-free-pH3.0 model (rmsd 0.693 Å and 0.827 Å, when compared
to the ligand-free-pH3.0 chain A and B, respectively). The only significant difference between
the models is located in loop β3α3 and it is caused by the different accommodation of Lys718.
In the ligand-free-pH7.5 and ligand-bound structures, Lys718 interacts with Glu716 and the
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phosphate from the ligand [FIG 3.22 a, b], whilst, in the ligand-free-pH3.0 structure, Lys718
points outwards from the active site [FIG 3.22 c]. The displacement of the loop β3α3 also
affects, to a less extent, the loop β4α4 since, in the ligand-bound model, the Arg719
guanidinium group “pulls” from the Phe752 aromatic ring, avoiding the disruption of the cationpi interaction.
In the ligand-bound model, a Ca 2+ cation is located in the active site, fixed by trigonal
bipyramidal coordination with Glu648, Asp650, Glu716, a water molecule, and the phosphate
and hydroxyl groups from the glycerol 3-phosphate ligand [FIG 3.22 a]. However, the electrondensity map of the ligand-free-pH7.5 crystal does not support a Ca 2+ cation and a Na+ cation was
placed instead [FIG 3.22 b]; a Mg 2+ would have also been supported by the electron-density
map, but the valence of the Na+ cation is more consistent with their environment according to
the CheckMyMetal [Zheng et al. 2014] analysis. The electron-density map of the ligand-freepH3.0 crystal does not show any electron density at that position [FIG 3.22 c]. Considering that
the purification involved EDTA (although to a low concentration) and no calcium was added
nor present in the conditions, it might be possible that the carboxyl triad Glu648-Asp650Glu716 acts as a chelant along the purification, preserving some Ca 2+ ions that are present in the
ligand-bound model. If that were the case, the loss of the Ca 2+ ion in the ligand-free models
should occur during the crystallization in absence of the ligand. The lack of any cation in the
ligand-free-pH3.0 model might be explained by the protonation of the carboxyl triad due to the
acidic pH of the crystallization buffer (15% w/v polyethylene glycol 8000, 83 mM MES pH
3.0), especially considering that titration of internal groups varies their soluble pKa [Harms et
al. J Mol Biol 2009]. Accordingly, the ligand-free models might be crystallographic artifacts,
particularly the ligand-free-pH3.0 model.
The ligand glycerol 3-phosphate is bound to the active site by a network of hydrogen
bonds and ionic interactions [FIG 3.22 a]. The 1-hydroxyl group interacts with Glu648, Glu716,
Gln751 and the Ca2+ cation. The 2-hydroxyl group interacts with His621, the Ca 2+ cation and a
water molecule. The phosphate group interacts with His621, Arg622, His663 (from the insertion
domain), Lys718, the Ca2+ cation and three water molecules. Additional residues are required for
the proper location of the interacting residues. Furthermore, Phe753, Leu773, Trp818, and
Phe838 form a hydrophobic pocket around the aliphatic chain of the glycerol. In the ligand-freepH3.0 model, the active site is occupied by a glycerol molecule from the cryoprotecting
solution, which establishes hydrogen bonds with Glu716, Gln751 and a water molecule. The
active site of the ligand-free-pH7.5 is occupied by water molecules, although a glycerol with
low occupancy might also be modeled in an equivalent position to that of the ligand-free-pH3.0
model.
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FIGURE 3.22. Active site of gp155(614-848). Representation of the active site of the (a) ligand-bound,
(b) ligand-free-pH7.5, and (c) ligand-free-pH3.0 models. The active site has a metal cation (Ca 2+ in the
ligand-bound model, Na+ in the ligand-free-pH7.5 model, and absent in the ligand-free-pH3.0 model)
fixed by Glu648, Asp650, and Glu716. The binding of the glycerol 3-phosphate involves: Ca 2+ cation,
His621, Arg622, Glu648, His663, Glu716, Lys718, and Gln751. (Interaction distances in Appendix F).

Two additional glycerol-phosphate ligands were included in the ligand-bound model
outside the active site. Their stereospecificity could not be determined since the electron-density
map for these ligands is not as clear as it is for the glycerol 3-phosphate from the active site
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FIGURE 3.23. Modelling of gp155(614-848) ligands. Fitting of the rac-glycerol 1-phosphate ligands
into the electron-density map of (a) the active site, (b) the insertion domain, and (c) the helix α3. Only the
stereospecificity of the binding to the active site can be identified: a sn-glycerol 3-phosphate is bound.

[FIG 3.23]. One of the extra-glycerol-phosphate is fixed by ionic interactions with Lys655
(located in the insertion domain) and it is replaced by an MES or HEPES molecule from their
respective buffers in the ligand-free models. The other extra-glycerol-phosphate has been
modeled near Lys734 (located in α3), although the occupancy was reduced to 0.6.

3.3.4. Negative-staining electron microscopy of gp155
The electron microscopy analysis of negative-stained gp155(1-848) [FIG 3.24]
confirmed the poor quality of the sample manifested in the SDS-PAGE analysis. The sample is
highly heterogeneous and the wide variety of particles is inconsistent with the projections of a
single particle type. The lack of homogeneity limits potential studies by cryo-EM.
Some particles appear as cones or conical frustums [FIG 3.24], which concurs with the
morphology expected from a spike complex. These particles average 28 nm length and 15 nm
wide.
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FIGURE 3.24. Negative-stained gp155(1-848). Two micrographs of negative-stained gp155(1-848) are
shown on the left (scale bars: 100 nm) and detailed spots are displayed on the right (scale bars: 10 nm).
Some particles agree with the predicted conical shape of the gp155 complex, but the sample is too
heterogeneous to assert it.
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4.1. Phage K receptor-binding proteins: gp146 and gp144
Phage K has two receptor-binding proteins: gp146 and gp144. Their crystal structure
revealed that they are closely related proteins with a common architecture. Their structural
organization is distinct from the previously described structures of receptor-binding proteins
from Gram-positive phages.
Receptor-binding proteins of phages are usually trimers organized in modules, which
enables evolution driven by module exchange [Dunne et al. 2018]. This modular organization
stands for phage K receptor-binding proteins gp146 and gp144. They both share the same core
structure: a trimeric axis formed by three shaft domains and a carboxy-terminal tip domain [FIG
4.1]. Protein gp146 has an extra domain (insertion domain) spliced to domain II.
The similarity between both receptor-binding proteins from phage K is palpable from a
sequence alignment [FIG 4.2]. Proteins gp146 and gp144 have a 24.28% of sequence identity
(clustalo1.2.4 [Sievers et al. 2011]); aligning their amino- and carboxy-terminal regions with a
gap corresponding to the insertion-domain. It has been suggested that their amino-terminal
similarity points to the connection to the same component of the baseplate [Takeuchi et al.
2016]. In my opinion, this is true when comparing orthologous genes (e.g., the receptor-binding
protein of other spounaviruses, like Listeria phage A511 [Habann et al. 2014]); the aminoterminal similarity of orthologs might be explained by baseplate interactions, whilst the
carboxy-terminal portion diverges because the host-interacting portion is subjected to
antagonistic coevolution with the host. However, the sequence similarity of the paralogous
genes encoding gp146 and gp144 is consequence of the closely evolutionary relationship
between both genes rather than a functional conservation due to the interaction with the same
baseplate protein, which would difficult the morphogenesis of the baseplate in order to include
both receptor-binding proteins (it would create heterogeneity in the virions, decreasing the
fitting of some of them). Sequence comparison is misleading since evolution does not act on
sequences but on function and protein function relies on structure. The alignment of gp146 and
gp144 proves that the sequence alignment does not correspond to the actual organization of the
domains and, despite the apparent high conservation of the amino-terminus, the alignment
matches better the disposition of the carboxy-terminal domains [FIG 4.2]. The amino-terminal
α-helix and the loop preceding domain I from gp144 are longer than those from g146; thus,
gp146 domain I starts at residue 37 and gp144 domain I starts at position 60.
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FIGURE 4.1. Structure of gp146 and gp144. Comparison of the ribbon (top) and topological (bottom)
representations of the crystal models of phage K gp146 (left) and phage K gp144 (right). Domain colorcode: I-green, II-cyan, III-blue, IV-red, insertion domain-orange.
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FIGURE 4.2. Alignment of gp146 and gp144. Sequence alignment of gp146 and gp144 (identity
24.28%). Domains are highlighted with the same color-code as [FIG 4.1]: I-green, II-cyan, III-blue, IVred, insertion domain-orange.

4.1.1. Shaft domains
The shaft domains constitute the central core of phage K receptor-binding proteins.
Superposition of the gp146 and gp144 shaft domains [TABLE 4.1] reveals that domains I and II
are more similar between them 1 than when compared to domains III. This differentiation was
expected from the description of the shaft domains since domain III of both gp146 and gp144 is
1

The relatively high rmsd (8.58Å) resultant from the comparison between gp146 domain II and gp144
domain I can be explained by the disruption caused by gp146 insertion-domain and the absence of a
proper β-strand A in gp144 domain I.
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TABLE 4.1. Statistical comparison of the shaft domains from phage K receptor-binding proteins
and similar domains. Statistical results of the superposition of the shaft-domain-like domains from
phage K gp146, phage K gp144, Pseudomonas aeruginosa R2-pyocin fiber (PDB:id 6CL6),
Acinetobacter phage vB_AbaP_AS12 tailspike gp42 (PDB:id 6EU4), phage ϕ11 receptor-binding protein
gp45 (PDB:id 5EFV) [Koç et al. 2016], and phage T4 proximal long tail fiber gp34 (PDB:id 5NXH)
[Granell et al. 2017]. From top to bottom: percentage of aligned-sequence identity in the all-atom
superposition, root mean square deviation including all atoms, root mean square deviation including only
Cα.

bigger and has an extra amino-terminal β-hairpin. Therefore, domain III establishes an
orthologous-like relation to its counterpart from the other receptor-binding protein and a
paralogous-like relation to domains I and II.
A DALI server [Holm & Laakso 2016] search showed that the shaft-domain topology
also appears in two domains (residues 360-439 and residues 445-530) from the carboxyterminal fragment of Pseudomonas aeruginosa R1-pyocin (PDB:id 6CL5) and R2-pyocin
(PDB:id 6CL6) fibers, a domain (residues 479-569) from the tailspike gp42 of Acinetobacter
phage vB_AbaP_AS12 (PDB:id 6EU4), the carboxy-terminal tower domains (residues 439-543
and residues 544-636) from the receptor-binding protein gp45 of S. aureus phage ϕ11 (PDB:id
5EFV) [Koç et al. 2016], and domain P5 (residues 1126-1163, 1185-1241) from proximal long
tail fiber gp34 of T4 (PDB:id 5NXH) [Granell et al. 2017] [FIG 4.3].
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FIGURE 4.3 Shaft domains from phage K receptor-binding proteins and similar domains. Location
of the shaft-domain-like domains (red) in phage K gp146, phage K gp144, Pseudomonas aeruginosa R2pyocin fiber (PDB:id 6CL6), Acinetobacter phage vB_AbaP_AS12 tailspike gp42 (PDB:id 6EU4), phage
ϕ11 receptor-binding protein gp45 (PDB:id 5EFV) [Koç et al. 2016], and phage T4 proximal long tail
fiber gp34 (PDB:id 5NXH) [Granell et al. 2017]. All models are oriented with their amino-terminus at the
top.
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The superposition of phage K shaft domains and similar domains from other proteins
[TABLE 4.1] resulted in higher rmsd (average rmsd: 6.18/6.21 Å in all-atom/Cα alignments 2)
than those obtained from the alignment of domains I and II from phage K receptor-binding
proteins, but comparable to the differences between domain III and domains I/II.
The disposition of the shaft-domain-like domains in their proteins suggests functional
diversification [FIG 4.3]. In the pyocin fibers, the domains are located in the amino-terminal
region, which points to a structural support role. Regardless of its position within the protein,
the structural role can also be presumed to the P5 domain from T4 gp34 [Granell et al. 2017],
since gp34 is the proximal protein of T4 fiber and it is not directly involved in host binding. The
shaft-domain-like domain of phage vB_AbaP_AS12 tailspike is placed near the carboxyterminus, which agrees with a possible host-interaction role. The host-binding function can also
be ascribed to the tower domains of ϕ11 gp45, which are found in the carboxy-terminal part of
the ϕ11 fiber [Koç et al. 2016]. Deletion of the tower domains on a similar protein of phage
S24-1 impairs the binding activity of the protein [Uchiyama et al. 2014], supporting a binding
role for those domains of ϕ11. The shaft domains of gp146 and gp144 are found as repeated
modules along the trimers, from the amino-terminal moiety to a relatively distal position.
Therefore, the shaft domains of phage K receptor-binding proteins probably have a dual role:
they serve as the building blocks that scaffold the trimers but they may also be involved in the
binding to the host receptor.

4.1.2. Tip domain
Domain IV or “tip” domain is the singular carboxy-terminal domain of phage K
receptor-binding proteins. The tip domains from gp146 and gp144 have a common β-strand
arrangement (rmsd: 2.3/2.44 Å in all-atom/Cα alignments) but there are some differences.
Loops T-U and V-W from gp144 domain IV are longer than those of gp146 [FIG 4.4 b]. Domain
IV from gp146 has a β-strand extra (strand Y), which forms, along with the longer carboxyterminal part of strand X, an additional hairpin [FIG 4.4 b]; this extra hairpin makes gp146
domain IV adopt a closer and pointier conformation. The tip domain from gp144 is topped by a
flat platform surrounded by the three protruding V-W loops.

2

The alignments involving gp146 domain II showed substantially higher rmsd due to the disruption
caused by gp146 insertion-domain.
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FIGURE 4.4. Tip domain from phage K receptor-binding proteins and T7 gp17. (a) Location of the
tip domains in phage K gp146, phage K gp144, and phage T7 gp17 (PDB:id 4A0T) [Garcia-Doval & van
Raaij 2012]. (b) Superposition of the tip domains highlighted in (a). T7-gp17 tip domain (red) is
appreciably shorter. Phage K gp146 tip domain (blue) has an extra hairpin (X-Y hairpin), whilst gp144 tip
domain has longer apical loops (T-U and V-W loops).
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The topology of the tip domain of gp146 and gp144 has also been found (DALI server
[Holm & Laakso 2016]) at the tip domain (residues 465-553) of T7 gp17 (PDB:id 4A0T)
[Garcia-Doval & van Raaij 2012] [FIG 4.4 a]. The tip domain from T7 gp17 is considerably
shorter (89 residues) than the tip domains from phage K gp146 (127 residues) and phage K
gp144 (122 residues). Superposition of the carboxy-terminal domains of phage K gp146 and
gp144 on that of T7 gp17 tip results in rmsd of 4.11/5.23 Å (all-atom/Cα) and 5.13/5.19 Å (allatom/Cα) respectively. All three domains are well fitted in the proximal portion of the domain
whilst the differences arise at the apex [FIG 4.4 b].
The carboxyterminal domain (residues 615-691) from Pseudomonas aeruginosa R1
(PDB:id 6CL5) and R2 (PDB:id 6CL6) pyocins fibers [FIG 4.3] have an akin topology. It was
not identified by the DALI server search [Holm & Laakso 2016] because it lacks the UV strands
and the caboxy-terminal domain includes an additional hairpin.
The singularity of the tip domains within the central axis of the trimers and its location
at the carboxy-terminal end of the complexes suggest that they might be involved in receptor
binding. Studies on gp146 ortholog from phiSA012 identified three point mutations that suffice
for redirecting the tropism of the phage [Takeuchi et al. 2016]; two of those mutations are in the
tip domain: Gly583Asp and Thr615Arg. Both mutations are situated in an external position in
loops at the very apex of the domain: Gly583 in the V-W loop and Thr615 in the X-Y loop [FIG
4.7 a]. Considering their location, these mutations should not affect the structure of the domain
but the interaction with the host. The binding role of the tip domain is also supported by T7
gp17 tip, which has been proposed as a possible binding domain [Garcia-Doval & van Raaij
2012] based on the identification of mutants with modified host-range [Heineman et al. 2008].

4.1.3. Insertion domain
The insertion domain of phage K gp146 is a galectin-like domain predicted as
carbohydrate-binding module. This domain does not establish homotypic trimerization
interactions but it individually protrudes from the shaft. The absence of this domain in gp144
[FIG 4.1] and their independent disposition in the trimer complex suggest that the domain is
result of an insertion, possibly coming from a host genome 3.
The galectin-like jelly-roll topology of the insertion domain is a very common structural
fold. Among the most similar domains in a DALI server search [Holm & Laakso 2016] are the
CBM1
3

from

Caldanaerobius

polysaccharolyticus

S-layer

associated

multidomain

A BLASTP (BLASTP 2.8.1+ [Altschul et al. 1997]) of the domain sequence on the S. aureus
proteome results in the identification of a 2733-aa-long hypothetical protein (NCBI:RefSeq
WP_064221713.1, 36% of identity, 53% of similarity in the fragment 2325-2476).
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endoglucanase (PDB:id 2ZEW) [Bae et al. 2008] (rmsd: 6.90/6.65 Å in all-atom/Cα
alignments), the xyloglucan binding module from Rhodothermus marinus xylanase (PDB:id
4BJ0) [von Schantz et al. 2014] (rmsd: 6.83/7.49 Å in all-atom/Cα alignments), MAM domain
(residues 260 to 427) of the human promeprin beta (PDB:id 4GWM) [Arolas et al. 2012] (rmsd:
5.95/5.41 Å in all-atom/Cα alignments), and domain VII (residues 976-1177) from Bacillus
thuringiensis pesticidal protein Cry1Ac (PDB:id 4W8J) [Evdokimov et al. 2014] (rmsd:
14.8/14.8 Å in all-atom/Cα alignments).
The GJOLM β-sheet of gp146 insertion-domain forms a cleft equivalent to the
carbohydrate binding sites of the C. polysaccharolyticus endoglucanase and the R. marinus
xylanase. The insertion-domain-like domains of promeprin beta and Cry1Ac also have a crevice
but it does not bind carbohydrates since the domains are involved in protein-protein
interactions. The crevice from gp146 insertion-domain has a more positive charge than the other
domains [FIG 4.5 a], which agrees with a possible role in the binding to the acidic receptor of
phage K: teichoic acid. The shape of the crevices also differs among the insertion-domain-like
domains; even though the β-strands of the folding motif match, the disparity of the loops
accounts for the differences in the cleft morphology. The singularity of gp146 insertion domain
relies on the length of the L-M loop [FIG 4.5 b].
Considering the predominant assignment of the galectin-like domains as carbohydrate
binding modules, it is expected that gp146 insertion domain is involved in the binding of wall
teichoic acid. Three point mutations on gp146 ortholog from phiSA012 prevent the infection of
S. aureus RN4220 due to the α-glucosylation of the teichoic acid [Takeuchi et al. 2016]; one of
these mutations (Asn248Asp) is located in I-J loop of the insertion domain [FIG 4.7 a].
Notwithstanding, Asn248Asp is one of the nine differences between phage K gp146 (Asp248)
and phiSA012 ortholog (Asn248) and it has been shown that phage K can be propagated in the
RN4220 strain [Alves et al. 2014]. Thus, the Asn248Asp mutation is probably not responsible
for the altered binding effect reported in that study, although the gp146:G1P model and,
especially, the gp146:SA378 model strongly support a possible contribution to binding.
Alternatively, gp146 insertion domain might carry out a structural function. A galectinlike β-sandwich has been identified in the carboxy-terminal domain of the Dit protein of
Lactococcus phage P2, where it forms a protruding connector to the receptor-binding protein
trimer [Dunne et al. 2018]. If that was the role of gp146 insertion domain, those protein-protein
interactions would be expected to stabilize the area and it should be visible in the cryo-EM map
of phi812. If the hypothetical protein-protein contacts were homotypic, those contacts would
have probably repeated in the crystal but they did not.

95

4. Analysis and discussion

FIGURE 4.5. Comparison of gp146 insertion domain and similar domains. (a) View of the crevices
of phage K gp146 insertion domain, CBM1 of the S-layer associated multidomain endoglucanase from
Caldanaerobius polysaccharolyticus (PDB:id 2ZEW) [Bae et al. 2008], xyloglucan binding module from
xylanase of Rhodothermus marinus (PDB:id 4BJ0) [von Schantz et al. 2014], MAM domain from human
promeprin beta (PDB:id 4GWM) [Arolas et al. 2012], and pesticidal protein Cry1Ac from Bacillus
thuringiensis (PDB:id 4W8J).The surface representation is coloured according to their electrostatic
potential calculated with Coulomb's law (φ = Σ[qi/(εdi)]). Blue = 10.0 kcal/(mol*e), red = -10.0
kcal/(mol*e). The crevice of gp146 insertion domain is positively charged. (b) Superposition of gp146
insertion domain (orange, thick string) and the similar domains (blue, thin string). The main peculiarity of
gp146 insertion domain is the longer L-M loop.
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4.1.4. Fitting of phage K receptor-binding proteins into the phi812 cryo-EM
map
The organization of the baseplate from phi812 has been unraveled by cryo-EM
[Nováček et al. 2016]. According to the 10.8-Å resolution cryo-EM map, the contracted
baseplate is a six-fold-symmetry structure arranged in six branches; each branch harbors two
receptor-binding complexes and a fiber. Considering the similarity between phage K and
phi812, the crystal structures of phage K receptor-binding proteins should fit into the phi812
map.
The crystal structure of the full-length gp144 is unequivocally fitted into the map
density assigned as fiber4 [FIG 4.6]. Notwithstanding, the contouring threshold level of the map
recommended by the authors only accommodates three of the four gp144 domains [FIG 4.6]. A
lower contouring threshold level shows an extra blob that fits the carboxy-terminal domain. The
additional blobs represented at this lower contouring level are incompatible with the native map.
Since the crystallographic data presented here validates the contracted map, the contradiction
points to an improper processing of the native data, possibly related to the symmetry operators
applied.
Assuming gp144 corresponds to the distal portion of the fiber, it would be expected that
gp146 matches the cryo-EM density ascribed to the receptor-binding protein complexes.
However, fitting of gp146 in this location is questionable [FIG 4.6]. The contour level used for
the fitting of the fiber does not show any consistent density at the distal part of both receptorbinding complexes; which would agree with the carboxy-terminal flexibility manifested in the
crystal structures. The interpretation of the EM density map at more proximal regions is
hindered by the interaction with other elements of the baseplate (presumably the tripod
complex). The crystallographic model of gp146 does not take into account the effect of these
heterologous interactions on gp146 structure and, conversely, the crystallization process may
obtrude constraints on the conformation of the protein, so the baseplate conformation may differ
from the crystal conformation. A small angle X-ray scattering (SAXS) assay was performed by
G. Hura (Lawrence Berkeley National Laboratory, University of California, Berkeley,
California, USA) on a purified sample of phage K gp146; the resultant shape of gp146 [FIG 4.7
b] agreed with the crystallographic model but it did not clarify the fitting of gp146 into the cryoEM map.

4

The attempts to characterize the protein predicted as fiber failed, see Appendix B.
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FIGURE 4.6. Fitting of phage K receptor-binding proteins into phi812 baseplate. On the top,
comparison of gp144 (ribbon representation, orange) and the cryo-EM map of phi812 tail contracted
baseplate (EMDB:id 8212 [Nováček et al. 2016]) at contouring threshold level of 1.10 (recommended by
authors) and 0.50. On the bottom, fitting of gp146 (ribbon representations, blue) and gp144 (ribbon
representation, orange) into the map of phi812 contracted baseplate (contour level 0.5). Gp144 fits in the
“fiber” of the map at a 0.5-contour-level. Gp146 does not fit in the cryo-EM map regardless of the
contour-level.
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FIGURE 4.7. Highlighted residues of gp146 and SAXS. (a) Location in the gp146 model of the
residues whose mutation in phiSA012 ortholog redirect the tropism (blue) and the residues that differ in
phi812 (yellow) and phi812-K1/420 (red) orthologs. (b) Result of the SAXS assay performed on gp146
by G. Hura (Lawrence Berkeley National Laboratory, University of California, Berkeley, California,
USA) (left) and fitting of gp146 crustal structure on the SAXS map (right).
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It might be argued that the discrepancies in the cryo-EM fitting might be due to
differences in proteins from phage K and phi812. Phage K gp146 and gp144 counterparts in
phi812 are gp125 and gp127, respectively. Despite being referred as phi812 [Nováček et al.
2016], the cryo-EM study was performed on phi812-K1/420, a broad host-range mutant isolated
from Stafal® (Supplementary material of [Nováček et al. 2016]). Phage K gp144 is identical to
phi812-K1/420 gp127 and phage K gp146 differs from phi812-K1/420 gp125 by one aminoacid: Gly475Cys. Gly475 is located in the C-D loop of domain III [FIG 4.7 a], near to the
domain III amino-terminal hairpin from an adjacent monomer. The substitution Gly475Cys
might create inter-chain sulfur-π). In the apex of the tip domain, the protruding V-W interactions [Ringer et al. 2007] with Tyr417 or Tyr420 from
the flanking amino-terminal hairpin, potentially stabilizing the arrangement of both structural
elements. Strikingly, phi812-K1/420 is closer to phage K than to wild-type phi812 5 and phi812K1/420 gp125 is more similar to phage K gp146 than to phi812 gp125. Phage K gp146 and
phi812 gp125 differ by three amino-acids: Val401Phe, Thr523Ser and Thr610Ser. Thr523 and
Thr610 are located on the tip-domain surface [FIG 4.7 a] and their substitution to serine in
phi812 gp125 should not affect the structure nor the putative involvement of these amino-acids
in receptor binding. Val401 is located at the axis of the trimer [FIG 4.7 a], interacting with
Val401 from the other monomers. According to the model, the substitution Val401Phe would
impose steric hindrance that might distort the center of the structure, so the structures are likely
to be locally different here. Considering the closest gp146 orthologous gene products (>98% of
amino-acid sequence identity), Phe401 is more common than Val401. Whether this mutation
justify the enhanced host range of phi812-K1/420 remains arguable, since other structural
proteins are also modified, including more drastic alterations such as premature stop codons
(Supplementary material of [Nováček et al. 2016]).

4.1.5. Binding of ligands to phage K receptor-binding proteins
Wall teichoic acid is the primary receptor of phage K [Xia et al. 2011]. The structural
characterization of the binding of several teichoic acid analogs (Appendix C) was attempted, but
it was only achieved with rac-glycerol 1-phosphate and SA-378 [FIG 4.8].
The binding of both co-crystallized ligands relies on the interaction of their phosphate
groups with cationic residues [FIG 4.9 a-e]. This has also been found true in the structure of an
antibody bound to a wall teichoic acid analog [Lehar et al. 2015] [FIG 4.9 f], which proves that
the chemical features of the ligands determine the docking requirements. Those requirements
shape the binding proteins by a selective mechanism, either evolutionary adaptation by natural
5

Phage K and phi812-K1/420 have a 99.99% of sequence identity on a 99% of cover. Phi812 and
phi812-K1/420 have a 99.96% of sequence identity on a 99% of cover. (BLASTN 2.9.0+ [Zhang et
al. 2000])
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FIGURE 4.8. Ligands co-crystallized with gp146 and gp144. (a) Chemical structure of S. aureus wall
teichoic acid. The structural equivalence of sn-glycerol 3-phsophate and sn-glycerol 1-phosphate within
the poly-(ribitol-5-phosphate) is indicated. PG = pepdtidoglycan; Y = D-alanine; X = α- or β-Nacetylglucosamine. (b) Chemical structure of SA-378 (provided by J. Codée (Leiden Institute of
Chemistry, Leiden, Nethelands)).

selection (phage K receptor-binding proteins) or the lymphocyte ontogenesis by clonal selection
(antibody).
The stereoisomers of rac-glycerol 1-phosphate mimic different portions of the
poly(ribitol 5-phosphate) chain of the wall teichoic acid of S. aureus [FIG 4.8 a], so the cocrystallization might have potentially unveiled binding sites of wall teichoic acid. Three
glycerol-phosphate molecules were modeled in gp146:G1P and one glycerol 3-phosphate was
assigned in gp144:G1P. Whilst the phosphate group drives the docking to a cationic amino-acid,
the binding of the glycerol moiety of the molecule is usually more loose, allowing the
hypothetical accommodation of a ribitol 5-phosphate polymer. The binding site of gp146
domain III do not allow the docking of a polymer in place of the glycerol portion of the ligand
[FIG 4.9 a]; notwithstanding, it might mimic the disposition of the decorations of S. aureus wall
teichoic acid (possibly D-Ala since its amine group could establish ionic interactions with
Asp471 or Asp473 or cation-π). In the apex of the tip domain, the protruding V-W interactions with Tyr450).
The co-crystallization of gp146 with SA-378 led to the identification of the insertiondomain cleft as probable binding site of the receptor wall teichoic acid; because SA-378 is
substantially similar to S. aureus wall teichoic acid [FIG 4.8] and it binds gp146 insertion
domain [FIG 4.10 b]. In the gp146:G1P model, the insertion-domain crevice domain includes a
glycerol 3-phosphate, a phosphate and a glycerol molecule [FIG 4.10 a]; the phosphate and
glycerol molecules fill a position equivalent to that of SA-378, but the glycerol 3-phosphate
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FIGURE 4.9. Electrostatic potential of the binding sites. Representation of the binding of glycerolphosphate ligands to (a) gp146 domain III, (b) the interface between domain II and the insertion domain
from gp146, (c) gp146 insertion domain, and (e) gp144 domain III. (d) Representation of the binding of
SA-378 to one of the insertion domains from the gp146:SA378 model. (f) Representation of the binding
of a wall teichoic acid analog to an antibody (PDB:id 5D6C) [Lehar et al. 2015]. The surface
representations are coloured according to their electrostatic potential calculated with Coulomb's law (φ =
Σ[qi/(εdi)]). Blue = 10.0 kcal/(mol*e), red = -10.0 kcal/(mol*e). The binding always involves the docking
of a phosphate group in a positively charged site.

deviates from the main crevice of the domain. The incomplete occupancy of the glycerol 3phosphate implies a weak binding that might be artifactual.
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FIGURE 4.10. Ligand binding to the insertion domain. Representation of the gp146 insertion domain
with its ligands in (a) the gp146:G1P model and (b) the gp146:SA378 model. Representation of the
CBM1 from C. polysaccharolyticus endoglucanase bound to (c) cellopentaose (PDB:id 2ZEX) and (d)
mannopentaose (PDB:id 2ZEY) [Bae et al. 2008]. The surface representation is coloured according to
their electrostatic potential calculated with Coulomb's law (φ = Σ[qi/(εdi)]). Blue = 10.0 kcal/(mol*e), red
= -10.0 kcal/(mol*e).

The arrangement SA-378 along gp146 insertion-domain crevice is comparable to that of
oligosaccharide ligands in the CBM1 from C. polysaccharolyticus endoglucanase. The C.
polysaccharolyticus CBM1 has been co-crystallized with cellopentaose (PDB:id 2ZEX) [FIG
4.10 c] and mannopentaose (PDB:id 2ZEY) [FIG 4.10 d]; both ligands interact with two
aromatic residues at the base of the cleft (Trp20 and Trp125) and with polar residues along the
flanks [Bae et al. 2008]. The cleft of gp146 insertion domain has a positively charged center,
which suits the acidic nature of the wall teichoic acid.
The co-crystallization assays allowed the identification of binding sites but their
characterization points to a low-affinity binding: either because of the relative lack of sharpness
of

the

electron-density

map

(gp146:G1P/insertion

domain,

gp146:G1P/domain

II,

gp146:SA378, gp144:G1P) or because of partial or alternative occupancy (gp146:G1P/domain
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III, gp146:G1P/insertion domain). The co-crystals in which no ligand was identified (Nacetylglucosamine, Fondaparinux) also suggest a low-affinity binding. Despite the apparent low
affinity of the individual binding sites, the attachment to the host might be enabled by
concurrent multiple binding sites along the receptor-binding complexes and multiple receptorbinding complexes per baseplate. The low affinity may allow the proper binding of polymers to
the receptor-binding complexes since a single binding site is not strong enough to keep the
binding. The low affinity would act as a security valve to release non-optimal interactions. The
concurrent binding of all receptor-binding sites of all receptor-binding complexes from a
baseplate is strong enough for attachment [Dowah & Clokie 2018] and allows the proper
orientation of the phage virion on the host surface.
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4.2. Phage K tail central spike: gp155
The tail central spike gp155 is a protein predicted to have a central coiled coil domain
and a carboxy-terminal glycerophosphodiester phosphodiesterase domain. The negative-staining
electron microscopy analysis on the full-length protein resulted inconclusive. The crystal
structure of the carboxy-terminal portion of gp155 has been solved, confirming the identity of
the expected glycerophosphodiester phosphodiesterase domain.
A glycerophosphodiester phosphodiesterase (EC 3.1.4.46) is an enzyme that catalyzes
the hydrolysis of a glycerophosphodiester to glycerol 3-phosphate and an alcohol. This enzyme
is present in Bacteria, Archaea, and Eukarya, and it is generally involved in
glycerophospholipid metabolism. Its structure has been extensively characterized as a TIMbarrel, one of the most frequent tertiary folds of common enzymes like triose phosphate
TABLE 4.2. Statistical comparison of gp155(614-848) and similar proteins. Statistical results of the
superposition of gp155(614-848) ligand-bound and the glycerophosphodiester phosphodiesterases from
Bacillus subtilis (PDB:id 5T9C, 5T9B, 5T91), Staphylococcus aureus (PDB:id 2P76, 2OOG), Bacillus
anthracis (PDB:id 4R7O), Caldanaerobacter subterraneus subsp. tengcongensis (PDB:id 2PZ0),
Cytophaga hutchinsonii (PDB:id 3CH0), and Oleispira antarctica (PDB:id 3QVQ). From top to bottom:
percentage of aligned-sequence identity, root mean square deviation including all atoms, root mean
square deviation including only Cα.
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FIGURE 4.11. Superposition of gp155(614-848). Graphical superposition of gp155(614-848) (red, thick
string) and the glycerophosphodiester phosphodiesterases (green, thin string) from Staphylococcus aureus
(PDB:id 2P76), Bacillus subtilis (PDB:id 5T9C), Bacillus anthracis (PDB:id 4R7O), Caldanaerobacter
subterraneus subsp. tengcongensis (PDB:id 2PZ0), Cytophaga hutchinsonii (PDB:id 3CH0), and
Oleispira antarctica (PDB:id 3QVQ). The main discordances are in the insertion domain loop and in
loops β3α3, β5α5, β6α6. The only particularity of gp155(614-848) is a shorter loop 689-699.

isomerases, aldolases, pyruvate kinases, or RuBisCo. According to a search on the DALI server
[Holm & Laakso 2016] using the gp155(614-848) model, the most similar structures available
in the PDB [Berman et al. 2000] are phosphodiester phosphodiesterases from Gram-positive (S.
aureus, B. subtilis, B. anthracis, Caldanaerobacter subterraneus subsp. tengcongensis) and
Gram-negative (Cytophaga hutchinsonii, Oleispira antarctica) bacteria. Considering that phage
K and its related phages infect Gram-positive hosts, it is expected that gp155 carboxy-terminal
domain is more similar to the glycerophosphodiester phosphodiesterases from Gram-positive
bacteria. Indeed, this domain has higher sequence similarity and lower rmsd at all-atom
superpositions when compared to proteins from Gram-positive bacteria than when compared to
proteins from Gram-negative bacteria [TABLE 4.2]. However, this similarity rule does not
apply when aligning only Cα [TABLE 4.2], which evidences the evolutionary preservation of
structure over sequence.
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The superposition of the structural models revealed that the core of the TIM-barrel is
evolutionary preserved [FIG 4.11], whilst differences arise at the loops; namely, the loops from
the insertion domain, loop β3α3, loop β5α5, and loop β6α6. Out of these differences, the only
peculiarity of phage K gp155 carboxy-terminal domain is the loop 689-699 from the insertion
domain,

which

is

sensibly

shorter

than

that

of

bacterial

glycerophosphodiester

phosphodiesterases. The functional implications of this unique feature of gp155(614-848) are
uncertain; in B. subtilis glycerophosphodiester phosphodiesterase, that loop from the insertion
domain is adjacent to the suggested docking location of the polymer whose glycerol 3phosphate end is going to be hydrolyzed [Myers et al. 2016], so this distinction might account
for the different substrate that gp155 glycerophosphodiester phosphodiesterase domain may
target.
The residues that constitute the active center are conserved in all the models used for
superposition. A cation (Ca2+, Zn2+, Mg2+, or Na+) is present in the active center bound to the
carboxyl triad Glu-Asp-Glu of the structural models analyzed except for the C. hutchinsonii
glycerophosphodiester phosphodiesterase structure (PDB:id 3CH0), in which a molecule of
water was modeled instead. Therefore, it can be assumed that gp155 glycerophosphodiester
phosphodiesterase

domain

follows

the

catalytic

mechanism

described

for

the

glycerophosphodiester phosphodiesterases of C. subterraneus subsp. tengcongensis [Shi et al.
2008] and B. subtilis [Myers et al. 2016]. The hydrolysis is performed by a two-step acid/base
reaction mediated by His621 and His663 [FIG 4.12]. The first reaction is a nucleophilic
substitution of the leaving alcohol by the attacking 2-hydroxyl from the glycerol 3-phosphate,
giving a cyclic intermediate; His621 activates the attacking nucleophile by accepting a proton
and His663 stabilizes the leaving group by donating a proton. The second reaction is the
substitution of the 2-hydroxyl by the nucleophilic attack of a hydroxide ion on the phosphorus;
His663 accepts a proton from a water molecule to generate the hydroxide and His621 donates a
proton to stabilize the final glycerol 3-phosphate. During the catalysis, the substrate is fixed on
the active center by interaction with the Ca2+ ion and other residues from the active site
(Arg622, Glu716, Lys718, Glu648, Gln751).

FIGURE 4.12. Catalytic mechanism of gp155 glycerophosphodiester phosphodiesterase domain.
The hydrolysis of the glycerophosphodiester is achieved by two consecutive nucleophilic substitutions.
His621 and His663 activate or stabilize the chemical groups involved in the reaction by donating or
accepting a proton.
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FIGURE 4.13. Active site of glycerophosphodiester phosphodiesterases. Aligned representation of the
active site of phage K gp155 carboxy-terminal domain (a) ligand-free-pH3.0 and (b) ligand-bound and
the glycerophosphodiester phosphodiesterases from (c) Staphylococcus aureus (PDB:id 2OOG), Bacillus
subtilis after (d) 5-min-soak (PDB:id 5T9B) or (e) 1-h-soak (PDB:id 5T9C) with substrate, (f) Bacillus
anthracis (PDB:id 4R7O), (g) Caldanaerobacter subterraneus subsp. tengcongensis (PDB:id 2PZ0), and
(h) Cytophaga hutchinsonii (PDB:id 3CH0). The metal cation in the active site is: Ca 2+ (gp155(614-848)ligand-bound, B. subtilis, C. subterraneus tengcongensis), Mg2+ (B. anthracis), or Zn2+ (S. aureus).
Glycerophosphodiester phosphodiesterase models from S. aureus, B. anthracis, and B. subtilis (5-minsoak) display a ligand-free-ph3.0 conformation; whilst models from C. subterraneus tengcongensis, C.
hutchinsonii, and B. subtilis (1-h-soak) have a ligand-bound conformation.
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Lys718 from gp155 interacts with the ligand in the ligand-bound model [FIG 4.13 b]
but it is budged in the ligand-free-pH3.0 model [FIG 4.13 a]. The equivalent lysine in the
similar bacterial models adopts a ligand-bound-like conformation in models from C.
subterraneus subsp. tengcongensis (PDB:id 2PZ0) [FIG 4.13 g], C. hutchinsonii (PDB:id
3CH0) [FIG 4.13 h], O. antarctica (PDB:id 3QVQ), and B. subtilis (PDB:id 5T9C) [FIG 4.13
e]; and a ligand-free-pH3.0-like conformation in models from B. subtilis (PDB:id 5T91, 5T9B)
[FIG 4.13 d], S. aureus (PDB:id 2OOG, 2P76) [FIG 4.13 c], and B. anthracis (PDB:id 4R7O)
[FIG 4.13 f]. Remarkably, models from B. subtilis display the ligand-free-pH3.0 conformation
in the absence of substrate (glycerophosphoglycerol) or after a 5-minute soak with the substrate
[FIG 4.13 d], whilst the ligand-bound conformation appears after a 1-hour soak [FIG 4.13 e].
The ligand-bound conformation modifies the arrangement of the hydrolyzed glycerol 3phosphate, bringing closer the phosphate and 2-hydroxyl groups to enable the first reaction of
the catalysis [Myers et al. 2016]. The models presented here support the role of Lys718 in the
catalysis, although the artifactual absence of the metal cation in the ligand-free-pH3.0 model
raises concerns on its validity.
No evidence of oligomerization was found in the crystal structure models of gp155(614848); neither within the asymmetric unit nor applying crystal symmetry operations. This,
together with the purification data, suggests that this domain is probably not involved in the
oligomerization interactions that account for the oligomers detected with fragments gp155(1848) and gp155(315-848). The related bacterial glycerophosphodiester phosphodiesterases
described so far are monomeric [Santelli et al. 2004, Myers et al. 2016] except that of
Caldanaerobacter subterraneus subsp. tengcongensis, which has been identified as a dimer
covalently bound by an inter-molecular disulfide bridge [Shi et al. 2008].
The vague results from the electron microscopy analysis on full-length gp155 did not
provide any clue on the arrangement of the carboxy-terminal domain in the oligomer. The 13.4Å-resolution cryo-EM map of phi812 native baseplate does not clarify the location of
gp155(614-848) [FIG 4.14], although this map might be misleading (see Section 4.1.4). It might
be possible that the glycerophosphodiester phosphodiesterase fragment is removed by
proteolysis; this conjecture would agree with the presence of a putative proteolytic fragment in
the purification of gp155(1-848), the fact that the orthologous-gene product in the spounavirus
Listeria phage A511 ends with the coil-coiled domain [Habann et al. 2014], and the morphology
of the central spike in the cryo-EM map at high contouring threshold level [FIG 4.14]. By
analogy with the proteolysis of the carboxy-terminal domain of the tail associated lysin of
lactococcal phages TP901-1 and Tuc2009 [Dunne et al. 2018], it might be speculated that the
carboxy-terminal domain of phage K gp155 might not be essential but beneficial for the
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FIGURE 4.14. Comparison of gp155(614-848) and phi812 baseplate. Surface representation of the
gp155(614-848) model (green, left) and cryo-EM map (blueish, right) of phi812 tail central spike
(EMDB:id 8210 [Nováček et al. 2016]) at contouring threshold level of (a) 2.00 (recommended by
authors), (b) 1.00, (c) 0.50, and (d) 0.20. The crystal model of gp155(614-848) does not fit into the tail
central spike of the phi812 baseplate regardless of the contour level of the map.

infection. In any case, the proteolysis of the carboxy-terminal domain of gp155 (if actual)
should not affect all cases since the integral full-length protein was also purified, so gp155(614848) must be part of (at least) some virions.
Functionally, glpQ, the glycerophosphodiester phosphodiesterase from B. subtilis, has
been characterized as a secreted enzyme that catalyzes the exo-degradation of wall teichoic acid
after phosphate-starvation induction [Myers et al. 2016]. It must be noticed that the wall
teichoic acid from B. subtilis 168 (the strain used at [Myers et al. 2016]) is composed of
glycerol 3-phosphate instead of ribitol 5-phosphate. The tight fitting of glycerol 3-phosphate in
gp155(614-848) active site does not allow a bigger substrate, so this domain is probably not
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involved in the degradation of the ribitol 5-phosphate backbone of S. aureus wall teichoic acid.
The function of this domain during phage K attachment and penetration on the cell envelope of
S. aureus might be either the removal of the linker from the wall teichoic acid, the exohydrolysis of lipoteichoic acids (which adopt an inner location in the cell envelope, so
gp155(614-848) should act after the tail peptidase gp157 removes the peptidoglycan), or the
degradation of deacylated glycerophospholipids from the membrane. Although unlikely, it
might be possible a rearrangement of the active site to accommodate the ribitol 5-phosphate
from the S. aureus wall teichoic acid, but, so far, there is no evidence supporting a
ribitophosphodiester phosphodiesterase activity. The presence of teichoicase activity has been
described in host-interacting proteins from other Gram-positive viruses like B. subtilis phage
ϕ29 neck appendages [Xiang et al. 2009], although this poly(glycerol 3-phosphate)-teichoicase
activity is located in the amino-terminal part of the proteins and it is not structurally related to
the glycerophosphodiester phosphodiesterase domain.
A possible anchoring role of gp155(614-848) may be conjectured based on the
identification of a putative secondary binding site in the insertion domain of the ligand-bound
and ligand-free models. In gp155(614-848) models, an oxyanion (phosphate in the ligand-bound
model or sulfate in the ligand-free models) interacts with Lys655. This ionic interaction points
to a potential binding to teichoic acids; especially considering that the binding to the group
bound to the oxyanion is lax and that the location is more accessible than the active site.
Regardless of its function, the glycerophosphodiester phosphodiesterase domain of
gp155 has been probably acquired from a host protein by recombination, which is evidenced by
the sequence- and structure-similarity to the bacterial proteins. The incorporation of a domain
from its host is a well-established feature of viruses [Guardado-Calvo et al. 2010] and one of the
mechanisms that enable their evolutionary success.
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5.1. Conclusions
5.1.1. Phage K receptor-binding proteins
•

Phage K has two receptor-binding proteins: gp146 and gp144. They are β-structure
trimers arranged in four modules: three shaft domains and a tip domain. An additional
insertion domain is exclusive of gp146.

•

The shaft domain is a mixed β-sheet similar to that of other phage fibers.

•

The tip domain is a β-sandwich whose topology also appears in the tip domain from T7
gp17.

•

The insertion domain of gp146 is a galectin-like domain. The positive charge of its cleft
might potentially enable the binding to teichoic acids.

•

According to co-crystallization assays, gp146-insertion-domain cleft is likely a receptor
binding site. Additionally, other possible receptor-binding sites are located in gp144
domain III, gp146 domain III, and the interface of gp146 domain II and the insertion
domain.

5.2.1. Phage K tail central spike
•

Phage K tail central spike is gp155. The carboxy-terminal domain of gp155 (residues
614-848) is a glycerophosphodiester phosphodiesterase very similar to that of bacteria.
As predicted, gp155(614-848) is folded in a TIM-barrel with an insertion domain. The
high conservation of the active site validates the catalytic mechanism described for
Bacillus subtillis glycerophosphodiester phosphodiesterase. Consequently, gp155
carboxy-terminal domain does not degrade wall teichoic acid during phage K infection
since S. aureus teichoic acid consists of ribitol 5-phosphate instead of glycerol 3phosphate.
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5.2. Future work
5.2.1. Phage K receptor binding proteins
The crystal structures of gp146 and gp144 are well described in this thesis.
Notwithstanding, the interaction of these proteins with receptors of phage K (wall teichoic acid)
should be further characterized:

•

The affinity of the binding to wall teichoic acid analogs could be quantified by
surface plasmon resonance or isothermal titration calorimetry.

•

The binding sites predicted in the co-crystals could be tested by site-directed
mutagenesis of the residues involved in binding (according to the model) and
binding analysis of the mutant proteins.

•

The binding-site identified in the gp146:SA378 model might be described in detail
by co-crystallization of gp146 with an individualized insertion domain in order to
try to improve the resolution of the structural model.

5.2.2. Phage K tail central spike
The thesis includes a detailed description of the crystal structure of the carboxy-terminal
glycerophosphodiester phosphodiesterase domain of gp155. This structural study might be
complemented with a colorimetric determination of the enzyme kinetics of the domain to
compare

it

with

the

enzymatic

properties

of

bacterial

glycerophosphodiester

phosphodiesterases.
Regarding the full-length gp155 protein, the size of the complex suffices for a cryoelectron-microscopy characterization attempt, although the issues with the sample purity and
homogeneity should be previously solved.
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Introduction
During the initial attempts of crystallization of the full-length gp146, a set of crystals
diffracted to a very high resolution for protein crystallography standards. These crystals
contained only the amino-terminal domain of gp146, so the crystal structure did not provide any
biologically significant insights. A lot of diffracting protein crystals have been discarded from
this thesis because of their poor quality or their redundancy and scientific irrelevance (see
Appendix D). The outstanding resolution of these particular crystals led to the inclusion of this
appendix not as a supplementary material, but as a technical anecdote.

Materials and methods
Sample production. The protein was produced from the construct pCri8agp146K, which
expressed the protein with an amino-terminal tag that encompasses a six-histidine tag and a
Tobacco Etch Virus (TEV) protease cleavage site. The pCri8agp146K construct was built with
the same methodology as for pET28a+gp146K (see Section 2.2.1), using the primers 5’-TACAC
CATGGCATTTAACTACACGCCTC-’3

and 5’-TTGTCTCGAGTTATCCTCTATTAATTCCCATAAT-3’, which

allowed the insertion of the amplicon into the expression vector pCri-8a [Goulas et al. 2014]
after digestion with FastDigest® NcoI and FastDigest® XhoI (Thermo Fisher Scientific Baltics
UAB, Vilnius, Lithuania).
Recombinant protein was expressed and purified with the procedure described for the
product of pET28a+gp146K (see Section 2.2.2), omitting the size-exclusion chromatography
step.
Crystallization. Vapor-diffusion crystallization was achieved in an isothermal room at 294 K,
using sitting-drop MRS crystallization plates (Swissci AG, Neuheim, Zug, Switzerland). Kits
JBScreen Classic 1 to 4 (Jena Biosciences, Jena, Germany) 1 were used for condition screenings
on 96 well plates with 50 µL reservoir and drops of 1 µL (equal volumes of reservoir and
protein solution; 0.5 µL each). Crystals were cryo-protected by transferring to reservoir solution
containing 20% v/v glycerol. Cryo-protected crystals were harvested on Litholoops (Molecular
Dimensions, Newmarket, Suffolk, England) and frozen for transportation to the synchrotron
radiation facilities.
Crystallographic data collection and processing. A cryoprotected crystal was diffracted in
remote at the X-ray beamline BL13-XALOC of the ALBA synchrotron (ALBA, Cerdanyola del
Vallès, Barcelona, Catalonia). Crystallographic data were automatically processed with
autoPROC [Vonrhein et al. 2011]; which employs XDS [Kabsch 2010] for indexing and
integration, POINTLESS [Evans 2006] for re-indexing, and AIMLESS [Evans & Murshudov
1

JBScreen Classic kits 1 to 4 contain 24 crystallization conditions each.
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2013] for data scaling. The subsequent processing was performed with programs from the CCP4
suite [Winn et al. 2011]. Phases were estimated by molecular replacement with PHASER
[McCoy et al. 2007]. The model was manually refined with COOT [Emsley et al. 2010] and
automatically refined with REFMAC5 [Murshudov et al. 2011]. The statistics of the model were
obtained with MOLPROBITY [Chen et al. 2010].

Results
Sample production. Three point-mutations were unintentionally included in the construct
during the cloning of pCri8agp146K: Tyr208Phe, Thr240Ala, Tyr346Phe. All three mutations
are located in the insertion domain of gp146. Neither of the mutations imposes any additional
steric hindrance on the structure and their only possible effect is the loss of three intra-chain
hydrogen-bonds. These three point mutations do not explain the proteolysis observed in the
crystal structure. The results of the purification were identical to those using the
pET28a+gp146K (see Section 3.1.1) and no hint of additional proteolysis was detected. The
similitude between both proteins was corroborated by the generation of full-length crystals in
the same conditions that confirmed the neutral effect of the mutations on the structure.
Conversely, the proteolysis might be propitiated by the lack of purity of the sample,
since the earliest purification batches did not include the size-exclusion chromatography.
Crystallization and crystal structure determination. Trigonal crystals of the H 3 space group
were grown with 25% w/v polyethylene glycol 4000, 100 mM tri-sodium citrate pH 5.6, 200
mM ammonium sulfate [FIG A.1]. The unit cell dimensions [TABLE A.1] of the crystals were
inconsistent with a full-length monomer; a single monomer of the full-length gp146 models
occupies 77050 Å3 and the asymmetric unit volume is 22649.6 Å 3 (the unit cell volume is
203846.4 Å3 and the H 3 unit cell encompasses nine asymmetric units). The actual content of

FIGURE A.1. Crystals of the amino-terminal domain of gp146. Crystals formed by the proteolysed
amino-terminal fragment of gp146 (a) in the crystallization drop (condition: 25 % w/v polyethylene
glycol 4000, 100 mM tri-sodium citrate pH 5.6, 200 mM ammonium sulfate) and (b) on the loop.
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TABLE A.1. Crystallographic statistics of gp146 amino-terminal domain. Crystallographic data
collection parameters and structure solution and refinement statistics. (Ramachandran plots in Appendix
E).
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FIGURE A.2. Structure of gp146 amino-terminal domain. Ribbon diagram of gp146 crystal-structure
model. Color code: β-strands - yellow, α-helix - red, loops - green.

the asymmetric unit is the amino-terminal domain of gp146, whose molecular weight is 9667.21
Da (VM = 2.34 Å3/Da, allowing a 47.53 % for solvent) and it occupies 10360 Å 3. The structure
was solved by molecular replacement using gp146 domain I as template. The asymmetric unit
of the crystal model includes residues 34 to 118 of gp146 and 78 water molecules.
Crystal structure of gp146 amino-terminal domain. The 0.96-Å-resolution model of gp146
domain I represents a trimer identical to domain I of the full-length models (rmsd 0.186 Å); i.e.,
a mixed β-sheet formed by a β-α-β motif (AB) and a five-stranded up-and-down sheet
(BCDEF), with a hydrophobic core resultant of the packing of loops A-B and B-C against the
side of the sheet not involved in trimerization [FIG A.2].

Discussion
In X-ray diffraction, the existence of a reflection requires compliance with Bragg’s law:
2 d sin θ = n λ,
where d is the distance between crystal lattice planes, θ is the scattering angle, n is an integer
(order of reflection) and λ is the wavelength of the X-ray. The resolution is the distance between
two distinguishable points:
d = (n λ) / (2 sin θ).
In ideal conditions, the resolution would only depend on λ (lower λ decreases d,
resulting in a better high-resolution limit). Notwithstanding, real crystals (especially protein
crystals) are not perfect (due to disorder and thermal vibrations), and those imperfections
weaken the intensity of the reflections at larger θ [FIG A.3 b], to the detriment of the high5
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FIGURE A.3. X-ray diffraction. (a) Simplified diagram of an X-ray diffraction setup. The collection of
the more peripheral reflection would require the reduction of the crystal-to-detector distance. (b) Detail of
an X-ray diffraction image from a gp146:SA378 crystal. The intensity of the peripheral reflections is
weaker than those closer to the beam (left part of the image).

resolution limit (lower d). The extent of this effect is weighted by the B-factor, so crystals that
diffract to a higher resolution have lower B-factors (more order) [FIG A.4]. The B-factors of
crystals with big unit cells tend to be higher than those of crystals with small unit cell [Blow
2002], which accounts for the higher resolution obtained from the crystals of gp146 aminoterminal fragment [FIG A.4].
In order to collect large-θ reflections (high resolution) it is required to set the detector
closer to the crystal [FIG A.3 a]. The shortening of the crystal-to-detector distances may lead to
the over-saturation of the reflections closer to the beam (small θ), so the low-resolution limit of
the data sets collected at high-resolution is generally affected [FIG A.4].
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FIGURE A.4. Effect of resolution on electron-density maps. Fitting of Tyr59 from gp146 in the
electron-density map generated with 0.96-Å-resolution data (top-left), 2.11-Å-resoolution data (middleleft), and 3.37-Å-resolution data (bottom-left). On the right, tables with parameters of the crystals (unit
cell and asymmetric unit volumes), the diffraction experiments (crystal-to-detector distances), and the
models (resolution, mean B-values).

The quality of the electron-density map typically increases with the resolution [FIG
A.4], although it does not depend exclusively on the resolution but also on the B-factors and the
phase quality. The 0.96-Å-resolution electron-density map enables an accurate identification of
the location of each individual atom (except hydrogen atoms), which might be usable for the
analysis of the inter-atomic features (bond-length, bond-angles). However, from a biological
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perspective, that resolution is not necessary since the chemical constraints on the geometry of
amino-acids permit a reliable determination of the amino-acidic conformations at lower
resolutions (e.g., 2.11 Å). The differences between the 0.96-Å-resolution model and 2.11-Åresolution model are not significant (rmsd 0.186 Å).
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Introduction
Gene product 150 (gp150) (NCBI:RefSeq YP_009041333.1) is a 1019-amino-acid
protein encoded by CPT_phageK_gp150 (formerly orf63). Full-length gp150 has a theoretical
molecular weight of 116277 Da and a pI 4.92 (calculated with ExPASy ProtParam [Gasteiger et
al. 2005]). Protein gp150 has been identified as a structural component of the phage K virion by
a mass spectrometry analysis and it has been predicted to function as tail fiber protein complex
(Supplementary material of [Nováček et al. 2016]). No conserved domains were found in a
search on the Conserved Domain Database (NCBI: CDSEARCH/cdd) [Marchler-Bauer et al.
2017]. A search on the HHpred [Hildebrand et al. 2009] detected similarity between gp150
amino-terminus and the T4 baseplate wedge protein gp6 and between the residues 575-681 of
gp150 and the cellulose-binding domain of the endoglucanase C from Cellulomonas fimi [FIG
B.1]; notwithstanding, this prediction is very weak (E-values: 11 and 110).

Materials and Methods
Construction of expression vectors of gp150. The complete CPT_phageK_gp150 gene
(gp150(1-1019)) and the fragments encoding gp150(407-1019), gp150(490-1019), gp150(5191019), gp150(574-1019), gp150(594-1019), gp150(693-1019), gp150(770-1019), gp150(7981019), and gp150(865-1019) were amplified by PCR using Taq DNA Polymerase (Roche
Diagnostics GmbH, Mannheim, Germany), a phage K genomic DNA template, and primers
(Sigma-Aldrich, Hamburg, Germany) [TABLE B.1] that added BamHI/XhoI or NcoI/XhoI
restriction sites to the 5'/3' ends of the amplicons. The PCR products were purified with
GeneJET PCR Purification Kit (Thermo Fisher Scientific Baltics UAB, Vilnius, Lithuania). The
BamHI/XhoI amplicons and the expression vector pET28a(+) (Novagen/Merck, Nottingham,
England) were digested with FastDigest® BamHI and FastDigest® XhoI (Thermo Fisher
Scientific Baltics UAB, Vilnius, Lithuania) and the NcoI/XhoI amplicons and the expression
vector pCri-8a [Goulas et al. 2014] were digested with FastDigest® NcoI and FastDigest® XhoI
(Thermo Fisher Scientific Baltics UAB, Vilnius, Lithuania). Restriction fragments were
separated by a 1%-agarose-gel electrophoresis, the proper size bands were cut and their DNA
extracted with GeneJET Gel Extraction Kit (Thermo Fisher Scientific Baltics UAB, Vilnius,
Lithuania). The digested vectors and inserts were ligated with the T4 DNA Ligase (Thermo
Fisher Scientific Baltics UAB, Vilnius, Lithuania) and transformed into freshly-prepared
chemically competent Escherichia coli DH5α cells [Sambrook et al. 1989]. The expression
constructs pET28a+gp150K, pET28a+gp150K490, pET28a+gp150K519, pET28a+gp150K574,
pET28a+gp150K594, pET28a+gp150K693, pET28a+gp150K770, pET28a+gp150K798, and
pET28a+gp150K865 harbor the proteins fused to an amino-terminal tag containing a six-
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TABLE B.1. Primers used for gp150 cloning. Sequence 5’→3’ of the primers used for the cloning of
gp150 inserts. The restriction enzyme target-sequence is underlined. The last column indicates the
constructs whose insert cloning required the respective primer.

histidine tail, a thrombin cleavage site, and a T7 tag. The expression constructs pCri8agp150K
and pCri8agp150K407 were designed to express the protein with an amino-terminal tag that
encompasses a six-histidine tag and a Tobacco Etch Virus (TEV) protease cleavage site. The
sequence of the inserts was confirmed by DNA-sequence analyses (Secugen S.L., Madrid,
Spain).
Expression and purification attempts on gp150. Large scale expression was performed in
four 0.9 L cultures of LB supplemented with 50 µg/mL kanamycin incubated at 310 K to an
optical density at 600 nm of 0.6-0.8. Cultures were cooled in ice and protein expression was
induced with 1 mM IPTG. Expression was allowed for 16 h at 291 K. The cultures were
centrifuged (10 min at 4000 x g, 283 K). Harvested cells were resuspended in 40 mL of 50 mM
Tris-HCl pH 8.5, 1 M NaCl [Guardado-Calvo et al. 2009] and frozen at 253 K. Bacteria were
lysed with a French press (Thermo, Needham Heights, Massachusetts, USA), a Stansted high
pressure cell disrupter (Stansted Fluid Power Ltd, Harlow, Essex, England), or a Q500 sonicator
(QSONICA, Newtown, Connecticut, USA). Insoluble material was removed by centrifugation
(45 min at 14000 x g, 280 K). The supernatant was incubated with 2 mL of Ni-NTA Agarose
resin (Jena Bioscience GmbH, Jena, Germany) for 1 h at room temperature and poured into an
empty Econo-Pac® Chromatography Column (Bio-Rad, Hercules, California, USA). The resin
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was washed with 50 mM Tris-HCl pH 8.5, 1 M NaCl, 10 mM imidazole and protein was eluted
with a step gradient from 50 to 1000 mM imidazole pH 8.0.
Fractions with his-tagged protein from the IMAC were dialysed against 10 mM TrisHCl pH 8.5, 1 mM EDTA and loaded onto a RESOURCE TM Q 6 mL anion-exchange column
(GE Healthcare Life Sciences, Little Chalfont, Buckinghamshire, England) and eluted with a
continuous NaCl gradient up to 1 M in 10 mM Tris-HCl pH 8.5 (gradient volume: 15 columnvolume; fractions: 3 mL, with new fraction when an 280-nm-absorbance peak is detected).
Fractions with protein were pooled and concentrated. Protein absorbance at 280 nm was
measured (NanoDrop ND-1000, Wilmington, Delaware, USA) to determine the concentration.
The purifications were assessed by SDS-PAGE (12% acrilamide [Sambrook et al.
1989]) using Mini-PROTEAN® Tetra Cell electrophoresis system (Bio-Rad, Hercules,
California, USA).
Crystallization attempts on gp150. Crystallization attempts were performed by vapordiffusion on sitting-drop MRS crystallization plates (Swissci AG, Neuheim, Zug, Switzerland).
Commercial screen formulation kits JBScreen Classic 1 to 10, JBScreen PEG/Salt 1 and 2, and
Pi-minimal Screen (Jena Biosciences, Jena, Germany) 1 were used for the crystallization
attempts on 96 well plates with 50 µL reservoir and drops of 1 µL (0.5 µL of protein sample
and 0.5 µL of reservoir). The crystallization conditions were optimized on 48 well plates with
100 µL reservoir and 2 µL drops. Crystals were cryoprotected by adding a solution of the same
composition as the crystallization condition supplemented with 20% v/v glycerol, and they were
subsequently fished with Litholoops (Molecular Dimensions, Newmarket, Suffolk, England)
and frozen in liquid nitrogen for transportation to the ALBA synchrotron light source facilities
(ALBA, Cerdanyola del Vallès, Barcelona, Catalonia).

Results
Expression and purification attempts. The expression was tried with eleven constructs
encoding the full-length gp150 (into two different expression plasmids) and nine carboxyterminal fragments of gp150 [FIG B.1], since gp150 was predicted as a fiber and phage fibers
usually interact with the host by the carboxy-terminal part. Expression tests were performed
with Escherichia coli expression strains JM109(DE3), BL21(DE3), and B834(DE3).
Considering the lack of similar proteins that would enable phasing by molecular replacement
and the lack of cysteine residues that would allow the binding to mercury, the expression efforts
were mostly focused on the strain B834(DE3), anticipating an eventual selenomethioninederivative production to solve the structure by experimental phasing. The expression of all the
1

JBScreen Classic kits 1 to 10 and JBScreen PEG/salt kits 1 and 2 contain 24 crystallization
conditions each. Pi-minimal Screen kit includes 96-crystallization conditions.
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FIGURE B.1. Fragments of gp150. Top diagram, linear representation of the full-length gp150 protein;
the boxes indicate the positions of the weakly-predicted T4-gp6 domain and cellulose-binding domain
[Hildebrand et al. 2009]. Bottom bars, representation of fragments cloned to attempt the expression of
gp150 for crystallographic purposes.

constructs was very poor with all strains and it did not improve when assessing the induction
time and temperature.
All constructs expressed very small or undetectable amounts of soluble protein. The
less-adverse expression results were obtained with constructs encoding medium-size products
(gp150(407-1019), gp150(490-1019), gp150(519-1019), gp150(574-1019), gp150(564-1019),
gp150(693-1019)), where most of the over-expressed protein was insoluble but a perceptible
amount of soluble protein was detected [FIG B.2]. The yield of soluble protein did not improve
with modifications (pH, ionic strength) or additives (up to 10% glycerol, 1 M urea, up to 0.5%
SDS) on the lysis buffer. Attempts of recovery of insoluble protein from inclusion bodies with 8
M urea or 6 M guanidinium also failed. Large scale production and purification was performed
on fragments gp150(490-1019), gp150(519-1019), and gp150(574-1019). After a IMAC and an
anion-exchange chromatography the sample did not reach crystallographic purity standards
[FIG B.2] but it was insufficient for additional purification steps.
Crystallization attempts. In the 19th century crystallization was considered a method of
purification [McPherson & Gavira 2014]; a crystal is an ordered precipitate consisting of the
translational repetition of the unit cell (which, in turn, is formed by one or more asymmetric
units), so the content of the unit cell (and the asymmetric unit) is separated from the rest of the
sample and, therefore, purified. Despite the lack of purity, the enriched samples were used for
crystallization attempts in the hope that a crystal might have been formed from the protein of
interest. Crystallization was tried with samples from gp150(490-1019), gp150(519-1019), and
gp150(574-1019). Small crystals appeared [FIG B.3 a] with the sample gp150(574-1019) in the
condition 1.2 M ammonium sulfate, 3 % w/v 2-propanol, 50 mM tri-sodium citrate. These
crystals were reproducible in optimization plates but their size could not be improved. The
crystals diffracted to 2.84-Å resolution. An analysis of the auto-processed data with the
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FIGURE B.2. Purification of gp150(490-1019). Features of the expressed recombinant-protein (table
top-left), calculated with ExPASy ProtParam [Gasteiger et al. 2005]. Purification outcome: IMAC (topright) (Pel: pellet; Sup: supernatant; FT: flow-through; W: wash), anion-exchange chromatography
(bottom-left) (the chromatogram plots absorbance (280 nm) vs elution volume; the dotted line represents
the conductivity), concentrated fractions eluted from the anion-exchange chromatography (bottom-right).
(*) Loaded sample.

ContaMiner [Hungler et al. 2016] revealed that the crystals were made of a common
contaminant from the expression organism (E. coli B834(DE3)). The contaminant was the
catalytic domain of the dihydrolipoamide succinyltransferase; i.e., the E2 component of the 2oxoglutarate dehydrogenase complex. This protein has already been structurally characterized
as a homo-24mer (PDB:id 1E2O [Knapp et al. 1998], 1SCZ). The identity of the contaminant
was verified by solving its structure [FIG B.3 b] by molecular replacement using a 2.2-Åresolution model (PDB:id 1SCZ) as template.

Discussion
The crystallographic characterization of gp150 failed because of the sub-standard
quality of the produced samples. The purity of the samples did not reach the 97%-requirement
6
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FIGURE B.3. Crystallization of gp150(574-1019). (a) Crystals grown from the enriched gp150(5741019)-sample in 1.2 M ammonium sulfate, 3 % w/v 2-propanol, 50 mM tri-sodium citrate. (b) Structure
of the dihydrolipoamide succinyltransferase crystallized from the gp150(574-1019)-enriched sample. This
protein is a component of the 2-oxoglutarate dehydrogenase complex from the expression organism (E.
coli).

for crystallization; which explains the crystallization of a contaminant. The quantity of the
obtained protein did not suffice for further assays (like partial proteolysis) to identify a stable
domain suitable for crystallization.
Functionally, gp150 has been assigned as tail fiber protein complex (Supplementary
material of [Nováček et al. 2016]). This thesis shows that the region identified as fiber in the
cryo-EM map of phage phi812 [Nováček et al. 2016] is not a single protein since the hostinteracting portion of the fiber consists of a gp144 trimer. Therefore, either gp150 is not a fiber
protein complex or it constitutes the proximal portion of the fiber complex. If gp150 is not a
distal protein (like gp146 or gp144), it would probably require the interaction with other
baseplate proteins to properly fold into a stable and functional conformation. This would
explain the outcome of the expression assays; the misfolded or unstable conformations might be
degraded (leading to an apparent lack of expression) or aggregated into exclusion bodies
(resulting in insoluble protein).
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The primary receptor of phage K is wall teichoic acid [Xia et al 2011]. Wall teichoic
acid from Staphylococcus aureus is a ribitol 5-phosphate polymer decorated with Nacetylglucosamine and D-alanine that is bound to the peptidoglycan by a linker of glycerol 3phosphate and a disaccharide. Co-crystallization was attempted with some wall teichoic acid
components, synthetic poly(ribitol 5-phosphate) oligomers, and a commercial drug.
The wall teichoic acid components whose co-crystallization was tested were: ribitol
[FIG C.1 a], rac-glycerol 1-phosphate [FIG C.1 b, c], sn-glycerol 3-phosphate [FIG C.1 b], Nacetylglucosamine [FIG C.1 d].
Co-crystallization was also attempted with the anti-coagulant Fondaparinux [FIG C.1 e]
(Arixtra®, GlaxoSmithKline, Glaxo Wellcome Production, Notre Dame de Bondeville, France).
This synthetic heparin had been co-crystallized with the wall teichoic acid glycosyltransferase
TarM, acting as an analog of the poly(ribitol 5-phosphate) [Sobhanifar et al. 2015].
Synthetic compounds were provided by J. Codée (Leiden Institute of Chemistry,
Leiden, Nethelands). These compounds are glycosylated poly(ribitol 5-phosphate) oligomers:
SA-325 [FIG C.2 a], SA-378 [FIG C.2 b], SA-385 [FIG C.2 c], and SA-463 [FIG C.2 d]. The
molecule SA-463 was successfully employed for soaking of crystals of the wall teichoic acid
glycosyltransferase TarP [Gerlach et al. 2018].

FIGURE C.1. Commercially available compounds used in co-crystallization attempts. (a) Chemical
structure of ribitol. (b) Chemical structure of sn-glycerol 3-phosphate. (c) Chemical structure of snglycerol 1-phosphate. (d) Chemical structure of N-acetylglucosamine. (e) Chemical structure of
Fondaparinux (Arixtra®).
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FIGURE C.2. Chemically synthesized compounds used in co-crystallization attempts. (a) Chemical
structure of SA-325. (b) Chemical structure of SA-378. (c) Chemical structure of SA-385. (d) Chemical
structure of SA-463. All the compounds were provided by J. Codée (Leiden Institute of Chemistry,
Leiden, Nethelands).
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A Ramachandran plot is a graphical representation of the amino-acids of a model
according the torsional backbone angles (phi (φ)and psi (ψ)) that shows which combinations of)) that shows which combinations of
φ and ψ)) that shows which combinations of are sterically possible.
This appendix includes the reports of Ramachandran analyses [Lovell et al. 2003] run
on MOLPROBITY [Chen et al. 2010]. Each report contains independent Ramachandran plots
for isoleucine and valine, pre-proline residues, glycine, trans-proline, cis-proline, and the rest of
amino-acids (general case).
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The tables of this appendix are an account of the inter-atomic distances of intermolecular interactions mentioned in the text of the thesis.

TABLE F.1. Interactions between gp146 and ions. Inter-atomic distances of the interactions between
gp146 and ions mentioned in the text. Each distance is associated with the atoms (excluding hydrogen)
involved in the interaction in the crystallographic models, the interaction type and the location in the
protein.
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TABLE F.2. Interactions between gp146 and ligands. Inter-atomic distances of the interactions
between gp146 and ligands mentioned in the thesis. Each distance is associated with the atoms (excluding
hydrogen) involved in the interaction in the crystallographic models, the interaction type and the location
in the protein.
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TABLE F.3. Interactions between gp144 and ligands. Inter-atomic distances of the interactions
between gp144 and ligands mentioned in the text. Each distance is associated with the atoms (excluding
hydrogen) involved in the interaction in the crystallographic models, the interaction type and the location
in the protein.

TABLE F.4. Interactions between gp155 and ligands. Inter-atomic distances of the interactions
between gp155 and ligands mentioned in the text. Each distance is associated with the atoms (excluding
hydrogen) involved in the interaction in the crystallographic models, the interaction type and the location
in the protein.
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